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CHAPTER 1
Introduction
Based on :
“Een nieuw licht op de dermatologie, 
fotodynamische therapie in de praktijk”
Ellen RM de Haas
Bussum 2003, ISBN 9090175156
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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
NON MELANOMA SKIN CANCER AND ITS INCIDENCE, REASON FOR CONCERN
Non melanoma skin cancer (NMSC) is the most common cancer in Caucasian 
people (1,2). NMSC mainly consists of squamous cell carcinoma (SCC) and basal 
cell carcinoma (BCC). Often Bowens disease (SCC in situ) and actinic keratosis are 
considered to be included although they are not invasive. It is an important and a 
growing healthcare problem. If current trends continue it is expected that there will 
be 80% more (new) skin cancer patients by 2015 compared to those in 2000. The 
number of BCC patients will increase by 78% and by 2015 there will be 26000 
new cases of ﬁ rst/primary BCC compared to 15000 in 2000 in the Netherlands. 
The largest increase in incidence is expected to be in younger age groups 15-64 
years (females 94%, males 66%), and due to an increase in superﬁ cial BCC (3,4). A 
typical BCC patient is female, becoming younger, and presenting with a superﬁ cial 
lesion. If current patterns of sun exposure do not change this increase in incidence 
will continue over time due to the ageing population (3,5). A serious rise in annual 
demand for care for non melanoma skin cancer  will occur. Although  NMSC is the 
most common cancer, death from NMSC is uncommon but it occurs. An estimated 
number of 1017 deaths due to squamous cell carcinoma (SCC) and 672 due to BCC 
in man and woman of all ages occurs yearly in Europe (6). In 20 % of the deaths 
due to skin cancer metastases of SCC are the cause of death(7).
The etiology of NMSC is endogenous and exogenous. Genetic predisposition 
like skintype (Fitzpatrick I-V) and/or genetic diseases (e.g. Basal Cell Nevus syndrome) 
are involved. The most important exogenous factor is exposure to ultraviolet 
light, sun exposure and tanning lamp exposure. Other riskfactors are exposure to 
carcinogens like tar, coal, arsenic, certain industrial oils, solvents, ionizing radiation 
(11,12). Medical conditions as human papilloma virus infections or immuno-
suppression (e.g. in organ recipients)( 13,14,15) or intense PUVA treatments (16) 
induce a risk for development of NMSC. Even tobacco smoking has been linked to 
the development of SCC(17).
The incidence on NMSC is hard to say because in most countries NMSC 
is not included in cancerregistry. In Germany the age-standardized rate for NMSC 
was 100.2 per 100 000 inhabitants for men and 76.6 per 100 000 for women per 
year (1998 and 2001), 80% of NMSC were BCC. It is estimated that more than a 
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million BCC’s and SCC occur every year in the United States. In the Netherlands 
incidence rates for BCC have been calculated to be 92 for men and 79 for women 
per 100 000 person years (4).  NMSC incidence is even generally recognized to be 
underestimated and is increasing (3,5).
 The therapeutic options for NMSC include surgery (micrographic or 
conventional), topical chemotherapy (5-ﬂ uouracil), immuno-modulating therapy 
(topical imiquimod), cryotherapy, curettage & electrodessication, radiotherapy 
and photodynamic therapy. The optimal treatment is dependent on the patient 
and the characteristics of the tumour. In most SCC surgical excision is ﬁ rst choice 
treatment (20). In BCC the treatment of choice is highly dependent on the growing 
pattern of the BCC: morpheiform, nodular, or superﬁ cial. For morphemic BCC 
surgery is regarded to be the treatment of choice. For nodular and superﬁ cial 
BCC different modalities as surgery, cryotherapy, curettage & electrodessication or 
PDT are commonly used.(21,22, 23) For the non invasive Bowens disease surgery, 
topical chemotherapy , cryotherapy, and PDT are used in daily practice (24). Actinic 
keratosis is mostly treated with cryotherapy, although the other superﬁ cial targeting 
modalities are also possible options (25, 26).Just recently guidelines on the use of 
PDT for NMSC have been published (27) which indicate there certainly is place for 
it.
PHOTOTHERAPY IN DERMATOLOGY: NOTHING NEW UNDER THE SUN
Light has fascinated man from the beginning of time and research into its 
fundamental properties and its effects on matter have been researched in ﬁ elds as 
diverse as physics and astronomy, medicine and philosophy. Even before the birth 
of Christ light was used to treat the skin. The Egyptians used light in combination 
with chemicals to provoke healing effects. The therapeutic effects of light alone 
are well known and these properties were utilized for many centuries (28). In 1903 
Niels Finsen received the Nobel price for medicine based on his use of phototherapy 
for the treatment of patients with lupus vulgaris and tuberculosis (29). Modern day 
photochemotherapy (PUVA), in which skin containing psoralens is exposed to long 
wave ultraviolet radiation (UVA) was introduced in 1976 (30). 
Another type of photochemotherapy is photodynamic therapy (PDT). PDT involves 
the combination of a light sensitive molecule, the photosensitiser and light of an 
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appropriate wavelength. The photosensitiser mediates the transfer of light energy 
to tissue oxygen and results in the production of reactive oxygen species, notably 
singlet oxygen. Singlet oxygen leads to the destruction of critical cellular and tissue 
components. Singlet oxygen is responsible for the photodynamic effect. 
HISTORY OF PHOTODYNAMIC THERAPY: WITHOUT KNOWLEDGE OF 
HISTORY YOU WON’T UNDERSTAND THE PRESENT
PDT has a long history. At the beginning of the twentieth century Jesionek and Von 
Tappeiner used eosin and light to treat skin cancer (31). Von Tappeiner discovered 
oxygen to be essential in the process which he called photodynamic reaction (32). 
Hematoporphrin was the ﬁ rst studied photosensitiser by Hausmann (33) and 
many others. This has led to the development of HpD (Photofrin) a mixture of 
porphyrin-monomers, dimers and oligomers (34). Meyer Betz himself experienced 
skin photosensitivity after admission of hematoporphrin. A day after admission of 
hematoporphrin to himself, he went outside and got severe edema and erythema 
(35).Prolonged photosensitivity of the skin after HpD admission is a clinical problem, 
patients had to stay in the dark for a long time. This has led to investigations to 
develop other photosensitisers in search for the ideal one. An ideal sensitiser should 
be biological stable, photochemically efﬁ cient, selective to  the target cells, and 
without toxicity to normal tissue. Second generation photosensitisers were introduced 
– porphyrin derivatives, chlorins, bacteriochlorins and porphyrin-like sensitisers, 
phtalocyanins (36, 37). A different approach was identiﬁ ed by Kennedy and Pottier 
in 1990 (38). Here a photosensitiser pre-cursor or pro-drug, aminolevulinic acid 
(ALA), which is part of the heme biosynthetic pathway, is administered exogenously. 
This leads to the accumulation of the endogenous photosensitiser protoporphyrin 
IX (PpIX).  Since 1990 hundreds of research articles have been published on the 
mechanisms of action underlying ALA-PDT. Many have investigated its use for 
the treatment of non-melanoma skin cancer. A major advantage of ALA-PDT in 
dermatology is the topical use of the prodrug and the almost absence of prolonged 
skin photosensitivity. The body of evidence in the literature and the minimal 
side effects of ALA-PDT resulted in 2001 in the approval of ALA and blue light 
(Levulan®) for treating actinic keratosis in the United States by the FDA (Food and 
Drug Administration) (39-42). Some years later the esterderivative of ALA, methyl-
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aminolevulinate (MAL, Metvix®) was approved in most European countries for the 
treatment of superﬁ cial basal cell carcinoma (sBCC) and Bowens disease (43-48). A 
historical overview of major experiments and publications which has been underlying 
the use of PDT or  support the development of PDT especially ALA-PDT is shown in 
table 1. Until now the risks of ALA-PDT are limited. No mayor side effect has been 
reported but a contact allergy to MAL (49). No carcinogenic or other danger is 
recognized in using PDT (50,51)  But we should not ignore lessons from history and 
remain alert and prepared to change concepts, thoughts and practice.
Table 1: History( 52,53)
3000 BC 
India
psoralens and light treatment used for vitiligo 
12th 
century 
ancient 
Egypt 
psoralens and light used for leukoderma
ancient 
Herodotus 
famous greek physician, father of heliotherapy
Discovery Antarctica, Fabian von 
Bellinghausen
1820
1834 Kalbrunner:isolation of 5-methoxypsoralen from 
bergamot oil
1871 Hausmann: ﬁ rst studies of biological effect 
hematoporphrin
First International Polar Year 
(IPY) Weyprecht:Solutions to the 
fundamental problems of meteorology 
and geophysics were most likely to 
be found near the Earth’s poles.12 
countries were involved, 15 
expeditions to the poles sent out. 
Beyond the advances to science and 
geographical exploration, a principal 
legacy of the First IPY was setting a 
precedent for international science 
cooperation.
1882-83
1900 Raab: Paramecium caudatum died within 2 h after 
exposition to acridine orange and light, not after 
one of these
1900 Prime: eosin orally used to treat epilepsy, failing 
treatment but dermatitis in sun exposed skin areas 
as result
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Scott and Shackleton reached 
82017’ZB, trying to reach the Pole
1902
1903  Niels Finsen: Nobel Prize for treatment tuberculosis 
with UV-light and development carbon arc 
phototherapy
1904 Van Tappeiner & Jodblauer: photodynamic effect: 
description oxygen consuming reaction in protozoa
1905 Von Tappeiner & Jesionek: experiences with eosine 
and artiﬁ cial light treating skin cancer , lupus 
vulgaris and other dermatological conditions
 
Shackletons second try to reach to 
Pole, he reached 880 23’ZB
1907
Roald Amudsen arrived at the south 
Pole
1911
 
Hausmann: hematoporphrin used as sensitiser in 
guinea pigs and mice
Scott arrived at the south Pole, but on 
the way back he died
1912
1913 Meyer-Betz: injected himself hematoporprin and 
became swollen after light exposition
World war I, la grande guerre 1914-18
1924 Policard: ﬂ uorescent porphrin localized in 
malignant tumour, sarcoma in rat when 
illuminated with Woods lamp
Second International Polar Year(IPY) 
40 nations participated.  it heralded 
advances in meteorology, magnetism, 
atmospheric science, and in the 
“mapping” of ionospheric phenomena 
that advanced radioscience and 
technology 
1932-33
World war II 1940-45
1942 Auler & Banzer: hematoporphrin more 
concentrated in certain tumours compared to 
surrounding tissue
1948 Figge & Weiland: hematoporphrin selectively 
absorbed into other cells
1951 Manganiello &Figge: 
studied effect of hematoporphrin in 3 head and 
neck cancer patients
1955 Rasmussen& Taxdal: intravenously hematoporprin 
in various conditions including skin cancer studied
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1955 Peck: studied diagnostic properties of 
hematoporphrin in biliary surgery
1955  Schwarz: demonstrated hematoporphrin to be 
mixture and developed  hematoporphrin derivative 
(HpD)
The International Geophysical Year 
(GPY, also IPY),celebration of the  
75th and 25th anniversaries of the 
First and Second IPYs was conceived 
by a number of post-WWII eminent 
physicists, including Sydney Chapman, 
James Van Allen, and Lloyd Berkner, at 
an informal gathering in Washington 
DC in 1950. These individuals realized 
the potential of the technology 
developed during WWII
1957-58
Article 1 Arctic Treaty : Antarctica shall 
be used for peaceful purposes only
1959
1960th Schwartz, Lipson, Baldes:  studies in use HpD for 
tumour detection
1961 Lipson: HpD used in bronchoscopy to localize 
suspected malignant disease
1967 Gray: cervical and vaginal HpD ﬂ uorescent 
diagnostics (malignant & benign)
1970th PUVA used as treatment for psoriasis
1971 Leonard & Beck:  HpD tumour detection in head 
and neck cancer
1972 Diamond: concept of tumour localizing 
ﬂ uorescence might be effective as treatment 
modality (Lancet)
1975 Dougherty: hematoporphrin puriﬁ ed derivative 
successfully used in treatment cutaneous 
malignancies with red light
1975 Kelly: human bladder cancer cell transplanted in 
mice can be destroyed by PDT
1978 Dougherty: ﬁ rst large series skin tumours treated 
with PDT
1983 Benson: demonstrated positive correlation 
between HpD ﬂ uorescence and histological severe 
dysplasia or carcinoma in situ.
1984 Mc Caughan: esophageal cancer treated with PDT, 
in all good palliation 
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1990 Kennedy: introduction topical sensitiser prodrug 
aminolevulinic acid (ALA)
1990 Divaris: proposal chemical porphyria as novel 
means of photosensitization for PDT
1992  Pottier: ALA metabolized to potent photosensitiser 
protoporphrin IX (PpIX)
1998 Fritsch: ALA & MAL more concentrated in AK than 
adjacent skin but MAL more speciﬁ c in keratotic 
cells
2001 FDA /US approval Levulan ®  kerastick (ALA&blue 
light) for AK
2004  FDA/ US approval MAL for non hyperkeratotic AK 
in face and scalp.MAL (Metvix ®)  registration in 
Netherlands for superﬁ cial BCC & Ak
2006 MAL (Metvix ®)  registration for M Bowen
fourth International polar year 
(IPY)covers two full annual cycles 
from March 2007 to March 2009 and 
will involve over 200 projects, with 
thousands of scientists from over 60 
nations examining a wide range of 
physical, biological and social research 
topics. It is also an unprecedented 
opportunity to demonstrate, follow, 
and get involved with cutting edge 
science in real-time
2007-9
PRINCIPLES OF ALA-PDT
In daily practice ALA-PDT is simple to perform; apply ALA wait for a deﬁ ned time-
interval typically 4 – 6 hours, and illuminate the lesion with visible light, delivering 
a deﬁ ned lightdose. This simplicity belies the fact the mechanism(s) underlying PDT 
are complicated. ALA-PDT is a treatment modality that involves the conversion of 
ALA to PpIX in tumour cells. Absorption of light by PpIX  initiates the transfer of 
energy to molecular oxygen present in the tissue. This results in the production 
of reactive oxygen species, notably singlet oxygen. Singlet oxygen is responsible 
for the destruction of tumour and normal cells within the treatment volume. 
There is clearly a number of important factors to consider. The combination of 
light, sensitiser and oxygen is inﬂ uenced by application time, illumination time, 
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the response of surrounding tissue, vessels and cells, and cellular products such as 
cytokines. PDT damage is the sum of achieved effects. The sum of tissue responses 
to the presence of light sensitive drugs / molecules illuminated by the appropriate 
wavelength. Tissue and cellular responses lead to direct and indirect cell death and 
a physiological response. 
Figure 1: The range of interdependent parameters that determine the response of tissues to photodynamic 
therapy.
PORPHYRIN SYNTHESIS IN ALA-PDT
The administration of exogenous ALA to cells results in the accumulation of 
porphyrins, in particular PpIX. PpIX is an intermediate in the biosynthetic pathway of 
heme (ﬁ gure 2), which consists of a number of steps that under normal conditions 
is tightly regulated by enzymatic control . The rate at which ALA is synthesized and 
enters the pathway is normally always less than the maximum rate of any of the 
subsequent steps. This means that intermediates in the pathway do not accumulate. 
However if the feedback mechanism between ALA and heme is bypassed by the 
presence of excess exogenous ALA, it is possible for one or more of the intermediates 
to accumulate. The extent to which this can happen is determined by the relationship 
between its rate of synthesis and the rate at which it is removed by the synthesis of 
18 | Chapter 1
the next intermediate. The last step of the pathway in which iron is incorporated 
into PpIX to form heme, catalyzed by the enzyme ferrochelatase, is rate limiting and 
this leads to the accumulation of PpIX on the inner mitochondrial membrane. While 
PpIX has been shown to be the predominant photosensitiser accumulated in most 
cell types the addition of exogenous ALA can result in the accumulation of any of 
the sensitisers boxed in ﬁ gure 2. While each of these has been shown to be photo- 
dynamically active in-vitro they are all highly soluble in water and are rapidly cleared 
from cells and tissues. In contrast PpIX is only slightly water soluble at physiological 
pH and shows a strong afﬁ nity for lipid membranes (38, 54) 
Figure 2: The bio-synthetic pathway of heme.
(adapted from In vivo analysis of the dynamics of photosensitiser ﬂ uorescence in photodynamic therapy, DJ 
Robinson University of Leeds UK Thesis)
Cellular uptake of the hydrophilic ALA is thought to be an active process.(55-57) 
cellular uptake takes time, in tumor cells the active uptake process is accelerated 
compared to normal cells (58). ALA esters, e.g.methylaminolevulinate are more 
lipophilic. As consequence of lipophilicity esters can also be taken up by a passive 
process, diffusion, through the epidermis (59, 60).ALA is known to be transported 
away from the area of topical application, MAL is accumulated intracellular 
and remains at the area of administration. Soon after cell penetration MAL is 
demethylated to ALA and therefore the subsequent metabolic steps of ALA and MAL 
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are thought to be identical. Although almost every cell is capable of PpIX production 
by the heme-bio-synthetic pathway, in malignant cells PpIX accumulation is ten fold 
higher than in normal counterpart cells (61). This has also been shown in tumour 
keratinocytes compared to healthy skin (62).
DISTRIBUTION OF PPIX IN SUPERFICIAL SKIN CANCER
Distribution of PpIX in cells, models and in vivo has been investigated extensively 
(59,63,64,65). At cellular level PpIX  distribution has been found to be in mitochondria 
at ﬁ rst , but in other cellular components as well. The longer the incubation the more 
PpIX is distributed in different organelles such as endoplasmatic reticulum. Using 
topical  ALA in  a mouse model, normal skin and UV induced tumours, ﬂ uorescence 
was mainly located in tumour, in the epidermis and in hairfollicles. Four hours after 
topical application tumor selectivity was higher compared to ﬂ uorescence directly 
after ALA-application (66). In vivo PpIX has been shown in the superﬁ cial layers of 
nodular BCC using a topical application of 20% ALA. Penetration enhancers such 
as dimethylsulphoxide or longer application time resulted in deeper penetration 
of the ALA and more PpIX production (67).Penetration studies of ALA have 
shown penetration of at least 2 mm from the lesion surface into the depth.(68) 
Intracutaneous injected ALA in nodular BCC’s  has resulted in higher PpIX induced 
ﬂ uorescence as well ( 69). Intravenous injected ALA resulted in a more homogenous 
distribution of PpIX in the whole nodular ulcerative BCC (67). In superﬁ cial BCC PpIX 
ﬂ uorescence was shown in the full thickness of the tumor. A variable pattern of 
ﬂ uorescence was found inter and intra tumours.(70). Mostly in the above mentioned 
studies surface techniques were used to detect PpIX ﬂ uorescence in vivo. 
LIGHT
The penetration of light in tissue is obviously an important factor in the response of 
tissue to ALA-PDT. The penetration depth is inﬂ uenced by the tissue optical properties 
and this will in turn have an impact on the light ﬂ uence (or dose) at depth and thus 
on the effect. These optical properties are characterized by absorption and scattering 
coefﬁ cients. The predominant absorbers in skin are oxy- and de-oxyhemoglobin, 
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melanin and water. Light scattering is also a very important factor that determines 
the distribution of light in skin. The absorption spectra of these components and the 
inﬂ uence of light scattering mean that there is an ‘optical window’ between 600 
and 670 nm where, long wavelength, red light penetrates tissue most efﬁ ciently. 
ALA-PDT is mostly performed using red light (610<λ<640nm) that overlaps with 
the absorption spectrum of PpIX. If light is assumed to be completely diffuse within 
tissue it is possible to show that the depth distribution of light has the formula
Φ(z)= Φ0keμeffz. 
The ﬂ uence rate, Φ, at depth z, is dependent on the ﬂ uence rate at surface, Φ0, a 
constant factor (k) and an exponent that contains information about the absorbing 
and scattering properties of tissue. The factor k accounts for the effect of light 
scattering just below the surface of the tissue.(71,72,73).Measurements in human 
skin (non pigmented) have shown a mean μeff =0.359 mm
-1 en k=2.63 at 630 nm. 
Therefore the effective penetration depth of red light in human skin is approximately 
2.8mm (74). While there are likely to be clear differences in light penetration depth 
between tissues with different concentrations of absorbers, in particular blood, 
2.8 mm represents a good estimate of the penetration depth of red light in skin. 
What is clear from this analysis is that ALA-PDT is not limited by the penetration 
depth of light and 2.8 mm is a sufﬁ cient penetration depth for most superﬁ cial non-
melanoma skin cancer. 
PHOTOPHYSICS AND PHOTOCHEMISTRY OF ALA-PDT
Absorption of light by the photosensitiser results in the transfer of energy to electrons 
within the molecule as illustrated in ﬁ gure 3. These electrons are able to share/
transfer energy in different ways within a molecule depending on their energetic 
status. Normally the photosensitiser is in a ground state (S0) that is characterized 
by paired electrons. Absorption of a photon leads to excitation into S1 S2 S3 etc. 
Energy transfer can then happen in two different ways: S1 Æ S0 by emission of a 
photon (ﬂ uorescence) or S1 Æ T1 Æ S0 by intersystem crossing to a triplet state of the 
photosensitiser. This triplet state of the photosensitiser is relatively long lived and this 
means that it can interact with its environment, in particular by transferring energy 
to surrounding molecules.  This can happen in two different ways. Processes that 
are termed type I and II reactions. In a Type I reaction triplet state S reacts directly 
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with molecules of the substrate via electron transfer resulting in the production 
of oxygenated S and reduced S. In hypoxic environment reduced S can react with 
superoxide radicals producing superoxide ions ultimately leading to highly reactive 
hydroxyl radicals. In a Type  II reaction energy is transferred to 3O2 to produce singlet 
oxygen 1O2 .Type II is an oxygen dependent reaction. Almost all of the evidence in 
the literature suggests that PpIX transfers energy to its environment via a type II 
reaction and singlet oxygen is the agent that is responsible for the damage to cells 
and tissues.(75,76)
Figure 3: Photophysics; energy states involved in the transfer of energy from light to molecular oxygen to 
produce singlet oxygen adapted from DJ Robinson.
PHOTOBLEACHING
One important side effect of the generation of singlet oxygen by a photosensitiser is 
the process that is termed photobleaching. Photobleaching is the loss of absorption-
capacity of the sensitiser, in effect the photosensitiser is being destroyed during the 
PDT process. Since photobleaching of PpIX is mediated by the same process that 
causes PDT damage it is a useful measure of the response of tissue to PDT and 
has been used as a predictor of tissue response (77). Following ALA-PDT, after the 
photobleaching of PpIX we and a number of investigators have observed continued 
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synthesis of PpIX and a reappearance of PpIX ﬂ uorescence. This is obviously an 
important factor when light fractionation is  considered. 
             
Figure 4:  Photobleaching, from DJ Robinson (77)
PHOTOBIOLOGY IN ALA-PDT 
As described above singlet oxygen is predominantly responsible for the response 
of tissues following ALA-PDT (78-80). The effect of a photosensitiser has been 
shown to be directly proportionate to the amount of  singlet oxygen produced (81). 
Because of the very high reactivity and the short lifetime of singlet oxygen PDT 
induced damage is conﬁ ned to the cell in which singlet oxygen is produced, which 
coincides with the localization of the photosensitiser.
  Apoptosis, Necrosis and physiological effects of ALA-PDT 
PDT leads to cell death by necrosis or by induction of apoptosis. Sublethal PDT 
damage still has an inﬂ uence on cell biology and physiology and thus on tissue 
response. In general cell death is the result of two different pathways, necrosis 
and apoptosis. Apoptosis requires several active processes within the cell. It can 
be considered to be an ordered process of a badly damaged cell. An apoptotic cell 
disposes itself to be resolved completely. Necrosis is less well controlled and leads to 
Introduction | 23
cell debris and crusts. 
In general the process of apoptosis can be activated by two different pathways, the 
extrinsic and intrinsic pathway. The extrinsic pathway is initiated by binding of death 
ligands (e.g.FasL) to their cognate surface death receptors resulting in a signaling 
complex. Intracellular  pro-caspase 8 and pro-caspase 10 are recruited and activated 
which in turn activates effector pro-caspases (3&7).
The intrinsic pathway is initiated by different extra- and intra-cellular stresses requiring 
permeabilization of the outer mitochondrial membrane which leads to the release 
of apoptogenic molecules (e.g.cytochrom-c) into the cytosol. Binding of  these 
molecules leads to activation of pro-caspases (9) and downstream caspases (e.g.3). 
Apoptosis induced by PDT shows a rapid release of mitochondrial cytochrom-c-into 
the cytosol. In the photodynamic reaction, as soon as singlet oxygen is formed 
it will react with PpIX at the mitochondrial membrane to introduce apoptosis. 
Depending on the PDT-dose cells can respond to sub-lethal damage by engaging a 
rescue response or by cell death. Depending on the photodynamic stress either an 
apoptotic cell death or a necrotic cell death will occur. The balance between death 
and survival is regulated by signaling pathways (e.g. mitogen activated protein 
kinase cascades (MAPK)). These protein kinases are used to connect cell surface 
receptors to critical regulatory targets within the cell which control a divers array of 
cellular programs including cell death. PDT has been shown in cell lines, to be able 
to activate this regulating system (82). 
Vascular effects
One of the responses to PDT is a destruction of tumour vasculature. Sensitive 
sites as vascular endothelium and the vascular basement membrane may get damaged 
leading to trombo-aggregation, release of vaso-active molecules, leucocyt-adhesion, 
increased vascular permeability, vessel constriction and haemorrhage(83,84).
Systemic administered ALA has been shown to lead to accumulation of PpIX in 
vascular endothelial cells indicating vascular damage after PDT (85). In a mice model 
vascular damage has been shown also after topical ALA (86).
PDT inﬂ uences on physiology 
PDT can alter the function of different immune and non-immune cells 
leading to an inﬂ ammatory response(87,88). In models monocytes, dendritic cells, 
Langerhans cells and activated lymfocytes can be selectively sensitized by ALA.(89) 
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In Photophrin- PDT neutrophylic granulocytes play a very important role (90), in 
ALA-PDT a bystander role (91).
The mode of cell death is important “in general” but it is potentially 
especially important in light fractionation. A cell + vascular + tissue + immune 
response will already happen after the ﬁ rst illumination before another illumination 
will be performed. Fractionation may result in a changed “cumulative” response 
after the complete treatment.
LIMITATIONS OF ALA AND MAL-PDT AND THE NEED FOR 
OPTIMIZATION
The response of tissues to PDT that are photosensitised with PpIX following 
the application of porphyrin-precursors is limited by a number of factors.  The 
penetration of ALA and MAL is limited by their diffusion through tissue layers, in 
particular the stratum corneum, but also by other tissue structures. ALA is known to 
be transported away from the area of topical application (92). This means that there 
is a limited amount of PpIX available for any single treatment. During illumination 
PpIX is also rapidly photobleached by the singlet oxygen generated during PDT. This 
limits the effective PDT dose that can be delivered in a single treatment as described 
in the following text. Despite the fact that ALA- and MAL-PDT is used clinically many 
research groups are investigating the mechanisms that underlie its effectiveness and 
are searching for methods to improve it. 
OPTIMIZING ALA-PDT; PPIX RE-SYNTHESIS AND LIGHT FRACTIONATION 
In search to optimize the results of PDT different approaches have been investigated, 
both clinically and experimentally. Clinically, considering the minimal side effects 
of ALA-PDT repeating the treatment is an used option (93,94). In fact the 
recommended regime for MAL-PDT  in the treatment of BCC and Bowens disease 
is two treatments, one week apart. Even further subsequent treatment sessions 
are often performed (95). Experimentally penetration enhancers have been used to 
enhance a single treatment. (96,97) Other techniques to enhance ALA penetration 
such as iontoforesis (67, 98) and tape stripping (99) have been investigated as well. 
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The effect to the distribution of PpIX of systemic ALA compared to topical has been 
investigated (67,100). However in patients only superﬁ cial necrosis was seen after 
systemic ALA-PDT for dysplasia in mouth and esophagus (101,102).  A number 
of animal studies have demonstrated that the response to PDT after systemic ALA 
administration can be improved by modifying the illumination scheme, for example, 
by reducing the ﬂ uence rate to improve oxygenation (77, 103, 104). Another option 
is the use of light fractionation (105,106). Here the length of the dark interval is an 
important parameter. Short-term light fractionation (with one or more interruptions 
of seconds or minutes) may allow re-oxygenation during the dark interval that leads 
to more singlet oxygen deposition during therapy.(107) We have been carefully 
investigating the use of light fractionated ALA-PDT in different models using different 
fractionation schemes (108-111).In all models an increased effect was seen. In mice 
models more and deeper damage was seen, in a solid tumor model (transplanted 
rhabdomyosarcoma) a signiﬁ cant growth delay was seen after fractionated ALA-PDT. 
Our initial hypothesis was that the kinetics of PpIX re-synthesis was the underlying 
mechanism behind the increased response following light fractionation. However 
we have found the mechanism underlying the response to light fractionation is far 
more complex than we initially adapted. We have shown that the rate of PpIX re-
synthesis after illumination is dependent on the PDT dose delivered (112). There is 
a ﬂ uence dependence for a ﬁ xed ﬂ uence rate; the higher the ﬂ uence the less PpIX 
is synthesized. And a ﬂ uence rate effect, where illumination at low ﬂ uence rate 
results in less re-synthesis for the same ﬂ uence. ( Figure 5 ) Besides the ﬂ uence and 
ﬂ uence rate the application time and  the length of the dark interval (113) have 
been shown to be important. In skin the dark interval should have a signiﬁ cant 
duration. Longer than 30 minutes is necessary to show an increased PDT effect by 
fractionation .Efﬁ cacy increases with the increasing length of the dark interval up to 
2 hours (113). Mostly an application time of 4 hours was used in our experiments 
(like the most used clinical application time of ALA). In our animal work however 
a reduction in overall treatment time was achieved by using a shorter application 
time combined with an accordingly changed ﬂ uence for the different fractions of 
light. The concentration PpIX available at 2 hours is approximately 50% of that at 
4 hours. It is therefore necessary to compensate for the reduced concentration of 
PpIX by increasing the ﬂ uence of the ﬁ rst illumination from 5 to 10 J cm-2 (112). 
The increase in efﬁ cacy using fractionated ALA-PDT is not due to an increasing PpIX 
content (113). There is an optimum of fractionation. In mice two fold ALA-PDT, in 
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which the illuminations are separated by a 2 hours dark interval,  5 + 95 Jcm-2 leads 
to signiﬁ cant more damage than 50 + 50 Jcm-2  which already leads to more damage 
than 100 Jcm-2  in a single illumination. (ﬁ gure 6) The second fraction should be 
substantial larger than the ﬁ rst fraction to achieve a signiﬁ cant increase in PDT 
effect (113).
Figure 5: PpIX ﬂ uorescence kinetics 6h after ALA to normal mouse skin● and during two fold illumination 
scheme 10+90 J cm –2  with a two hours dark interval Δ from DJ Robinson (112)
Figure 6: amount of PpIX that is synthesized during the 2 h dark interval between two lightfractions as a 
function of the ﬂ uence of the ﬁ rst light fraction 4 h after ALA application, DJ Robinson (112)
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In conclusion, the results of our studies show that fractionated PDT results in 
signiﬁ cantly higher responses compared to PDT performed with a single illumination. 
The time interval between ALA application and the ﬁ rst light fraction and its relation 
to the synthesis of PpIX have been shown to be important. Also the inﬂ uence of the 
ﬂ uence (rate) of the individual light fractions and  the time interval between light 
fractions has been shown to be critical. Enhanced PDT response is achieved if two 
light fractions (a small and a substantially larger) are delivered 4 and 6 hours after a 
single application of ALA, separated by a 2 hours dark interval. These results have 
lead us to a ﬁ rst clinical study in sBCC using an illumination scheme 45Jcm-² + 45Jcm-
²  separated by a two hours dark interval. A follow up of mean 59 months (range 
44-82) with a complete response rate of 84% and excellent cosmetic outcome in 
88%.(114) 
AIMS AND OUTLINE OF THIS THESIS
The  purpose of this thesis was to investigate the role of light fractionated ALA-
PDT in non-melanoma skin cancer. Our ﬁ rst aim was to show if the increase in 
effectiveness that has been demonstrated in a range of pre-clinical models and in 
a small pilot study using light fractionated ALA is also a signiﬁ cant effect in non-
melanoma skin cancer. The second aim was to investigate the mechanism behind 
the use of light fractionation in clinical ALA-PDT. The third aim was to establish the 
importance of light fractionation in guidelines  for treating NMSC with ALA-PDT.
The clinical studies will be described ﬁ rst;  we designed a prospective 
randomized clinical study investigating the response of sBCC  to fractionated ALA-
PDT using a 4 hours application time after a single application of 20% ALA topically, 
a small ﬁ rst illumination of 20 J cm-2 followed by a dark interval of 2 hours and a 
second illumination of 80 J cm-2 compared to a single illumination scheme of 75 
J cm-2 . The results will be described in chapter 2. A study investigating the same 
treatment scheme for Bowens disease will be described in chapter 3.
Investigating the mechanism of ALA-PDT we performed PpIX ﬂ uorescence 
studies related to immunohistochemical studies which are described in the following 
chapters. In chapter 4 PpIX ﬂ uorescence in human sBCC is described. In chapter 5 
we describe the results we achieved  investigating the mechanism of cell death 
especially apoptosis in human sBCC. In chapter 6 a comparison of ALA-PDT to MAL-
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PDT in mice using fractionated illumination is described.
Evidence based medicine and guidelines are unmistakably very important 
in dermatology. In chapter 7 the results of an appraisal of the existing clinical 
guidelines in dermato-oncology are described. The results we achieved in Rotterdam 
for sBCC, nBCC, Bowens disease and AK which are described in  chapter 8 should 
have consequences in future guideline development. 
Dermatological oncological care is changing, not only because of the 
development of new treatments as PDT but also due to changed opinions of 
patients and their physicians. The impact of quality of life in treatment decision and 
outcome is the subject of chapter 9. In the general discussion  we critically review 
our achieved  results and place them in perspective to the future.
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ABSTRACT
Photodynamic therapy (PDT) of superﬁ cial basal cell carcinoma (sBCC) using topical 
5-aminolevulinic acid (ALA) and a light ﬂ uence of 75–100 J cm-2 yields unsatisfactory 
long-term results. In several animal models, illumination with two light fractions 2 
hours apart was considerably more effective than single illumination. Response is 
further enhanced if the ﬂ uence of the ﬁ rst light fraction is reduced, although the 
cumulative ﬂ uence is maintained. We compared the response of sBCC to a single 
illumination and 2-fold illumination scheme in which two light fractions of 20 and 
80 J cm-2 are performed 4 and 6 hours after the application of a single dose of 20% 
ALA. We randomly assigned 154 patients with a total of 505 primary sBCC into 
two treatment groups. Two hundred and forty-three lesions were treated using a 
single illumination of 75 J cm-2 at a ﬂ uence rate of 50mWcm-2. Fractionated PDT, at 
the same ﬂ uence rate, was performed on 262 lesions. The complete response (CR) 
following a 2-fold illumination scheme is signiﬁ cantly greater than that following a 
single light fraction (P <0.002, log-rank test). Twelve months after therapy, CR rate 
to a 2-fold illumination is 97%, whereas the CR to a single illumination is 89%.
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INTRODUCTION
Photodynamic therapy (PDT) of superﬁ cial (non-) malignant skin lesions, using topically 
applied 5-aminolevulinic acid (ALA) to endogenously generate the photosensitiser 
protoporphyrin IX (PpIX), was introduced by Kennedy et al. in 1990. Initially, high 
(80–100%) complete response (CR) rates were reported for topical ALA-mediated 
photodynamic therapy (ALA-PDT) in the treatment of superﬁ cial nonmelanoma skin 
cancer (1-5). However, comparing the results of ALA-PDT, a considerable variation in 
CR rates is observed; long-term response rates vary from 30 to 100% (6). To achieve 
higher CR, some investigators have treated lesions more than once (7,8). The success 
of topical ALA-PDT is dependent on several factors. In addition to penetration of 
ALA into the skin(-lesion) and the formation of a therapeutic concentration of PpIX, 
CR depends signiﬁ cantly on tumor thickness and duration of ALA application (9). 
Curettage before topical ALA-PDT may signiﬁ cantly improve CR rates, in particular 
for nodular basal cell carcinoma (10,11). In an attempt to increase the effectiveness 
of ALA-PDT, modiﬁ ed prodrugs of ALA have also been used such as a methyl 
aminolevulinate (MAL) and other esters (12-14). Although no comparative study 
has been performed to compare the clinical response using ALA and MAL, clinical 
studies published using MAL-PDT also show a variation in response rate. Horn et 
al. (15) reported a recurrence rate of 18% in a study of 94  basal cell carcinomas 
that were treated with MAL-PDT (two treatments a week apart, follow up (FU) 24 
months. Soler et al. (16) reported the treatment of 350 curettaged nodular basal 
cell carcinoma and superﬁ cial basal cell carcinoma (sBCC) using MAL-PDT in two 
sessions with a CR of 79% (FU 22–24 months). The approved scheme of MAL-PDT 
in Europe consists of two treatments a week apart. Rhodes et al. (17) performed a 
comparative study using MAL-PDT versus surgery for nodular basal cell carcinomas, 
achieving 10% recurrence rate in the MAL-PDT group versus 2% recurrence rate in 
the surgery group. Recently, Van Iersel et al. (18) reported their results after primary 
surgery for a basal cell carcinoma being a 5-year cumulative risk of only 2.1%. These 
studies support the need to improve the response of sBCC to both MAL and ALA-
PDT. We have performed series of pre-clinical studies investigating the effects of 
fractionating the illumination in PDT in a variety of model systems (19-24). We have 
shown increased efﬁ cacy of ALA-PDT using fractionated illumination with relatively 
long dark intervals between two light fractions (19). For topical administration, we 
have shown that a 2-hours dark interval is necessary to achieve a signiﬁ cant increase 
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in response. We have shown that choice of ﬂ uence (rate) for the ﬁ rst light fraction is 
critical, and that a high ﬂ uence for the second light fraction is necessary for maximal 
tissue response (23). Our ﬁ rst clinical pilot study using fractionated ALA-PDT using 
two equal light fractions of 45 J cm-2 with a 2-hours dark interval resulted in a CR 
rate of 84% (mean FU 59 months; range 44–82 months, n=67) (25). This was an 
encouraging result, but we were unable to show a statistically signiﬁ cant increase in 
response compared to a single illumination. This is probably owing to the choice of 
a non-optimized illumination scheme and the small number of lesions treated. Here, 
we report on a randomized  comparative prospective open clinical study between 
a standard ALA-PDT treatment scheme using a ﬂ uence of 75 J cm-2, 4 hours after 
the administration of ALA and a 2-fold illumination using 20+ 80 J cm-2, delivered 
4 and 6 hours after the administration of ALA. We also investigated the kinetics of 
PpIX ﬂ uorescence during the 2-fold illumination scheme and their relation to the 
mechanism of response.
MATERIALS AND METHODS
Patients
All patients were diagnosed as having an sBCC within the Erasmus MC in Rotterdam. 
ALA-PDT was performed according to two treatment protocols, described in detail 
below, approved by the local ethics committee, according to the Declaration of 
Helsinki Principles. All patients gave informed consent.  Diagnosis was determined 
histologically (4mm punch biopsy) and clinically in approximately equal proportions 
within each treatment group. Every patient had at least one histologically diagnosed 
primary sBCC. Our patient population consists of both ﬁ rst-line and secondary 
dermatological care. All patients are adult Caucasians. We treated 100 patients who 
had in total 243 lesions, using a single illumination scheme. Fifty-ﬁ ve patients with 
a total of 262 lesions were treated using a 2-fold illumination scheme, described 
below. Both groups were in the same age range; in the group that received a single 
fraction, the mean age was 57 years (minimum 32, maximum 81, median 57), 
and in the 2-fold illumination group, the mean age was 56 years (minimum 31, 
maximum 83, median 56). Also, both treatment groups included a similar number 
of higher risk patients as shown in Table A .
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Table A: High risk patients.
75 Jcm-2 20+80 J cm-2
Patient group patients lesions patients lesions
Immune compromised 7 7 2 6
Previous Radiotherapy 8 33 5 20
Goltz Gorlin syndrome 5 46 4 17
High sun exposure 2 16 2 28
Topical arsenic use - - 1 9
Immune compromised: HIV positive, organ recipient or using immuno-suppressive drugs 
High sun exposure: patients who have lived more than 15 years in tropical countries and had Fitzpatrick 
skin type 1.
ALA application and local  anesthesia 
A topical ALA ointment we used was prepared by our Hospital Pharmacy using 
20% ALA (FLUKA, The Netherlands) in Instilagel (Medeco BV, Oud Beijerland, The 
Netherlands). Instilagel was used as vehicle because it contains lidocaine (2%), 
which is considered a possible advantage in pain management (26). The ointment 
was freshly prepared and stored in a refrigerator and used within 3 days. Before 
application of ALA, crusts and scaling were gently removed using a disposable curette. 
The lesion was covered with a margin of 1 cm and dressed with a semipermeable 
dressing (Tegaderm 3M, The Netherlands) and light-protecting covering (aluminium 
foil). Patients were instructed to stay out of the cold because of the negative effect 
of low temperatures on ALA metabolism (27). In addition to the topical anesthetic in 
the ALA ointment, patients received  paracetamol, lidocaine (without epinephrine), 
or bupivacaine, if required.
Light sources and illumination scheme
Three light sources were used in this study. A 630nm diode laser (Carl Zeiss, 
Oberkochen, Germany) was used to provide 630nm illumination. Light was coupled 
into a 600 μm optical ﬁ ber and projected onto the lesion using a combination of 
lenses to assure a uniform ﬂ uence rate across the beam diameter. Two commercially 
available broadband light sources were also used. The ﬁ rst had a spectral output 
between 590 and 650nm (Medeikonos, Gothenburg, Sweden). The second was a 
light-emitting diode, light source with a spectral output centered on 633nm with 
a bandwidth of 20nm (Omnilux, Waldmann, Tiel, The Netherlands). All three light 
sources were used to illuminate lesions with a margin of at least 5mm at a constant 
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measured ﬂ uence rate of 50mWcm-2. It was necessary to shield areas outside this 
margin for both broadband light sources. In the single illumination group, lesions 
were illuminated 4 hours after the application of ALA to a ﬂ uence of 75 J cm-2. In 
the 2-fold illumination group, lesions received light fractions of 20 and 80 J cm-2, 4 
and 6 hours after the application of ALA. ALA was applied once. Again, both light 
fractions were delivered at a ﬂ uence rate of 50mWcm-2. During the 2-h dark interval 
between light fractions, lesions were covered with light-protective bandage. Table 
B shows the number of lesions treated with each light sources in each illumination 
group.
Table B: CR of lesions treated with each light source in each illumination group
75 Jcm-2 20+80 Jcm-2
Light source n CR (%) n CR (%) P-value
Diode laser (630nm) 160 91 42 98 0.236
LED Omnilux (633nm) 21 85 152 97 0.347
Medeikones (590-650nm) 62 89 68 97 0.093
total 243 89 262 97 0.002
Fluorescence measurements PpIX ﬂ uorescence measurements were acquired from 
a subgroup of 17 lesions in the 2-fold illumination group to investigate the kinetics 
of PpIX ﬂ uorescence during therapy. In this subgroup, PDT was performed using the 
diode laser. Data were acquired before ALA application, immediately before and after 
the ﬁ rst illumination and immediately before the second illumination. Measurements 
were performed with a custom applicator attached to a ﬂ uorescenceimaging 
camera (TRICAM, Storz, Tuttlingen, Germany). A uniform excitation light ﬁ eld (400–
450 nm) was obtained from a ring of ﬁ ltered blue light-emitting diodes mounted 
around the camera. Fluorescence emission from PpIX was collected over a period 
of 0.25 seconds. Scattered excitation light was blocked using a longpass ﬁ lter 
(Schott KV 500). Fluorescence emission from PpIX (600–710 nm) was collected over 
a period of 0.25 seconds. Images acquired at different time points are registered 
under translation and rotation using landmarks in the skin surrounding the lesion 
(e.g. hair follicles). Typically, a rectangular area of 4-6 cm is imaged. Within this 
area, a circular region of interest approximately 0.25cm in diameter is deﬁ ned and 
the average pixel intensity was used as a measure of the ﬂ uorescence intensity 
from an individual lesion. Measurements on a sheet of white plastic were used as 
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a reference to correct the ﬂ uorescence measurements of BCC for any changes in 
the output of the excitation light source or the sensitivity of the detection system. 
Autoﬂ uorescence was measured before each ALA application and was subtracted 
from the PpIX ﬂ uorescence intensity acquired before and after each illumination. 
Response and Follow up 
We deﬁ ned CR as the absence of clinical visual basal cell carcinoma. All patients 
treated in our department are seen for FU according to the national dermatological 
guidelines of the Netherlands (NVDV). In the ﬁ rst year after treatment, FU was 
performed four times a year, thereafter twice yearly. Patients with a propensity of 
developing numerous skin lesions were seen more frequently in an individualized 
scheme. FU ends 5 years past the last treated basal cell carcinoma. Some of the 
patients are referred to us by peripheral primary dermatologists and are treated 
as secondary dermatological care patients and then referred back to their primary 
dermatologist for further FU. We only considered FU performed by our staff members 
and residents within our University hospital. A minimal FU of 12 months is necessary 
for inclusion in the study. In the single illumination group, FU varied from 12 to 41 
months, mean 21 months. In the 2-fold illumination group, FU varied between 
12 and 32 months, mean 17 months. Lesions that did not respond to therapy or 
recurred in the ﬁ rst 12 months after treatment were included in the data analysis 
as NR or recurrence. Cosmetic outcome was not the primary goal of the study, but 
remarks of patients and dermatologist were asked for and noted. The patient and 
dermatologist judged cosmetic outcome to be either good, fair, or poor.
Statistical analysis
Kaplan–Meier analysis was performed on relative CR rates after therapy and the log-
rank test was used to compare the signiﬁ cance of differences between treatment 
groups. The primary and overall response rates of lesions treated with different 
illumination schemes were compared using Fisher’s exact test. Differences in 
ﬂ uorescence intensity were compared using Student’s t-test. P<0.05 was considered 
statistically signiﬁ cant. 
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RESULTS
A 2-fold illumination scheme of 20+80 J cm-2 with a 2-hours dark interval results 
in a signiﬁ cantly better clinical response to ALA-PDT over a single light fraction 
The relative CR of lesions to ALA-PDT using a single light fraction and a 2-fold 
illumination scheme is shown in Figure 1.
Figure 1: Kaplan-Meier curves for disease-free rates for relative complete response of superﬁ cial basal cell 
carcinoma using a single light fraction of 75 J cm-2, 4 hours after the application of ALA ( ― -- ― --) and a two-
fold illumination scheme of 20 + 80 J cm-2 4 and 6 hours after the application of ALA. (———).
The CR using a 2-fold illumination is signiﬁ cantly greater than that following a single 
light fraction (P<0.002, log-rank test). Twelve months after therapy, the relative CR 
in the 2-fold illumination group is 97%, whereas the corresponding CR in the single 
illumination group is 89%. Of the 243 lesions in the single illumination group, 32 
lesions failed to respond or recurred during the FU period. Of these lesions, 10 
lesions were retreated with ALA-PDT, with ﬁ ve lesions receiving a second single 
illumination and ﬁ ve were retreated using a 2-fold illuminated scheme; all resulted 
in CR (minimum FU 12 months). These lesions were not included as responders 
in our statistical analysis of CR. The remaining 22 lesions were surgically excised 
and consisted 17 nodular, one micro-nodular, two morphemic, and two sBCC. 
Only 10 of the 262 lesions in the 2-fold illumination group did not show CR. Five 
lesions were excised and found to be nodular (n=3) or morphemic (n=2) basal cell 
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carcinomas and ﬁ ve were retreated with 2-fold illumination ALA-PDT and responded 
(FU 7, 8, 11, 14, and 16 months without recurrence). These were included as non-
responders, although after a second treatment CR was seen. A sub-group analysis 
in which only histologically proven sBCCs are included shows a similar pattern of CR 
between the single- and 2-fold illumination groups. Twelve months after therapy, 
the relative CR in the 2-fold illumination group is 98%, whereas the corresponding 
CR in the single illumination group is 85% (P<0.0003, log-rank test). PDT was well 
tolerated in both illumination groups, and all patients completed therapy. A minority 
of patients (14%) required pain relief in addition to 2% lidocaine already present in 
the ALA ointment. The majority of patients, 133 out of 154 (86%), did not require 
additional pain relief during or after the therapeutic illumination. The details of 
patients who required pain medication are shown in Table 1 (see below). 
A greater number of patients required pain relief in the 2-fold illumination group 
than in the single illumination group. In the single illumination group, ﬁ ve patients 
required pain relief for six of 32 treated lesions. In the 2-fold illumination group, 15 
patients required pain relief for 44 of 64 treated lesions. There was no consistent 
difference in pain during each of the 2-fold light fractions, although in general 
patients reported more pain during the ﬁ rst illumination. Pain resolved quickly 
during the dark interval. Our pre-clinical  animal data suggested that the acute 
response to therapy might be more severe in the 2-fold illumination group. In the 
2-fold illumination, crusts formed following therapy in 15 lesions in six patients. In 
the single illumination group, crusts were seen in two lesions in two patients.
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Table 1: painmanagement  (cosmetic outcome in these lesions good)
Paracetamol patient single lesions Localization Two fold lesions Localization remarks
A x 4 trunk 4 out of 7 were painfull, all 
6 in single not, pain during 
one treatment day, other 
days not, all lesions on trunk
B x 1 vertex Taken after illumination
C 4 face, trunk x 2 face Taken in dark interval
D 5 arm x 2 arm, face Taken in dark interval
E 2 trunk x 7 arm 3, 
trunk 3,
leg 1, 
Taken in dark interval
F 15 face 2
trunk 10
arm 3
19 trunk 13
arm 6
Not used but at end of day 
tired and little pain in two 
fold treated lesions
G x 1 face 1 face
H x 2 face Complaint afterwards, 
responded no pain at 
treatment time
I x 4 Leg Taken in dark interval
J x 4 trunk 2
leg 2
Taken in dark interval (2)
Taken in advance(2)
lidocain K x 1 face Pre second fraction
L x 1 face Pre second fraction, crusts+
M x 4 face 1
arm 2
trunk 1
Pre second fraction, 
rheumatic patient
N x 1 arm
O x 2 trunk Pre second illumination
P x 2 face During illumination
bupivacain Q x 1 vertex Block, pre ﬁ rst fraction
R x 4 face Block pre ﬁ rst fraction and 
local during ﬁ rst fraction
S x 1 face During illumination
T x 1 vertex Block pre ﬁ rst fraction, still 
painfull in second fraction
U x 2 arm During ﬁ rst illumination
total 21 5 32 15 61
Despite crust formation, cosmetic outcome was good in all lesions. The relationship 
between acute response and the need for pain relief is shown in Table 1. One patient 
showed a pustular skin reaction in 11 of 16 lesions, which lasted 5 days. This was 
cultured and proven to be nonbacterial. A small number (19) showed persistent 
hypopigmentation at the illumination site 1 year after therapy. There was no signiﬁ cant 
difference in  response rates for the different light sources used. The response rate 
following a 2-fold illumination scheme was greater for each light source. We found 
no statistically signiﬁ cant difference between the response rates for the different 
light sources within each illumination group. A comparison of the response of lesions 
to a single- and a 2-fold illumination scheme for each individual light source is shown 
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in Table B (see above in materials and methods).The kinetics of PpIX ﬂ uorescence 
were in accordance with that found in pre-clinical animal models. Figure 2 shows 
the mean ﬂ uorescence intensity present before and after the ﬁ rst light fraction of 20 
J cm-2 and 2 hours later, immediately before the second light fraction.
Figure 2: The kinetics of PpIX ﬂ uorescence intensity in sBCC during ALA-PDT with a two-fold illumination 
scheme (a). The relative PpIX photobleaching during therapy with 20 J cm-2 and the re-synthesis during the 
dark interval between light fractions (n =17 lesions), (b)
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The PpIX ﬂ uorescence before the ﬁ rst light fraction varied considerably, between 
the lesions of each patient as well as between patients. When the ﬂ uorescence 
of all lesions is normalized to 100%, the mean ﬂ uorescence after the illumination 
is 47% and rises to 69% before the second illumination. There was considerable 
variation in PpIX ﬂ uorescence between lesions and between patients. Likewise, 
photobleaching varied widely, despite ﬁ xed illumination parameters. The average 
extent of photobleaching of 47% during the ﬁ rst light fraction is similar to that we 
have found in our pre-clinical studies. The amount of re-synthesis during the dark 
interval and the total amount of PpIX utilized in a single illumination compared to 
that in a 2-fold illumination scheme is also consistent to that we have seen in our 
pre-clinical studies (23). 
DISCUSSION
We have demonstrated that a statistically signiﬁ cant improvement in CR rate can be 
achieved using a light fractionation scheme with a 2-hours dark interval between 
light fractions of 20 and 80 J cm-2 compared to a single light fraction (97% versus 
89% CR, 12 months FU, P<0.002, log-rank test). The lower response rate found 
with a single light fraction (89%) is similar to our previous results (4) and is consistent 
with the other investigators who have performed ALA-PDT in a single treatment 
session. Our choice of 2-fold illumination scheme is based on data from a range of 
pre-clinical animal studies that showed that following light illumination, tissues 
continue to synthesize PpIX. Apparently, the heme synthesis cycle is still (partly) 
intact and there is still ALA available to be converted into PpIX. PpIX ﬂ uorescence 
has been observed after PDT with both systemic ALA and topical ALA (19-22,28,29). 
However, these pre-clinical studies also demonstrate the  complexity of the response 
of tissues to ALA-PDT and highlight the challenge for optimization (23). It is not 
simply a matter of performing a second illumination at some arbitrary time point 
after a standard single illumination. The time interval between light fractions is a 
very important consideration. A 2-hour time interval is necessary to yield a signiﬁ cant 
increase in response. Also, the ﬂ uence delivered in the ﬁ rst light fraction has a 
dramatic impact on the response to a 2-fold illumination. Although the response to 
a light  fractionation scheme of 50+50 J cm –2 with a 2-hours dark interval is greater 
than a single illumination of 100 J cm–2 , the increase is not statistically signiﬁ cant. 
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Reducing the ﬂ uence of the ﬁ rst light fraction to 5 Jcm–2 and delivering a large 
ﬂ uence in the second (95 J cm–2 ) signiﬁ cantly increases the effectiveness of PDT. In 
fact, this represents the most effective illumination scheme that we have yet devised. 
A similar pattern of response to light fractionation seems evident in clinical ALA-PDT 
of sBCC. In a clinical pilot study treating sBCC with two equal light fractions of 
45+45 J cm–2 , separated by a 2-hours dark interval, we have shown an increase in 
long-term CR over that reported by other investigators (25). We were, however, not 
able to show a statistically signiﬁ cant improvement in CR at 12 months over a single 
illumination of 75 J cm–2 . This study shows that reducing the ﬂ uence of the ﬁ rst light 
fraction to 20 J cm–2 and maintaining that of the second light fraction to deliver a 
cumulative ﬂ uence of 100 J cm–2  results in a signiﬁ cant improvement in CR rate, just 
as predicted by our pre-clinical animal studies. We note that one other factor 
inﬂ uenced the design of the clinical illumination scheme. sBCCs are in general more 
pigmented and signiﬁ cantly thicker than normal mouse epidermis. A higher light 
ﬂ uence of 20 J cm–2  was used, instead of the 5 J cm–2 that found to be optimal in 
our animal study, to ensure the deposition of sufﬁ cient ﬂ uence at the base of each 
lesion. The cumulative ﬂ uence in each of the illumination groups is not equal. A 
ﬂ uence of 75 J cm–2  was delivered in a single light fraction compared to 100 J cm–2  
in the 2-fold illumination scheme. This is a direct consequence of our intention to 
deliver a large ﬂ uence in the second light fraction (23). The inﬂ uence of this additional 
cumulative ﬂ uence on the clinical response we observe is an important issue. A 
number of pre-clinical studies have shown that photobleaching of the PpIX limits 
the PDT dose that can be delivered in a single light fraction at ﬁ xed ﬂ uence rate (30). 
We have shown in normal mouse skin that 100 J cm–2  does not result in signiﬁ cantly 
more damage than 50 J cm–2 . The relationship between response to ALA-PDT and 
ﬂ uence has not been systematically investigated in the clinic. Only Oseroff (31) has 
emphasized the importance of light ﬂ uence in the treatment of sBCC by topical 
ALA-PDT, and this regards the delivery of very high light ﬂ uences at high ﬂ uence 
rate. He reported that a CR rate of 95% after 200 J cm–2 (at a ﬂ uence rate of 
150mWcm–2 ) fell to 70% after 150 J cm–2 . Most other investigators have applied 
both lower light ﬂ uence (rate) and cumulative ﬂ uences both below 75 J cm–2 and 
above 100 J cm–2 , with little evidence for a correlation between ﬂ uence and 
response. Large variations occur in our ﬂ uorescence data. Several factors may be 
involved here, such as variations in tissue optical properties, in oxygenation, and in 
heterogenity of the PpIX distribution in the lesions (32). The variations in ALA-
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induced sBCC ﬂ uorescence reported by af Klinteberg et al. (29) seem somewhat 
less, but these authors only report standard errors. Golub et al. (33) also measured 
large variations in ALA-induced ﬂ uorescence on normal human skin and psoriasis 
and actinic keratosis lesions. Such variability is widely observed in ALA-induced 
ﬂ uorescence of normal human skin and skin lesions (25,34,35,36). Accepting the 
large variations that seem to be a feature of clinical ﬂ uorescence measurements, we 
do see a similar trend in the kinetics of PpIX ﬂ uorescence after illumination with 20 
J cm–2 . Importantly, we note that the original rationale for performing a 2-fold 
illumination scheme was to utilize additional PpIX that continued to be synthesized 
after PDT with a single light fraction. Our recent clinical data (25) and pre-clinical 
data (23) do not  support the hypothesis that signiﬁ cantly more PpIX is utilized in the 
2-fold illumination scheme, as 50+50 and 5+95 J cm–2 result in approximately the 
same amount of cumulative PpIX photobleaching (P<0.12, Student’s t-test). The 
spectral output of the light sources used in this study may have inﬂ uenced the 
response to a 2-fold illumination scheme. Our pre-clinical studies have shown that 
the response of tissues to PDT using the 2-fold illumination scheme is quite sensitive 
to the small differences in ﬂ uence and ﬂ uence rate of the ﬁ rst light fraction. Some 
investigators have suggested that there may be differences in response to PDT with 
(a) light sources that deliver a lower effective ﬂ uence rate by virtue of the overlap of 
their spectral output with the absorption spectrum of PpIX (37) and (b) light sources 
that additionally excite the ﬂ uorescent photoproducts of PpIX (38). The fact that we 
did not see differences in response between light sources suggests that these effects 
are small and do not impact signiﬁ cantly on the effective dose  of the ﬁ rst light 
fraction. This means that the current ﬂ uence and dark interval ﬁ ndings in the current 
study are also applicable for the large proportion of investigators that use 
commercially available non-laser light sources. Our data stratiﬁ ed by light source 
(Table B) show that there is approximately the same increase in response of all the 
light sources investigated. We expect that statistical signiﬁ cance would be achieved 
if larger numbers of lesions were investigated. During the whole FU period, a 
signiﬁ cantly greater number of recurrent or non-responding lesions was observed in 
the single illumination group; 32/243 (13%) compared to the 2-fold illumination 
group 10/262 (4%) (P<0.0002, Fisher’s exact test). Of the 32 lesions that did not 
show CR in the single illumination group, 20 were found not to be sBCC: nodular 
(18); micro-nodular (1); and morphemic (2) at recurrence. Of the 10 lesions that did 
not show CR in the 2-fold illumination group, ﬁ ve were found not to be sBCC at 
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recurrence, but nodular (3) and morphemic (2). The presence of nodular lesions in 
these data was not  unexpected as diagnosis was based on clinical appearance for 
a signiﬁ cant proportion of lesions. Fifty-four percent and 49% of lesions were 
diagnosed clinically in the single- and 2-fold illumination group, respectively. Clinical 
diagnostic accuracy in a dermatology university faculty has been shown to be 
approximately 70% for BCC (39). If a similar accuracy were assumed in this study, 
we would expect to see 38 and 35 nodular lesions in our single- and 2-fold 
illumination groups, respectively. Three recurrent or non-responding nodular BCC’s 
in the 2-fold illumination group represents a signiﬁ cantly lower number than 
expected (P<0.0003, Fisher’s exact test). Although it was not out primary intention 
to treat nodular lesions, we have  previously shown that the 2-fold illumination 
leads to deeper histological damage in pre-clinical models (21,23). Determining the 
maximum depth of BCC that can be treated with ALA-PDT is clearly an area for 
future study. The increased severity of the acute response following therapy shows 
a similar pattern to the increase in damage induced in our pre-clinical animal studies. 
This and the fact that we see an accompanying increase in CR after 12 months FU 
provides encouraging evidence for the value of PDT optimization in pre-clinical 
animal studies. In our animal studies, the increase in the effectiveness of the 2-fold 
illumination scheme leads to scarring in some cases. Although the clinical acute 
response is greater than a single illumination, the cosmetic outcome remains good 
in 90% of the lesions. We are also encouraged by the fact that patients did not 
experience signiﬁ cantly more pain during the 2-fold illumination scheme. A central 
aim of the current study was to achieve an optimal response to PDT in a single 
treatment session (i.e. with a single application of ALA). We note that repeating 
such an optimalized treatment regimen on subsequent treatment days may lead to 
an even higher CR rate in sBCC and/or a higher CR rate for other skin lesions. In 
conclusion, we have demonstrated a signiﬁ cant increase in the CR rate of sBCC to 
ALA-PDT using an illumination scheme in which two light fractions of 20 and 80 J 
cm–2 are delivered 4 and 6 hours after the application of ALA  compared to a single 
illumination scheme of 75 J cm–2 .Further FU is now necessary to determine if this 
high CR rate is maintained. We note that the value of these results may extend 
beyond the skin, into other organs such as the esophagus and brain, where ALA-
PDT is under investigation as a treatment modality (40,41). 
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ABSTRACT
Objectives: To determine the response of Bowens disease (squamous cell carcinoma 
in-situ) to topical PDT using aminolevulinic acid using a single and a two-fold 
illumination.
Design: An open randomised pilot study.
Setting: A University Hospital in the Netherlands.
Patients and Patches: Forty patients were enrolled in this study with a total of 50 
patches of Bowens disease. Twenty-ﬁ ve patches were randomly assigned to each 
illumination scheme group.
Interventions: Aminolevulinic acid 20% in Instilagel® was applied topically for a 
period of 4 hours. One group was illuminated with a single light fraction of 75 
J cm-2. The second group was illuminated with a two fold illumination scheme 
consisting of 20 J cm-2 and 80 J cm-2 separated by a 2 hours dark interval. The 
ﬂ uence rate for each light fraction was 50 mW cm-2.
Main outcome measures: Complete response after a minimum follow up of 12 
months. Healing time, adverse events and cosmetic outcome were determined as 
secondary outcome measures.
Results: Complete response rates to a single and two-fold illumination scheme, 12 
months after therapy, were found to be 80% and 88% respectively. The combined 
average complete response rate in all patches was 84% after 12 months and 80% 
for a mean and median follow up of 24 months. Healing time in PDT treated areas 
was less than three weeks. Cosmetic outcome was good to excellent in all but 2 
patches of Bowens disease, which were treated with two-fold illumination, due to 
persistent hyperpigmentation at 12 months.
Conclusion: Bowens disease can be successfully treated using ALA-PDT in a single 
treatment session and we found an increased response of Bowen’s patches to PDT 
using a two-fold illumination scheme. This indicates the potential for a larger, higher 
powered study to determine if this effect is statistically signiﬁ cant.
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INTRODUCTION
The use of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for the treatment 
of Bowens disease (squamous cell carcinoma in-situ) is gaining acceptance (1). 
However there is rather limited evidence for the most appropriate treatment regime 
and clinical follow up remains short. The treatment of ﬁ rst choice for Bowens 
disease is surgery. Five year response rates were recently published by the Australian 
skin cancer foundation and showed a recurrence rate of 19.0% after conventional 
surgery and 6.3 % after Mohs’ micrographic surgery (2). In a comparative study 
investigating the response of Bowen’s to ALA-PDT or cryotherapy, results were 
signiﬁ cantly in favour of PDT (3). In a comparative study of ALA-PDT versus topical 
5-ﬂ uouracil recurrence rates at 12 months were 7% following PDT compared to 
27% for 5-ﬂ uouracil (4). In a recent review of the literature Morton found 11 PDT 
studies using broadly similar protocols in which a response rate was found to be 
between 90 and 100% after 1 to 3 treatment sessions (5). An average recurrence 
rate of 12% was calculated from these studies. Importantly however the follow 
up period for these studies varied widely, between 3 and 36 months. Also in many 
cases therapy was repeated. Over the past decade we have been investigating the 
role of light fractionation in the response of tissues to ALA-PDT and in particular the 
enhanced response that can be achieved using ALA-PDT with long dark intervals. 
Several animal studies (6-9) have shown that a signiﬁ cant increase in response 
can be achieved with a small and large fraction separated by a dark interval of 
the order of 1 – 2 h between light fractions. While the speciﬁ c light treatment 
parameters of each fraction are important for the optimisation of response (10) we 
have shown in a clinical pilot study that light fractionation increases the long-term 
response of superﬁ cial basal cell carcinoma (sBCC) to ALA-PDT (11). Most recently 
in a randomised comparative study of the response of sBCC to ALA-PDT we have 
shown a signiﬁ cantly higher complete response rate at one year (P=0.002, n=505) 
using a two fold illumination scheme (20 + 80 J cm-2) with a two hours dark interval 
compared to a single illumination (12). In the light of these pre-clinical and clinical 
studies we have investigated the response of Bowens disease to ALA-PDT and the 
effect of fractionated illumination (20 + 80 J cm-2) using a two-hours dark interval 
compared to a single illumination.
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METHODS
Study design
Fifty patches of Bowens disease were identiﬁ ed and randomly assigned into two 
equal treatment groups that recieved a single or two-fold illumination as described 
below.
Patients
The ethics committee of the Erasmus University Medical Centre granted approval 
for the study. Forty patients were recruited sequentially, on the basis of written 
informed consent, from those attending the department. The group consisted of 17 
males and 23 females, 4 patients were organ recipients (1 liver, 1 heart, 2 kidney). 
The youngest was 49 years old, the oldest 91 years, mean age 74 years.
Bowen’s patches
All patches were biopsy proven Bowens disease. Diagnosis was determined 
independently both by a pathologist and a dermatologist. The locations of the 
Bowen’s patches are shown in table 1. The diameter of the patches ranged from 5 
to 40 mm (mean 14.5 mm) and was more than 10 mm in 34 lesions and less than 
10 mm in 16 lesions. The mean diameter of the patches in each illumination group 
was 13.4 and 15.6 mm respectively. 
Table 1: Locations of Bowen’s patches
Number of lesions 75 J cm-2 20 + 80 J cm-2
Hand 8 3 5
Arm 1 1
Face
     Check / nose 3 1 2
     Eyelid 2 1 1
     Ear 7 5 2
     Frontal/temporal 1 1
Scalp 1 1
Upper leg 4 1 3
Lower leg 11 5 6
Trunk 12 8 4
Total 50 25 25
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ALA application and lesion preparation 
Topical ALA ointment was prepared by our University Pharmacy using 20 % 
aminolevulinic acid (FLUKA, The Netherlands) in Instilagel® (Medeco B.V. The 
Netherlands). The ointment was freshly prepared and stored in a refrigerator and 
used within 7 days. Instilagel® contains 20.9mg/ml of Lidocaine hydrochloride, and 
hydroxyethylcelluIose water and a number of preservatives. This ointment was used 
in our earlier work and has been shown to be stable by our Pharmacy. Surface scale 
or crusts were gently removed. ALA ointment was applied for a period of 4 hours, 
with a margin of 1 cm around each patch. Patches were covered with a semi-
permeable dressing (Tegaderm®, 3M) and a light protecting Aluminium foil between 
ALA administration and therapy.
Anaesthesia 
We administered local anaesthesia (Lidocaine 2% without epinephrine) using a 
ﬁ eld-block technique only if patients required it. 
Illumination schemes 
The fractionated illumination scheme used in the present pilot study is based on an 
optimised scheme determined in pre-clinical models (6-10) and validated for the 
treatment of sBCC (11,12). Four hours after the application of ALA patches in the 
single illumination group were illuminated with a ﬂ uence of 75 J cm-2, at a ﬂ uence 
rate of 50 mW cm-2. In the two-fold illumination group patches were illuminated 4 
and 6 hours after the application of ALA with ﬂ uences of 20 J cm-2 and 80 J cm-2 
separated by a dark interval of 2 hours. Light in each fraction was delivered at a 
ﬂ uence rate of  50 mWcm-2 ALA was administered once. In the dark interval patches 
were covered with a semi-permeable and light protective dressing (Tegaderm® and 
Aluminium foil). 
Light sources  
We have previously shown in sBCC that the light source does not signiﬁ cantly effect 
the response to ALA-PDT using light fractionation (12). Therefore two light sources 
were used in this study. A diode laser (Carl Zeiss, Oberkochen, Germany) was used 
to provide 630nm illumination and an LED light source (Omnilux®, Waldmann, Tiel, 
The Netherlands) with a spectral output centred on 633 nm with a bandwidth of 
20 nm. Light from the laser was coupled into a 600 μm optical ﬁ bre and projected 
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onto the patch using a combination of lenses to assure a uniform ﬂ uence rate across 
the beam diameter. Patches were illuminated with a 5 mm margin. The diode laser 
was used to illuminate 16 patches the remaining 34 used the LED light source. A fan 
and/or wet gauze was used to cool the area of skin surrounding the lesion during 
the illumination.
Follow up and clearance rate 
Patients were reviewed initially after 4 weeks and then at 3 monthly intervals. 
Response was classiﬁ ed as complete response being no clinical evidence of disease, 
with macroscopically normal skin at the treated site. Patches that responded partially 
were considered to be non-responders.
Adverse events, healing time and cosmetic outcome
No serious adverse effects were seen. All patients suffered a degree of discomfort 
during treatment but all ﬁ nished the therapy. At ﬁ rst follow up patients were asked 
the time it took for the patches to heal. Healing was also assessed at the ﬁ rst follow 
up visit. Cosmetic outcome was scored good, fair or poor both by the dermatologist 
as the patient at 12 months.
Statistical Analysis 
The primary response and recurrence rates of patients treated with different 
illumination schemes were compared using Fisher exact test. Kaplan-Meier analysis 
was performed on relative complete response rates after therapy and the log-rank 
test was used to compare them between treatment groups. P < 0.05 was considered 
statistically signiﬁ cant.
RESULTS
RESPONSE
The relative complete response rate of patches treated in this study is shown in 
ﬁ gure 1: 
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Figure 1: Kaplan-Meier curves for disease-free rates for relative complete response of Bowens disease 
following ALA-PDT using a single light fraction of 75 J cm-2, 4 hours after the application of ALA(―---―--
), a two-fold illumination scheme of 20 + 80 J cm-2 4 and 6 hours after the application of ALA. (----------), 
(n=25 in each group). The combined disease-free rate for all Bowen’s patches (⎯⎯⎯), (n=50); tick marks 
show maximum lesion follow up, the number of lesions remaining at the end of the period shown is 14/50. 
Statistical signiﬁ cance between illumination schemes is tested for one-year follow up (P=0.408 log rank 
test).
In the single illumination group a complete response was achieved in 20 patches (80%) 
at 12 months. Recurrent Bowen’s patches were excised in two cases (after a FU of 7 
and 12 months, histology showed Bowen’s). Four recurrent patches were retreated 
with PDT and responded. In the two-fold illumination group complete response was 
recorded in 22 patches (88%) at 12 months. Three recurrent patches were retreated 
with PDT and have resulted in complete response to date. One recurrent patch 
on the face was excised after 24 months, histology showed Bowens disease that 
extended deep into the hair follicles. In each treatment group re-treated patches are 
not included in responders group. We found a better response of patches treated in 
the two-fold illumination group compared to the single illumination group, 88% vs 
80%, but this increase in response did not reach statistically signiﬁ cance (p=0.408 
log rank test). Pooling the data from each illumination group the average CR in all 
patches was 84% at one year follow up. The progression of clinical response of 
all lesions in time after 12 months is shown in ﬁ gure 1 (see above). Patches with 
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follow up between 12 and 28 months are shown as ticks in the Kaplan–Meier curve. 
Overall the complete response is 80% with a mean and median follow up of 24 
months. Recurrent patches were located on the leg (2), face (3), trunk (3) and arm 
(2). The diameter of patches that recurred varied from 5 to 23 mm, with an average 
diameter of 12 mm. While the numbers of recurrent patches is small, recurrence to 
PDT does not seem to be related to location or size.
Pain and discomfort 
In the single illumination group none of the patients complained of pain during 
therapy. In the two fold illumination group 5 patients complained about pain in the 
treatment of 6 patches. Lidocaine without epinephrine was used in 4 patches. While 
all patients suffered some degree of discomfort all completed therapy. 
Healing time 
At the ﬁ rst follow up visit all patches were completely healed, patients reported that 
all patches healed completely within 3 weeks after therapy. 
Cosmetic outcome 
The cosmetic outcome in both groups was good, determined both by dermatologist 
and patient. In 2 patches in the two-fold illumination group the cosmetic outcome 
was scored to be fair due to persistent hyper-pigmentation at 12 months.
COMMENTS
Response 
We studied the response of Bowens disease to ALA-PDT using two different 
illumination schemes, with a minimum follow up of one year. PDT in a single light 
fraction of 75 J cm-2 resulted in a complete response rate of 80%. Fractionated 
illumination in which two light ﬂ uences (20 + 80 J cm-2) are delivered separated by 
a two-hours dark interval resulted a higher complete response rate of 88%. This 
increase in response rate is not statistically signiﬁ cant (P=0.408). It is however of the 
same order of magnitude that we have previously observed in sBCC(12), where a 
CR of 97% at one year is signiﬁ cantly higher than that following PDT with a single 
light fraction 89% (P=0.002). The response rate of Bowens disease is lower than the 
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corresponding response rate for sBCC for both the single and 2-fold illumination 
scheme12. While these differences are not statistically signiﬁ cant (P=0.25 and P=0.09 
respectively) possibly due to the relatively small number of patches in the present 
pilot study. It may be regarded as an illustration of the general observation that 
Bowens disease responses less well to all therapy modalities as the recurrence rate 
of the gold standard surgery is also 19%(2). Both sets of clinical response data are 
supported by our pre-clinical animal data in which we have shown that PDT with 
a two-fold illumination scheme results in signiﬁ cantly more severe acute response 
which is accompanied by deeper damage seen in histology (6-10). In Bowens disease 
we consider deeper damage to be an advantage partly because of the follicular 
involvement that is often observed. Repeated treatment is known to achieve better 
complete response rates in other skin conditions. Repeated treatment in Bowens 
disease showed higher response rates in earlier published studies (3,5,13). In our 
study 7 recurrent patches were retreated with PDT and responded completely in 
all cases. We believe optimising PDT in the ﬁ rst instance is superior to repeating 
treatment. In comparing reported response rates critical regard should be paid to 
both frequency of treatment and follow up time.
Use of different total ﬂ uence 
It is important to recognise that the cumulative ﬂ uence in each of the illumination 
groups is not equal. 75 J cm-2 was delivered in a single light fraction compared to 
100 J cm-2 in the two-fold illumination scheme. This is a direct consequence of our 
intention to deliver a large ﬂ uence in the second light fraction since we have shown 
that this is essential for an optimal response(10). A number of pre-clinical studies 
have shown that photobleaching of PpIX limits the PDT dose that can be delivered in 
a single light fraction at ﬁ xed ﬂ uence rate (14). The relationship between response 
to ALA-PDT and ﬂ uence has not been systematically investigated in the clinic. Only 
Oseroff has emphasised the importance of light ﬂ uence in the treatment of sBCC 
by topical ALA-PDT (15), and this regards the delivery of high light ﬂ uences at high 
ﬂ uence rate. He reported that a CR rate of 95% after 200 J cm-2 (at a ﬂ uence 
rate of 150 mW cm-2) fell to 70% after 150 J cm-2 (16). Most other investigators 
have applied both lower light ﬂ uence (rate) and cumulative ﬂ uences both below 75 
J cm-2 and above 100 J cm-2, with little evidence for a correlation between ﬂ uence and 
response. There is some clinical evidence, albeit limited, that PpIX photobleaching 
limits the response to a single light fraction following ALA-PDT of AK (17).
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Light sources 
As described above we have previously shown that there is no signiﬁ cant effect of 
light source on the enhanced response to ALA-PDT using light fractionation with a 2 
hours dark interval (12). A variety of light sources have previously been used for PDT 
for Bowens disease (3, 12, 18-20) and there are conﬂ icting data on the inﬂ uence of 
the light source spectral output and ﬂ uence rate used in ALA-PDT (21,22). While the 
present study is insufﬁ ciently powered to investigate the effects of light source we 
do not believe that the light source plays a signiﬁ cant role in the response of tissues 
to ALA-PDT using light fractionation. Our own data in sBCC (12) and recent data in 
ALA-PDT of AK (23) support this conclusion.
Adverse events and cosmetic outcome 
In our pre-clinical animal studies investigating the two-fold illumination scheme we 
have found signiﬁ cantly deeper damage that is accompanied by an inﬂ ammatory 
inﬁ ltrate in the dermis (10). In some cases we have observed scarring in normal mouse 
skin. We were therefore careful to note the incidence of adverse events and cosmetic 
outcome in patches illuminated using the two-fold illumination scheme. Cosmetic 
outcome was good in all but 2 patches due to persistent hyperpigmentation. This 
result is similar to our previous clinical studies involving the two-fold illumination 
scheme in sBCC were we did not ﬁ nd a signiﬁ cant difference in cosmetic outcome 
between a single and two-fold illumination scheme (11, 12). Patients treated with 
a two-fold illumination scheme tend to have more discomfort. Patients were asked 
for adverse events and healing time and reported only discomfort like edema, 
erythema and minor crusting healed within three weeks. Only patients in the two-
fold illumination group required local anesthesia which was sufﬁ cient to relieve the 
pain. Comparing these results to other treatment modalities PDT using the two-fold 
illumination scheme can be regarded as an attractive treatment option. In patches 
treated with cryotherapy adverse effects such as ulceration are seen and healing 
time is sometimes long (3,24). Reported response rates following curettage & 
cautery (25) may be high but the healing time is much longer than that associated 
with PDT.
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CONCLUSION
Two-year response rates to PDT and conventional surgery are comparable and in 
our view PDT may offer the best treatment option for Bowens disease. Surgery may 
be contraindicated for general health reasons (e.g. mean age of the current study 
is 74). Also Bowens disease is often located on areas that are difﬁ cult to treat such 
as the lower legs and the face. For patches in these areas, and in particular for the 
larger ones, there is a signiﬁ cant need for an alternative to surgery. The present 
pilot study shows the potential of light fractionation for enhancing the response 
of Bowens disease following ALA-PDT by the same order of magnitude that we 
have shown in sBCC and illustrates the need for a larger, suitably powered, study to 
determine if this is a statistically signiﬁ cant effect.
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ABSTRACT
Background: Light fractionation in ALA-PDT using a small ﬁ rst fraction and a 
substantial larger second fraction separated by a two hours dark interval, has been 
shown to enhance the response in several animal models and in superﬁ cial non 
melanoma skin cancer. PpIX ﬂ uorescence kinetics has been studied to date with 
limitations, but showed the improvement is not due to an increased amount of 
PpIX. 
Methods: We studied 32 superﬁ cial basal cell carcinomas, 7 control lesions and 25 
treated lesions. The treatment scheme we used: after topical 20% ALA, 20+80 Jcm –2 
separated by a two hours dark interval, red light. Both surface and microscopic PpIX 
ﬂ uorescence were studied. Biopsies were taken just before the second illumination 
(6 hours after ALA application, or two hour after the ﬁ rst illumination). Each biopsy 
was immunohistochemically stained for the proliferation marker Ki-67.
Results: A large variation in PpIX ﬂ uorescence was found between the control and 
the treated biopsies as well as within a biopsy. Despite the variation a reasonable 
correlation was found between the two techniques, surface and microscopic 
ﬂ uorescence, we used. There is no trend in depth of PpIX in the studies samples. 
Re-appearance of ﬂ uorescence is found just before the second illumination. 
The distribution of positive stained cells for Ki-67 follow the PpIX ﬂ uorescence 
distribution.
Conclusion: Spatial microscopic PpIX in superﬁ cial basal cell carcinoma shows a 
wide variation between and within biopsies. PpIX ﬂ uorescence conﬁ rmed relative 
resynthesis in the dark interval in a two-fold illumination scheme consistent with 
our earlier work.
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INTRODUCTION
Light fractionation using a 2-hours dark interval signiﬁ cantly enhances the clinical 
response of superﬁ cial basal cell carcinoma (sBCC) to 5-aminolevulinic acid (ALA) 
based photodynamic therapy (PDT) (1, 2). The increased effectiveness of this 2-fold 
illumination scheme was ﬁ rst demonstrated in a series of pre-clinical studies and 
optimised in the hairless mouse model (3, 4, 5, 6). Despite these encouraging results 
the mechanism behind the increased effectiveness has yet to be fully elucidated. We 
have shown that the overall amount of PpIX re-synthesised in time after the ﬁ rst 
light fraction of the two-fold illumination does not correlate with the response to 
the treatment (6, 7, 8). Increasing the length of the dark interval from one to two 
hours leads to a signiﬁ cant increase in visual skin response despite the fact that 
the amount of PpIX utilised is not signiﬁ cantly different (7). We have also shown 
that light fractionation using methyl aminolevulinate (MAL), an ester derivative of 
ALA, does not increase the response of normal mouse skin above that following 
a single light fraction (9). This is despite the fact that the application of MAL 
results in identical ﬂ uorescence pharmacokinetics during the two-fold illumination. 
A signiﬁ cant disadvantage of surface ﬂ uorescence measurements is that the 
depth distribution of photosensitiser is not fully resolved. For thin tissues such as 
the normal skin of pre-clinical models, the depth distribution of PpIX is normally 
neglected (6, 10 - 13). For thicker lesions such as basal cell carcinoma it is likely that 
the depth distribution is a signiﬁ cant confounding factor in the determination of 
the pharmacokinetics of PpIX. Microscopic analysis of tumour biopsies, sectioned 
and imaged using ﬂ uorescence microscopy, has previously been used to determine 
the distribution of PpIX in BCC and in other organs (14 -18). These studies have, 
for the majority, investigated distribution of PpIX in nodular BCC. Only one has 
investigated the microscopic distribution in superﬁ cial BCC after topical ALA (19). 
Also the spatial distribution of PpIX re-synthesis in BCC has not been investigated. 
For these reasons, in the present study, we have investigated the spatial distribution 
of PpIX in sBCC undergoing light fractionated ALA-PDT comparing both surface 
and ﬂ uorescence microscopy. In addition we have investigated the presence and 
distribution of the proliferation marker Ki-67. Ki-67 is a protein that is detected 
in the nucleus in phase G1, S, G2 and M of the cell cycle. Ki-67 is considered to 
be vital for proliferation. The number of cells with Ki-67 is used to estimate cell 
proliferation. In some malignancies, for example breast cancer, Ki-67 has prognostic 
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value. In basal cell carcinoma an average of 20% positive cells is been reported (20 - 
23). A uniform distribution of Ki-67 positive cells has been reported (24) suggesting 
an equal proliferation in neoplastic cells over the bulk of the tumour and in tumour 
islands. A more recent study by Tilly et all found proliferate activity restricted to 
the periphery of tumour nests in superﬁ cial and nodular basal cell carcinomas 
(25). In aggressive and recurring basal cell carcinomas Ki-67 expression  has been 
shown to be higher (26). Vidal et al studied the expression of Ki-67 among others 
in BCC in response to topical imiquimod treatment. They found pre-treatment a 
high percentage positive Ki-67 cells (39%) and showed no signiﬁ cant modiﬁ cation 
during imiquimod treatment (27). Here we have compared the distribution of Ki-67 
with the distribution of PpIX in sBCC undergoing light fractionated ALA-PDT.
MATERIAL AND METHODS
Patients and ALA application
Eight patients, diagnosed with multiple superﬁ cial basal cell carcinomas, 
were recruited to investigate the superﬁ cial and microscopic distribution of PpIX 
during light fractionated ALA-PDT. The design was approved by the ethical committee 
of the Erasmus MC, according to the Declaration of Helsinki Principles. All patients 
gave informed consent. Thirty two lesions were included in the present analysis. 
Where possible four lesions were identiﬁ ed in each patient. The location of lesions 
was dependent on the patient but sites on the back, chest, arm, face and leg were 
used. One lesion was randomly designated as a control lesion to which ALA was 
administered but was not illuminated. The remaining three lesions underwent light 
fractionated ALA-PDT. Topical ALA ointment was prepared by our Hospital Pharmacy 
using 20 % aminolevulinic acid (FLUKA Netherlands) in Instilagel ® (Medeco B.V. 
Oud Beijerland, The Netherlands). The ointment was freshly prepared and stored 
in a refrigerator to be used within 7 days. Before application of ALA, crusts and 
scaling were removed using a disposable curette. Control and treatment lesions 
were covered with a margin of 1 cm and dressed with a semi permeable dressing 
(Tegaderm® 3M, Netherlands) over aluminium foil to protect the lesion from light 
during application of ALA.
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Photodynamic therapy and biopsy collection
Illuminated lesions received light fractionated ALA-PDT using a two-fold illumination 
scheme in which 20 + 80 J cm-2 was delivered separated by a 2 hours dark interval 
(1). A light ﬂ uence of 20 J cm-2 was delivered 4 hours after the administration of 
ALA, at a constant uniform ﬂ uence rate of 50 mW cm-2, using a 630 nm diode laser 
(Carl Zeiss, Oberkochen, Germany). Immediately after the therapeutic illumination 
lesions were re-covered with a light protective dressing for a dark interval of 2 hours. 
Immediately before the second light fraction, 6 hours after the administration of 
ALA, a 5 mm punch biopsy was obtained from the centre of each lesion. Biopsy 
sites were stitched, swabbed and applied with light pressure until any bleeding had 
stopped. The remaining lesions then received a second light fraction of 80 J cm-². A 
margin of at least 5 mm around each lesion was included in each treatment ﬁ eld. 
Control lesions that  did not receive the ﬁ rst light fraction were biopsied at the 
corresponding time point, 6 hours after the administration of ALA. After the punch 
biopsy was taken control lesions were stitched and swabbed. Control lesions did not 
undergo PDT in this treatment session but were allowed to heal and subsequently 
treated using light fractionated ALA-PDT.
Superﬁ cial PpIX ﬂ uorescence imaging
Superﬁ cial PpIX ﬂ uorescence images were acquired  to investigate the spatial kinetics 
of PpIX re-synthesis. Data were acquired immediately  before ALA-application, 
immediately  before and after the ﬁ rst illumination, and immediately before the 
second illumination. Measurements were performed as we have described previously 
using a custom applicator attached to a ﬂ uorescence-imaging camera (1).  Images 
acquired at different time points were registered under translation and rotation 
using landmarks in the skin surrounding the lesion (e. g. hair follicles). Typically 
a rectangular area of 4 x 6 cm is imaged that includes the whole lesion and the 
biopsy site. Where possible the site of the biopsy was identiﬁ ed in each series of 
3 images (acquired before and after the ﬁ rst light fraction and before the second 
light fraction). An additional image was acquired after the end of the second light 
fraction, used to aid the localisation of the biopsy site in the series images. A circular 
region of interest approximately 0.5 cm in diameter is deﬁ ned and the average pixel 
intensity was used as a measure of the ﬂ uorescence intensity from an area of tissue 
that coincided with the area from which the biopsy was taken. Autoﬂ uorescence 
was measured before each ALA application and was subtracted from the PpIX 
ﬂ uorescence intensity acquired before and after each illumination.
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Fluorescence microscopy
Frozen skin samples were handled under subdued light conditions. Tissue-Tec® II 
embedding compound (Leica, Leiden, The Netherlands) was used to mount the skin 
sample on the sample holder of a cryostat (Leica, Leiden, The Netherlands). Cross 
sections were cut and singularly mounted on glass slides (Menzel, Braunschweig, 
Germany). Each tumour biopsy was sectioned at three depths collecting one 20 
μm section and three 5 μm sections at each depth. Tumour sections were allowed 
to thaw at room temperature for 30 minutes to one hour after sectioning before 
imaging. Very low intensity red light using a high pass 695 ﬁ lter was used to localise 
the section and focus its image. Fluorescence images were acquired using a slow 
scan CCD camera (Proscan, Lagerlechfeld, Germany) mounted on a ﬂ uorescence 
microscope (Leitz DM RB, Leica, Leiden, The Netherlands) equipped with an N2.1 
ﬁ lter block. This ﬁ lter combination  includes a 515-560 nm band pass excitation ﬁ lter 
and dual dichroic and long pass detection ﬁ lters (RKP580 and LP590 respectively, 
Leica, Leiden, The Netherlands). Light from the sample was then ﬁ ltered using 
an additional 635±5 nm interference ﬁ lter (BP635, Melles Griot, Zevenaar, The 
Netherlands). Background and reference (KV470 ﬁ lter, Schott, Tiel, The Netherlands) 
images were recorded for each set of ﬂ uorescence images. The ﬂ uorescence 
images were corrected by subtracting the corresponding background image and 
dividing the resulting image with the corresponding KV470 image. All images were 
corrected for variations in excitation light intensity. A 120 second integration time 
was necessary to maximise the signal to noise ratio for the detection of PpIX. Longer 
integration times reduced the signal to noise due to PpIX photobleaching during 
image acquisition. 
Immunohistochemical staining
For each biopsy an additional 5 μm tumour cross section was cut immediately 
adjacent  to the ﬁ nal section of the ﬂ uorescence analysis. These sections were 
analysed for the presence of the nuclear antigen Ki-67 proliferation marker using a 
method adapted from that suggested by DAKO (Heverlee, Belgium).
Fluorescence image analysis and assay scoring
For each frozen tumour biopsy, three sets of 5 and 20 μm sections cut more than 
250 μm apart were used to determine the relative intensity and spatial distribution 
of PpIX. Twenty micron sections were imaged using 50x magniﬁ cation and 5 μm 
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sections were imaged using the 400x magniﬁ cation. Low magniﬁ cation imaging 
was chosen so that the full thickness of the tumour and the underlying dermis could 
be acquired in a single image. High magniﬁ cation sections provided a more detailed 
image of the boarder between tumour and normal tissue. The spatial distribution of 
PpIX ﬂ uorescence within the section was noted at both high and low magniﬁ cation. 
Also within each image three areas of tumour were identiﬁ ed and the PpIX 
ﬂ uorescence intensity and its standard deviation was measured in a square region 
of interest. The size of these regions of interest were approximately 50 x 50 and 5 x 
5 μm using 50x and 400x magniﬁ cation respectively. Immunohistochemical scoring 
was performed without prior knowledge of the distribution of PpIX ﬂ uorescence. 
The overall Ki-67 score was calculated as the percentage of positively stained cells 
to total cells.
RESULTS
Figures 1a and 1b show the variation in the mean PpIX ﬂ uorescence intensity, 
measured in sections acquired from superﬁ cial BCC, six hours after the administration 
of ALA in control lesions (C1-7) and in lesions (1, 2 4-25) at the end of the dark 
interval 2 hours after the delivery of the ﬁ rst light fraction of 20 J cm-2, 4 hours 
after the administration of ALA. Panels a and b show the results from ﬂ uorescence 
analysis and 400x (5 μm sections) and 50x (20 μm sections) magniﬁ cation 
respectively. It was not possible to identify a control lesion in one patient. Figure 
1c shows the relationship between the average PpIX ﬂ uorescence intensity using 
the two magniﬁ cation / sectioning techniques. There is a reasonable correlation 
between the ﬂ uorescence intensity recorded with each technique (R2 = 0.86). For 
both analyses  of the distribution in PpIX ﬂ uorescence there are large variations 
in PpIX ﬂ uorescence intensity between individual control and illuminated lesions. 
The standard deviation of PpIX ﬂ uorescence calculated from weighted average of 
3 regions of interest in 3 sections per biopsy are large, approximately 20 - 25% of 
the average absolute ﬂ uorescence intensity in an individual biopsy. The ﬂ uorescence 
intensity in control biopsies is greater than that in illuminated lesions 2 h after the 
end of the ﬁ rst light fraction. There is no signiﬁ cant difference between the standard 
deviations within and between regions of interest from individual biopsies for the 
control and illuminated lesions. Figure 1d shows the relationship between the 
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average PpIX ﬂ uorescence intensity measured using the surface collection technique 
and the microscopic analysis using the 400x magniﬁ cation. We were able to localise 
the biopsy site in each of the three pre-biopsy surface images in 17 of the 25 lesions 
that were illuminated. There is a weak correlation between these two methods of 
determining the PpIX ﬂ uorescence intensity (R2 = 0.54). The standard deviations for 
each technique are again large.
Figure 1:  PpIX ﬂ uorescence image analysis during ALA-PDT of superﬁ cial basal cell carcinoma. Showing the 
average microscopic ﬂ uorescence intensity measured using (a) 50 and (b) 400x magniﬁ cation in control (c1 
– 7) un-illuminated lesions 6 hours after the application of 20% ALA and in treated lesions (1-25) 2 hours 
after 20 J cm-2. The correlation between the microscopic ﬂ uorescence intensity measured using 50 and 400x 
magniﬁ cation is shown in panel (c). Panel (d) shows the correlation between the  surface and microscopic 
ﬂ uorescence intensity. In all cases error bars  represent standard deviations.
Figure 2 a - e shows 5 representative tumour sections that have been analysed for 
PpIX ﬂ uorescence distribution, (left red image) and Ki-67 positively stained cells 
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(centre and right image). The centre Ki-67 image has undergone spectral unmixing 
in the right hand image, to show positively stained brown cells above the blue 
background due to haematoxylin. Panels a and b show sections of control lesions that 
were biopsied 6 hours after the administration of ALA. Panels c – e show sections of 
lesions that were biopsied 2 hours after 20 J cm-2, 6 hours after the administration 
of ALA. Overall, analysing all of the sections under high magniﬁ cation, an average 
of 20% of tumour cells were positively stained for Ki-67 compared to the total 
number of tumour cells. There was no difference in the proliferation index between 
control or illuminated lesions. Panel a shows a superﬁ cial BCC that extends into 
the upper dermis. Tumour cells in the region show signiﬁ cant ﬂ uorescence that 
extends into the upper dermis . There is a relatively uniform distribution of PpIX 
ﬂ uorescence in the tumour cells that includes cells that are stained Ki-67 positive 
and cells that are not. Panel a also shows signiﬁ cant ﬂ uorescence deeper which 
seems to be associated with collagen ﬁ bres. Panel b shows a 50x magniﬁ cation 20 
μm section of a control biopsy that shows the deeper extension of BCC into the 
dermis. The section illustrates peripheral palissading and retraction artefact at the 
boundary between tumour cells and the surrounding dermis, that are characteristic 
of BCC. In this section there are signiﬁ cant differences in the distribution of PpIX 
ﬂ uorescence. In the island of BCC on the left of the section there is a rather uniform 
distribution of ﬂ uorescence. The island of BCC on the right of the section shows a 
peripheral distribution of PpIX in which the centre of the island shows very little PpIX 
accumulation. There is no obvious general trend for a depth distribution of PpIX 
ﬂ uorescence in BCC. Regions of high PpIX ﬂ uorescence intensity are clearly seen in 
islands relatively deep in the dermis. Note that the very centre of this island shows 
a ﬂ uorescence artefact that is probably due to ﬂ uorescence from the glass beneath 
the section that is exposed due to the hole in the section clearly seen in the central 
Ki-67 image. In this section the distribution of Ki-67 positive cells closely follows the 
distribution of PpIX. The interior of the island on the right shows very little or no 
Ki-67 positive cells while the island on the left of the sections shows a more uniform 
distribution of Ki-67 positive cells. Panel c shows a section of an illuminated lesion 2 
hours after PDT showing the basal layer of the epidermis an island of BCC between 
the epidermis and a deeper lying region of tumour cells. In the superﬁ cial layers 
of the section there is a relatively uniform distribution of PpIX ﬂ uorescence that 
includes cells that are stained Ki-67 positive and cells that are not. In the tumour 
island and in the lower region of the image PpIX ﬂ uorescence closely corresponds 
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to Ki-67 positive cells. Panels d and e show  in more detail the border between 
tumour cells and cells of the dermis. Again there is a moderate correlation between 
PpIX ﬂ uorescence intensity and Ki-67 positive cells in regions of tumour cells outside 
the epidermis where positive and negative Ki-67 cells accumulate PpIX. Again we 
did not observe a systematic trend for differences in the overall distribution of PpIX 
between control and illuminated lesions. However PpIX ﬂ uorescence in biopsies that 
were illuminated and imaged at 400x magniﬁ cation were somewhat more diffuse 
than control images. This suggests that there may have been a slightly different 
sub-cellular distribution of PpIX 2 hours after PDT compared to the distribution of 
PpIX 6 hours after the administration of ALA. It is important to note that an intense 
ﬂ uorescence signal is observed in all sections that include the most superﬁ cial layers 
of the skin that include either intact stratum corneum or tumour crusts.
a
b
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c
d
e
Figure 2: Representative microscopic images of sections of sBCC. Left image: PpIX ﬂ uorescence distribution, 
middle and right image Ki-67 staining. The middle image has been spectrally unmixed to show the distribution 
of Ki-67 positive cells. Panels a & b are control lesions, 6 hours after 20% ALA-application, Panels c-e are 
sections 2 hours after 20 Jcm-2, also 6 hours after 20% ALA application. See detailed description of ﬁ gure 
in text.
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Figure 3 shows the variation in mean surface PpIX ﬂ uorescence during before and 
after the ﬁ rst light fraction and at the end of the dark interval immediately before 
the second light fraction. Again it was only possible to recover data for the whole 
sequence of images in 17 of the 25 lesions that received PDT. The PpIX ﬂ uorescence 
before the ﬁ rst light fraction varied considerably. The mean normalised ﬂ uorescence 
after the illumination is 48% of that before the ﬁ rst light fraction and rises to 63% 
during the 2 hours dark interval. This compares with a mean surface ﬂ uorescence 
intensity in control, non-illuminated lesions, that is 119% of the average immediately 
prior to the ﬁ rst light fraction, 4 hours after the administration of ALA. During PpIX 
ﬂ uorescence photobleaching varied widely, despite ﬁ xed illumination parameters. 
The average extent of photobleaching of 47% during the ﬁ rst light fraction is 
similar to that we have found in our pre-clinical studies. Also shown is the average 
ﬂ uorescence intensity measured using from the corresponding biopsy sections as a 
relative comparison.
Figure 3: The kinetics of superﬁ cial PpIX ﬂ uorescence intensity in sBCC during ALA-PDT with a two-fold 
illumination scheme (open squares) delivering 20 J cm-2 and the re-synthesis during the 2 hours dark interval 
between light fractions and the PpIX ﬂ uorescence in un-illuminated control lesions (open circles). The 
corresponding average microscopic PpIX ﬂ uorescence intensity (closed symbols) is shown for comparison. 
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DISCUSSION
The purpose of this study was to investigate the distribution of PpIX in superﬁ cial BCC, 
during light fractionated ALA-PDT, using ﬂ uorescence microscopy. We found wide 
variations in the average intensity of PpIX ﬂ uorescence in biopsies of control lesions 
and in biopsies of lesions 2 hours after illumination with 20 J cm-2. We also found wide 
variations in ﬂ uorescence intensity within individual sections of biopsies. The large 
variability in ﬂ uorescence intensity measured in adjacent tumour sections is likely 
to be a consequence of the difﬁ culty of making sections of reproducible thickness. 
Also since tissue sectioning is known to disrupt cell and organelle membranes it is 
possible that PpIX bound at lipophilic sites within the tissue localises in different 
environment(s) that induce unpredictable variations in ﬂ uorescence quantum yield of 
PpIX. This is a particular problem for thin (5 μm) sections. Given these large standard 
deviations on average ﬂ uorescence intensities we found a reasonable correlation 
between the two different methods of performing ﬂ uorescence microscopy, as 
shown in ﬁ gure 1c. The biopsy average PpIX ﬂ uorescence intensity determined 
using 20 μm sections and 50x magniﬁ cation was similar to that determined using 5 
μm sections and 400x magniﬁ cation. This is an encouraging result that adds some 
weight to the use of semi-quantitative ﬂ uorescence microscopy as a method of 
determining PpIX intensity. Large variations in microscopic PpIX content after ALA 
administration have been observed previously in sBCC (19). Martin et al attributed 
these variations to differences in ALA penetration through intact stratum corneum 
and ALA transport within individual tumour. The transport of ALA in large nodular 
tumours is clearly an important parameter that inﬂ uences the synthesis of PpIX at 
depth. However in the present study we have shown for superﬁ cial BCC, where ALA 
penetration and transport are unlikely to be limiting factors, there remain regions 
of tumour that accumulate and re-synthesise relatively small amounts of PpIX. It is 
also clear that regions of low PpIX ﬂ uorescence accumulation are not located at 
the base of superﬁ cial tumours and high PpIX ﬂ uorescence is often observed at 
the periphery of tumour islands at the base of the tumour, as seen in ﬁ gure 2b. 
Clearly there are other more important mechanism(s) that inﬂ uence the synthesis of 
PpIX in sBCC when high concentrations of ALA are present. As long ago as 1997, 
Peng et al were able to review the literature and conclude that PpIX is preferentially 
synthesised in tumours and in rapidly dividing cells (28). Our present data support 
these general conclusions. More rapidly dividing tumour cells at the base of s-BCC, 
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that are Ki-67 positive synthesise relativity more PpIX. The underlying mechanism 
behind the differential synthesis is complex but though to be a consequence of the 
relative activity of enzymes within the biosynthetic pathway of heme, in particular 
porphobilinogendeaminase and ferrochelatase (29). In the present study we have 
shown that even in s-BCC, where the local availability of ALA is not a limiting factor, 
signiﬁ cant numbers of tumour cells synthesise relatively low amounts of PpIX. 
Reduced PpIX synthesis, at depth, where the concentration of ALA is limited has 
been suggested as a important factor in the reduced response of nodular BCC 
following ALA-PDT. Our results suggest that the ability of cells to synthese PpIX is 
also an important consideration. In this case modiﬁ cation of heme biosynthesis, 
particularly in cells that do not synthese sufﬁ cient PpIX, seems an attractive option 
(30).
The large spatial variations in distribution of PpIX ﬂ uorescence, in particular the 
variations associated with depth, illustrate the challenge for ﬂ uorescence detection 
of s-BCC, that is frequently advocated a method of optical diagnosis (31-34). 
Recently Stenquist (35) published data describing the use of ﬂ uorescence imaging 
to demarcate the boundaries of basal cell carcinoma during Mohs’ micrographic 
surgery. A mapping precision of +/-3mm was estimated The authors uncorrected 
in-vivo ﬂ uorescence imagining.
As noted above we observe a ﬂ uorescent layer in the most superﬁ cial layers of the 
stratum corneum, the origin of this ﬂ uorescence is unknown and may be an artefact 
of the sectioning process.
The fact that we have found similar spatial distributions of PpIX, 2 hours after the 
ﬁ rst light fraction of 20 J cm-2, compared to un-illuminated control biopsies conﬁ rms 
our recent pre-clinical ﬁ ndings that there is no signiﬁ cant inﬂ uence of PDT on the 
ability of cells or tissue to re-synthesis of PpIX and that there is little evidence for 
a systemic component of PpIX re-synthesis (36). The average amount of PpIX that 
is re-synthesised during the two hours dark interval after the ﬁ rst light fraction 
measured using ﬂ uorescence microscopy and superﬁ cial imaging are consistent 
with those that we have observed previously (1, 2). The present study does however 
illustrate the inherent weakness of spatial averaging of tissues in which there is large 
variation in the spatial (re-) synthesis of PpIX.
We are continuing to investigate the mechanism behind the response of tissues to 
light fractionated ALA-PDT. With regard to the underlying mechanism it is important 
to note that all of the illuminated lesions investigated in the present study all showed 
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complete response to light fractionated ALA-PDT 24 months after therapy. This is in 
spite of the signiﬁ cant variations in microscopic PpIX ﬂ uorescence intensity measured 
immediately before the second light fraction. While the mechanism behind this 
increased response is not yet completely clear we have recently shown that the 
average kinetics of superﬁ cial PpIX ﬂ uorescence may be misleading (37). Our data 
in normal mouse skin indicate that the microscopic distribution of PpIX re-synthesis 
after the application of ALA is an important aspect in the response of tissues to light 
fractionated ALA-PDT.
In conclusion we have measured the spatial microscopic distribution in PpIX in s-
BCC and we have shown the wide variations between tumour cells within and 
between tumour biopsies. We have conﬁ rmed that the relative re-synthesis of PpIX 
after PDT is consistent with that we have recently found in pre-clinical models. We 
have shown that highly proliferating normal and tumour cells synthesise relatively 
more PpIX and that this corresponds with ki-67 staining. We have shown that even 
in s-BCC are signiﬁ cant regions of tumour cells that do not synthesize PpIX even 
when there is sufﬁ cient ALA availability.
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Apoptosis markers in ALA- PDT treated 
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ABSTRACT 
Background: ALA-PDT is an established therapy modality for sBCC. The mechanism 
of cell death in PDT is partly due to apoptotic processes. We have shown that 
fractionated ALA-PDT leads to higher complete response rates in superﬁ cial BCC’s , 
AK and Bowens disease. In search to enlighten this increased response as well as to 
elucidate the PDT mechanism we investigated some apoptotic markers.
Methods: 43 histological proven sBCC’s were included:  7 control lesions, 10 lesions 
treated with a single dose of  75 Jcm-2  and 25 lesions treated with a fractionated 
regime (20 + 80 Jcm-2 separated by a two hours dark interval). One lesion in one 
patient was treated with the fractionated regime and serial biopsied, 6, 12 and 24 
hours after the completed treatment. In the control lesions a biopsy was taken after 
6 hours of ALA application. In the single illuminated lesions a biopsy was taken after 
2 hours after 75 Jcm-2 .In  the fractionated treated lesions a biopsy was taken after 
2 dark hours after an illumination of  20 Jcm-2. In all treated lesions ALA was applied 
for 4 hours, a  ﬂ uence rate of  50mWcm-2 and a diode laser system as light source 
was used. Immunohistochemical staining for Bcl-2, Bax, caspase 3 were done in 
frozen sections.
Results: In almost all biopsies positive stained tumour cells for Bcl-2 were found. 
In the staining for Bax in control lesions some positive tumour cells were found. In 
the majority of biopsies after 20 J cm-2  positive cells for Bax were shown. After 75 
J cm -2  also positive cells for Bax staining were found. In all illuminated lesions an 
upregulated expression of caspase 3 was shown. 
Conclusion: Early, after two hours,  after a 75 J cm -2 and after a small dose of 20 
J cm -2 apoptotic markers show altered expression indicating apoptosis is occurring. 
Apoptosis induced by the mitochondrial pathway plays a role in cell death in ALA-
PDT in sBCC. 
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INTRODUCTION
Photodynamic therapy (PDT) is gaining acceptance in the treatment of superﬁ cial 
basal cell carcinoma (sBCC). PDT relies on the use of an appropriate photosensitiser 
which accumulates selectively in tumour cells and illumination with an appropriate 
wavelength of light. The generation of relative oxygen species  results in tumour 
destruction. In dermatology, porphyrin pre-cursors, aminolevulinic acid (ALA) or 
methyl-aminolevulinate (MAL) are used as photosensitiser-precursors and are 
combined with illumination using red light . The production of reactive oxygen leads 
to a complex interplay between direct cytotoxicity to tumour cells and secondary 
damage to the tumour and adjacent tissue. Cell death can be due to necrosis 
and / or apoptosis. Necrosis can be considered as a passive process associated with 
cellular injury inciting an inﬂ ammatory response. Apoptosis is an active process 
which involves a cascade of cellular changes leading to clear tumour cells. Apoptosis 
is generally accepted to play an important role in the response to PDT (1) and has 
been shown to occur in many cancer cells in vitro and in tumours in vivo. The 
dose delivered during PDT is known to be an important factor in determining the 
balance between apoptotic and necrotic cell death. Treatment schemes that utilise 
high doses of drug and light (i.e. high ﬂ uence or low ﬂ uence rate) are known to 
induce necrosis. Low doses of PDT, soon after the administration of photosensitiser 
and / or low light ﬂ uence and/or high ﬂ uence rate have been shown to preferentially 
induce apoptosis (2). In normal skin members of the Bcl-2 family are expressed in 
different layers and in different amounts. The family is considered to exist of pro and 
anti apoptotic members. For example Bcl-2 inhibits apoptosis while Bax promotes 
apoptosis. Caspase 3 is known as the executor caspase in the apoptotic process.Our 
optimised light fractionated illumination scheme for ALA-PDT involves the delivery 
of relatively low PDT dose (20 J cm-2 at 50 mWcm-2) 4 hours after the administration 
of ALA. (3,4,5). Delivering higher doses in this ﬁ rst light fraction ≥ 50 J cm-2 removes 
the therapeutic effect of light fractionation (4,6). With PDT dose dependent effect 
in mind and the aim to investigate the mechanism of cell death at early time points 
after ALA-PDT we investigated the induction of apoptotic markers in superﬁ cial 
basal cell carcinoma. We report on the presence of apoptotic markers Bcl-2, Bax 
and caspase 3 in human sBCC biopsies acquired 2 hours after high dose (75 J 
cm-2 ) and low dose (20 J cm-2). 6 hours after the ALA-application undergoing light 
fractionated PDT. We have also investigated the induction of apoptosis over longer 
time scales in sBCC by performing serial biopsies in a single lesion.
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PATIENTS, MATERIALS AND METHODS 
Lesions 
Forty three histological proven sBCC’s were included in this study. All patients gave 
informed consent. The study design was approved by the ethical committee of 
Erasmus MC according to the declaration of Helsinki principles.
ALA application 
After lesion preparation using a disposable curette to remove gently crusts and 
scalling 20 % ALA was applied with a margin of 1 cm on all lesions. The ALA 
ointment (20% ALA (FLUKA, Zwijndrecht, The Netherlands in Instilagel®, Medeco 
B.V. Oud Beijerland, The Netherlands) is freshly prepared  by our University Hospital 
Pharmacy to be used within 7 days. The application time in the control lesions was 
6 hours, in the treated lesions 4 hours.
Treatment schemes 
A 630 nm diode laser (Carl Zeiss, Oberkochen, Germany) was used as light source. 
Light was coupled into a 600 μm optical ﬁ bre and projected onto the lesion 
using a combination of lenses to assure a uniform ﬂ uence rate across the beam 
diameter. Lesions illuminated using a single light fraction received 75 J cm-2 In the 
light fractionated scheme 20 + 80 J cm-2 were delivered separated by a two hours 
dark interval. All lesions were illuminated with a constant measured ﬂ uence rate of
50 mWcm-2.
Biopsies 
In the control lesions (n=7) a biopsy was take 6 hours after ALA-application. Control 
lesions did not undergo PDT in this treatment session but were allowed to heal 
and subsequently treated using light fractionated ALA-PDT. In the single illuminated 
lesions (n=10) biopsy was taken two hours after the treatment. In the fractionated 
regime biopsy (n=25) was taken just before the second illumination, 6 hours after 
ALA-application, two hours after the ﬁ rst illumination of 20 J cm-2 . In one patient 
serial biopsies were taken 6, 12 and 24 hours, after a fractionated illumination.
Immunohistochemical staining
For each biopsy three 5 micron tumour cross sections were cut. These sections were 
Apoptosis markers in ALA- PDT treated superﬁ cial basal cell carcinomas | 93
analysed for the presence of the oncoprotein Bcl-2,  and Bax using a method adapted 
from that suggested by DAKO (Heverlee, Belgium). All sections were microscopically 
scored for the presence of positive stained cells to Bcl-2, Bax and caspase 3 using 
40 times magniﬁ cation by three of the authors (EdH, RdB DR).  Results are noted : 
absent (-), present (+) or abundant (++).  
RESULTS
A descriptive analysis is presented, illustrated with representative images. 
BCL-2 
In all control biopsies a positive staining present and abundant present,  was seen 
for Bcl-2 in the tumour. In the fractionated treated lesions (T1-25) in 10/25 Bcl-2 
staining was abundantly positive, in 12/25 only a relatively small number of positive 
tumour cells (scored present) were seen in a pattern like a normal epidermis. Due 
to artefact in sectioning 3 biopsies were not suitable for analysis. In the single 
illuminated lesions at 2h  (S1-10)  2/10 showed abundant Bcl-2 positive staining 
in tumour cells , 8/10 were scored present. The serial biopsies showed signiﬁ cant 
amounts of edema and a small number of Bcl-2 positive tumour cells in all three 
specimens 6, 12 and 24 hours after illumination.
Figure 1a shows a lesion 2 hours after illumination with 75 J cm-2 stained for Bcl-2. Positive Bcl-2 staining is 
clearly seen in tumour cells and in the basal layer of the epidermis.
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Figure 1b1-2 shows a lesion 2 hours after 20 Jcm-2,just before the second illumination in a fractionated 
illumination scheme stained for Bcl-2. Positive staining for Bcl-2 is clearly shown in the tumour cells and in 
the epidermis.
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Figure 1c1-2 shows a lesion after 20 Jcm-2 ,just before the second illumination in a fractionated illumination 
scheme stained for Bcl-2. Positively staining for Bcl-2 in tumour cells are shown. The epidermis also shows 
positively stained cells
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Figure 1d shows a control lesion after 6 hours of ALA-application stained for Bcl-2. Positive stained cells for 
Bcl-2 in the tumour are shown.
BAX 
In the control lesions 30% showed scattered positive staining. In 80% of the 
fractionated treated lesions (T1-25) positively stained cells were found in the 
sections, mostly in small groups scattered (60%) but also in the basal cell carcinoma 
cells (40%)  and mostly in the epidermis (12%). Sometimes in all layers of the skin 
as well as in tumour cells positive staining was seen. In the single illuminated (S1-
10) biopsies in 4/10 positive staining was found in the tumour in 4 other biopsies 
some positive staining cells for Bax were found scattered in the biopsy .In the serial 
biopsies positive tumour cells were found at 6 and 12 hours after fractionated ALA-
PDT.
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Figure 2a1-2 show a control lesion , 6 hours after ALA application stained for Bax. Some positive stained cells 
for Bax are shown, tumour cells are mostly not positively stained.
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Figure 2 b 1-2 shows a lesion after 20 J cm-2 , just before the second illumination in a fractionated illumination 
scheme stained for Bax. Positive tumour cells for Bax are shown. Some positive cells for Bax are clustered in 
the periphery of the tumour.
Apoptosis markers in ALA- PDT treated superﬁ cial basal cell carcinomas | 99
Figure 2 c1 shows a lesion 2 hours after illumination with 75 Jcm-2stained for Bax.  Some positive cells for 
Bax are shown, but clearly not the majority of cells and not in all biopsies. Figure 2c2 shows an example of a 
biopsy not staining for Bax.
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CASPASE 3
Control lesions show in 30% positive cells that are scattered throughout the tumour. 
In the fractionated treated lesions (T1-25) 96% of the biopsies showed positively 
stained cells 2 hours after 20 J cm-2 illumjnation, scattered, but in one third of the 
biopsies also clearly in the tumour. In the single illuminated lesions (S1-10) in 6/10 
positive staining was shown in the tumour. In the serial biopsies at 6 and 12 hours 
after a fractionated treatment positive stained tumour cells for caspase 3 were 
found, At 12 and 24 hours some positive cells were present around the tumour.
                                      
 
 
 
 
 
 
 
 
Figure 3 a shows a  control lesion 6 hours after ALA application stained for caspase 3.Just some scattered 
lonely positive tumour cells are shown.
                            
 
Figure 3 b shows a lesion after illumination with 75 Jcm-2 stained for caspase 3. Positive tumour cells for 
caspase 3 as well as positive cells surrounding the tumour are shown.
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Figure 3c1-2 shows a lesion after  20 Jcm-2  ,just before the second illumination in a fractionated illumination 
scheme stained for caspase 3. Positive tumour cells for caspase 3 are shown as well as positive cells surrounding 
the tumour.
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Table 1: immunohistochemical results in sBCC-biopsy taken at 6 hours ALA application (controls C1-7) and 
at 6 hours  after a  20Jcm-2 illumination, 4 hours application time plus 2 hours dark interval (T1-25) and 2 
hours  after a single illumination 75Jcm-2 after 4 hours ALA-application (S1-10). One serial biopted sBCC at 6, 
12 and 24 hours after a fractionated ALA-PDT treatment. (F1,2,3). 0 not analyzed due to artefact, - absent, 
+present, ++ abundantly present.
Bcl-2 tumour Bax Bax tumour Casp-3 Casp-3 tumour
C1 + + - + -
C2 ++ - - - -
C3 ++ - - - -
C4 ++ - - + -
C5 + + - - -
C6 + - - - -
C7 ++ - - - -
T1 + + + + -
T2 + + + + -
T3 + + - + -
T4 + + + + -
T5 + + + + +
T6 ++ + - + -
T7 0 - - + -
T8 ++ - - + -
T9 ++ - - + -
T10 ++ + + + -
T11 ++ ++ + + +
T12 + + - + -
T13 ++ + - + -
T14 + + + + +
T15 0 + - + -
T16 ++ - - + -
T17 0 + - + -
T18 + + - + +
T19 ++ + + - -
T20 + + - + +
T21 + + - + -
T22 + + + + +
T23 + + - + -
T24 + + + + +
T25 ++ + - + -
S1 + + - - +
S2 + - + - -
S3 0 - + - +
S4 ++ - + - +
S5 + + - - -
S6 + + - - +
S7 + - - - -
S8 ++ - + - +
S9 + - - - -
S10 + + - - +
F1 + - + - +
F2 + - + + +
F3 + + - + -
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A summary of the results per biopsy per staining is shown in table one as well as 
a differentiation in positive staining epidermal/dermal cells to tumour cells for Bax 
and caspase 3.
DISCUSSION
In sBCC we found positive staining for Bcl-2 in the tumour and in the basal 
layer of the  epidermis. These positive patterns were not different after ALA-PDT, 
after either a single illumination of  75 J cm –2  or after a light fractionated treatment 
scheme using 20+ 80 J cm –2. In normal skin Bcl-2 is expressed in the basal layer. 
Most BCC’s show positive stained cells for Bcl-2. The ﬁ rst reports on PDT mediated 
apoptosis suggested that mitochondrial damage could result in degradation or 
down regulation of Bcl-2 and related proteins that normally function as apoptotic 
suppressors (7,8).Contradictory are Bcl-2 transfected Chinese hamster ovarian cells 
partial resistant to PDT induced apoptosis (9). It has been reported also that over-
expression of Bcl-2 can block the activation of caspases and downstream events 
instigated by PDT (10). Kim at al, however showed that over-expression of Bcl-2 in 
a human breast cell line resulted in enhanced apoptosis by PDT (11).Our ﬁ ndings 
suggest ALA-PDT does not inﬂ uence the staining pattern for Bcl-2.
The pro-apoptotic member of the Bcl-2 family, Bax was also investigated 
in our biopsies. A scattered pattern of Bax –positive cells was found in two of  our 
control lesions. Normally Bax is under- expressed in the basal layer of the epidermis, 
but up-regulated in upper layers (12). Tilli conﬁ rmed this in normal skin but she 
described an increased expression in BCC (13). Rosen reported contrary ﬁ ndings, he 
found a decreased expression of Bax in BCC (14).The number of our control lesion 
is too small to make deﬁ nite conclusions on Bax in BCC. In biopsies after 75 J cm –2 
as well as in biopsies after 20 J cm –2 Bax expression is increased. In both regimes, 
after 2 hours, positive tumour cells and positive cells surrounding the tumour are 
shown in the staining for Bax. These ﬁ ndings support the idea apoptosis is induced 
early after ALA-PDT. A relatively large cell population Bax-positive cells in BCC seems 
to be prone to apoptosis.  The fact that in  the fractionated regime, just before the 
second illumination the vast majority of sBCC’s do show Bax-positive cells in and 
around the tumour suggests a small dose of ALA-PDT , 20 Jcm-2 at a ﬂ uence rate of 
50 mWcm-2 ,  can induce a changed pattern of the pro-apoptotic protein Bax within 
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2 hours.  In general Bax can be seen as  an actor in  tumour suppression by enabling 
cell loss through apoptosis (15).Over-expression of Bax in mammalian cells results 
in induction of apoptosis according to Chiu et al (16) mainly through the release of 
cytochrom c and activation of caspases including caspase 3. The consequences of 
our ﬁ ndings in relation to the increased response in fractionated ALA-PDT compared 
to a single illumination scheme clearly need further investigations. It would be 
interesting to observe expression of Bax in time in the same group after PDT. It can 
be regarded as a shortcoming of our study we only took one specimen of most 
lesions. Only in one patient we took serial biopsies. In these biopsies a decreasing 
Bax expression was seen in time. This may be due to an ongoing apoptotic response 
to PDT in time. But these data are not sufﬁ cient to make deﬁ nitive conclusions.  In 
a human leukaemia cell line (HL60) ALA-PDT has been shown to deregulate the 
expression of Bcl-2 and Bax within 2 hours after PDT (17). We did not observe a 
decrease in expression of Bcl-2. And contrary to Grebenova we observed increased 
expression of Bax as described above. The fact we can not conﬁ rm the results of 
Grebenova may be due to a leukaemia-cell line used compared to in vivo obtained 
histology from sBCC in humans.
In our control biopsies caspase 3 positive cells are not observed. Two 
hours after an illumination with 75 Jcm-2  as well as after a small dose of 20 Jcm-
2   tumour cells positive for caspase 3 are found. In the biopsies two hours after an 
illumination with 20 Jcm-2  many positive cells for caspase 3 are shown surrounding 
the tumour within 2 hours, this pattern is not seen in the biopsies two hours after 75
J cm-2. Caspase 3 expression is apparently up-regulated at this early time point. 
This ﬁ nding is in agreement with the literature ; the group of Peng observed within 
15 minutes release of cytochrom c and within 30 minutes caspase 9 and 3. Four 
hours after PDT using hexyl-ALA in a human T-lymphoma cell line 80% of cells 
show apoptotic features in short time. In this study both caspase dependent as 
caspase independent apoptotic pathways seem to be activated (18). The obtained 
results in caspase 3, the executor caspase, are concordant in our data to the data 
published by Grebenova and others (16,18-21). A rapidly increasing expression of 
caspase 3 is seen in almost all biopsies in our data 2 hours after a single small 
dose of ALA-PDT suggesting early apoptosis induced by ALA-PDT. In cell line an 
increase in caspase 3 expression was observed within 1 hour which declined in time 
(17). In the above mentioned serial biopsies of one patient we found a decline in 
caspase 3 after 12 and after 24 hours. But again this in only one patient. The just 
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mentioned results in literature are all obtained in different material to sBCC’s and 
may be not applicable to sBCC after  ALA-PDT but support strongly mitochondrial 
apoptosis is involved in PDT mediated cell death. Although  we only investigated 
and described staining of a limited number of biopsies a rapid and clear apoptotic 
process is revealed. For understanding the mechanism in PDT a tissue response can 
not be extrapolated from cellular obtained results due to the underlying cooperation 
between tumour, sensitiser, oxygen and tissue response. For understanding the 
impact of the fractionated regime deﬁ nite further investigations are necessary. The 
observed early apoptosis support the importance of the ﬁ rst illumination in this 
regime. In future serial observations in time and quantitative analysis may contribute 
to a better understanding of the apoptosis induced by ALA-PDT in human BCC. 
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ABSTRACT 
Previous work demonstrated that fractionated illumination using two fractions 
separated by a dark interval of 2 hours, signiﬁ cantly enhanced the clinical efﬁ cacy 
of photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA). Considering the 
increasing clinical use of methyl 5-aminolevulinate (MAL) and the expected gain in 
efﬁ cacy by light fractionation we have investigated the response to MAL-PDT using 
a single and a two-fold illumination scheme and compared that with ALA-PDT. Our 
results show that fractionated illumination does not enhance the efﬁ cacy of PDT 
using MAL as it does using ALA despite the comparable ﬂ uorescence intensities at 
the end of the ﬁ rst light fraction and at the start of the second light fraction. Only 
the initial rate of photobleaching was slightly greater during ALA-PDT although the 
difference was small. Previously we hypothesized that cells surviving the ﬁ rst fraction 
are more susceptible to the second fraction. Since this is not true for MAL-PDT our 
data suggest that the distribution of MAL and ALA in tissues, and therefore the site 
of PDT induced damage, is an important parameter in the mechanism underlying 
the 2-fold illumination scheme.
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INTRODUCTION
Photodynamic therapy employing the administration of porphyrin precursors has 
been under investigation for over a decade (1). It is now the treatment of choice for 
superﬁ cial non-melanoma skin cancer (2) and an experimental therapy for a number 
of other conditions (3,4). Recently we have shown that light fractionation using 
a 2-hours dark interval enhances the response of superﬁ cial basal cell carcinoma 
(sBCC) to ALA-PDT signiﬁ cantly (5,6). The increased effectiveness of this type of 
illumination scheme was ﬁ rst shown in a series of pre-clinical studies (7-10). Initially 
the ﬂ uence was split in two equal light fractions. In a further series of pre-clinical 
studies using the hairless mouse model we optimised the illumination scheme (10-
12). The efﬁ cacy of the two-fold illumination scheme increases when the ﬂ uence of 
the ﬁ rst light fraction is relatively low compared to the second light fraction. These 
data guided us to the design of two clinical studies. The ﬁ rst, a pilot study used a 
non-optimised two-fold illumination scheme with equal light fractions (5). While 
the long-term response data in this study showed that complete response rate (CR) 
remains high compared to CR in the literature, we found no signiﬁ cant difference 
in CR 1 year after PDT. The second, large-scale randomised comparative study using 
the optimised illumination scheme showed a signiﬁ cant increase in CR of sBCC at 
one year compared to ALA-PDT in a single light fraction (6). A number of alternative 
approaches targeted at enhancing the efﬁ cacy in ALA-PDT have been investigated. 
These have focussed on improving the uptake of ALA and/or the accumulation of 
protoporphyrin IX (PpIX) using penetration enhancers, iontophoresis, iron chelators 
(13-17). An important development in this area has been the use of other porphyrin 
precursors that are derivatives of ALA (18-21).The use of methyl 5-aminolevulinate 
(MAL/Metvix®) has been studied extensively both in-vitro and clinically. MAL based 
PDT is now an approved treatment modality for actinic keratosis (AK) in the USA 
and for non-melanoma skin cancers, such as sBCC and Bowens disease, in Europe 
and Australia. The recommended treatment protocol involves the topical application 
of MAL cream (160 mg/g) for 3 hours followed by a single red light illumination 
and a repetition of this treatment one week later (22).Considering the increasing 
clinical use of MAL and the expected gain in efﬁ cacy by light fractionation we 
have investigated the response of normal hairless mouse skin to MAL-PDT using 
a single and a two-fold illumination scheme. Although every two-fold illumination 
scheme ever investigated using ALA resulted in more damage compared to a single 
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illumination scheme we chose to investigate the most effective scheme (11,12). 
We compare these data to our earlier published data on ALA-PDT using the same 
illumination schemes (12).
EXPERIMENTAL
Animal model 
Female inbred albino hairless mice (SKH1 HR, Charles River, Someren, The 
Netherlands), aged between 8 and 10 weeks, were included in this study. Prior to 
treatment animals were fed on a chlorophyll free diet (Hope Farms b.v., Woerden, The 
Netherlands) for a minimum of two weeks in order to remove the autoﬂ uorescence 
emission from mouse skin centered on 675 nm attributed to pheophorbide-a. The 
animal experiments committee of the Erasmus University Medical Centre approved 
the experimental protocol.
Chemicals 
The ALA cream was freshly prepared as described previously (37). Twenty 
percent 5-aminolevulinic acid (ALA, Medac, Hamburg, Germany) dissolved in 3% 
carboxymethylcellulose in water. To prevent skin irritation, the ALA solution was 
prepared to approximately pH 4 by the addition NaOH (2 M). MAL (Metvix®, 160 
mg/g, Galderma, Freiburg, Germany) or ALA was topically applied to a 7 mm 
diameter area on the dorsal skin and covered with a thin layer of gauze. A polythene 
dressing (Tegaderm, 3M, The Netherlands) was used to occlude the area for 4 
hours prior to treatment. Before application of cream animals received anaesthesia 
(Hypnorm; ﬂ uanisol/fentanyl mixture, Janssen Pharmaceutics, Belgium or Ketamine; 
Alfasan Woerden, The Netherlands and Diazepam, Centrafarm b.v., Etten-Leur, The 
Netherlands) to alleviate possible anxiety caused by the dressing. 
EXPERIMENTAL DESIGN
The visual and histological response to MAL-PDT using either a single or a two-
fold illumination was investigated in two separate series of experiments using the 
normal mouse model. We have previously shown that visual response data obtained 
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in this model correlates well with the visual response of UVB induced tumour and 
tumour growth delay (4,5). We have also shown that optimisation of response in 
normal mouse skin can lead to the design of clinically relevant fractionation schemes 
(1,2). In the ﬁ rst series the visual skin damage in the ﬁ rst 7 days after MAL-PDT 
was investigated (n=6, in each) and compared to that after ALA-PDT using data 
obtained previously (12). A power analysis showed that this number of animals 
would be sufﬁ cient to resolve a difference in response to the single and two-fold 
illumination similar to that observed after ALA-PDT. In a second series of experiments 
the histological damage after PDT with ALA and MAL was investigated. In total 14 
groups of mice (n=5-6) were treated. Two groups served as ALA and MAL dark 
controls in which skin samples were collected at the end of the application period. 
In the 12 remaining groups skin samples were collected at 2.5, 24 or 48 hours after 
the end of illumination. In both series the PpIX ﬂ uorescence kinetics were recorded 
during illumination. 
PDT LIGHT DELIVERY AND FLUORESCENCE DETECTION
After 4 hours of topical application with ALA or MAL the skin was illuminated using 
either a single light fraction of 100 J cm-2 at 50 mW cm-2 or a two-fold illumination 
scheme with 5 + 95 J cm-2 at 50 mW cm-2 separated by a 2 hours dark interval. The 
experimental set-up used for the PDT illumination and ﬂ uorescence detection was 
based on that described previously (29). The 514 nm output from the argon ion laser 
was focussed on a 7 mm diameter spot of homogeneous proﬁ le on the skin of the 
mouse. The ﬂ uorescence emission from the illuminated area was focussed through a 
system of lenses onto a CCD camera (ORCA-ER, Hamamatsu, Japan). Excitation light 
was ﬁ ltered using a dichroic mirror (535 nm, Omega Optical, Barttleboro, US) and 
a 635 nm interference ﬁ lter (Melles Griot, Didam, The Netherlands). Fluorescence 
images were collected before pre-cursor application, during application and during 
illumination using the therapeutic light without interruption of the illumination using 
different light ﬂ uences and different integration times. Before each measurement 
a ﬂ uorescence standard was recorded to correct for these differences. The ﬂ uence 
used for each ﬂ uorescence measurements before and during the application period 
was approximately 0.005 J cm-2 at 0.5 mW cm-2. Mice were anaesthetized with a 
combination of 2 % Ethrane or Isoﬂ urane (Abbott, Amstelveen, The Netherlands) 
oxygen and N2O for each illumination or ﬂ uorescence measurement.
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VISUAL SKIN DAMAGE
The biological damage to the irradiated area was assessed daily by two 
independent observers (HSB and APH) blinded from the treatments using the visual 
skin damage scoring system described previously (33). No change in skin colour 
was scored as 0. Scores 1 to 3 were used for increasing discoloration of the skin, 1 
meaning minimal redness and 3 meaning severe redness. Thin crust formation was 
scored as 4 and thick crust formation was scored as 5. Damage was observed to 
be inhomogeneous in a number of treatments. Photographs were taken regularly 
in order to determine the degree and distribution of damage. The damage score 
of the total illuminated area in one animal at one time point was calculated by 
scoring areas according to the degree of damage related to the contribution to the 
total illuminated area. The visual skin damage of a single mouse was quantiﬁ ed by 
calculating the area under the curve of skin damage when plotted against time, 
over the ﬁ rst 7 days resulting in the integrated damage score. 
PpIX ﬂ uorescence imaging and data analysis 
Fluorescence images were recorded before application of the precursor 
(autoﬂ uorescence), during the application period at 1 and 2 hours and during 
illumination (every 10 seconds). The mean gray scale value was calculated 
over a large ﬁ eld at the centre of the illuminated area (approximately 65%). To 
calculate the absolute PpIX ﬂ uorescence the background values and the individual 
autoﬂ uorescence were subtracted. A series of measurements during an illumination 
was normalised to the ﬁ rst measurement of that illumination. The rate of 
photobleaching over the ﬁ rst 5 J cm-2 of each illumination was determined as the 
slope of the reciprocal of the normalised PpIX ﬂ uorescence using linear regression 
ﬁ tting (30). In total 79 mice were illuminated. Data of 16 mice were excluded from 
analysis due to technical reasons like computer storage failures or focussing and 
movement problems, resulting in n=12 for the two ALA-PDT groups and n=20 and 
19 for the MAL-PDT groups treated according to a single or a two-fold illumination 
scheme respectively. 
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HISTOLOGY
A pathologist (KH) blinded from the treatments scored the histological response 
by analysing the H&E stained sections of the obtained skin samples. The response of 
the different layers of the skin was scored separately. We distinguished the epidermis, 
the upper dermis, the lower dermis and muscle. Tissue damage was observed 
and scored according to 4 categories: ++ for coagulative necrosis (eosinophilia, 
loss of structure and undetectable nuclei), + for karyorrhexis (eosinophilia, loss of 
structure but (fragmented) nuclei could still be recognised) +- for pyknosis (nuclei 
were shrunk and showed basophilia) and - for no visual damage. The most severe 
damage observed was scored. Epidermal thickening (hyperplasia) and demarcation 
of dead tissue by dense polymorphonuclear inﬁ ltrates/crust formation were signs of 
sub-lethal and lethal cellular damage, respectively. Expected late effects are loss of 
hair follicles and sebaceous glands and dermal ﬁ brosis.
STATISTICS
The signiﬁ cance of differences in PDT damage and rate of photobleaching was 
determined using the student-t test and P<0.05 was considered signiﬁ cant. Results 
are shown as mean ± standard deviation.
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RESULTS
RESPONSE TO PDT
 
The mean visual skin damage scored over the ﬁ rst 7 days post MAL-PDT with a 
single or a two-fold illumination scheme is plotted in ﬁ gure 1. 
Figure 1: The visual skin damage scores for the ﬁ rst 7 days after MAL-PDT. All groups were illuminated with 
50 mW cm-2 to a cumulative light ﬂ uence of 100 J cm-2 delivered in a single fraction (■) or in two fractions 
(5+95 J cm-2 with a 2 hours dark interval) (□). Mean ± SD.
Thin crusts were formed already at day one after MAL-PDT using a single light 
fraction that developed into thick crusts over time. These crusts became detached 
at day 4. Light fractionation using the two-fold illumination scheme didn’t show 
a signiﬁ cantly different response. The skin damage at day 1 was less pronounced, 
crusts were formed in all animals but became detached between day 3 to 5. 
 The mean of the integrated visual skin damage scores over day 1-7 was 22.6 ± 
1.2 and 21.1 ± 3.1 for the single and the two-fold illumination scheme respectively. 
The use of a two-fold illumination scheme after MAL application did not result in 
signiﬁ cantly more PDT induced visual damage compared to a single illumination 
scheme (P=0.29) in contrast to the results previously obtained with ALA-PDT (8).
 In general, the histological observations were in agreement with the visual 
skin damage scores; after a single illumination MAL-PDT resulted in more damage 
compared to ALA and the increase in damage after a two-fold illumination was 
not seen using MAL. At 2.5 hours after the end of PDT all groups showed a similar 
picture of no damage or only slight pycnosis in the epidermal layer. Thereafter 
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marked differences occurred. While with ALA both a single and a fractionated 
illumination resulted in a variable response that slightly increased from 24 to 48 
hours, MAL-PDT showed a deeper damage in more animals for both illumination 
and both time points. Figure 2 shows the mean histological response score for each 
skin layer at each time point for both ALA and MAL. Note that the most severe 
damage observed in the tissue layer is scored and that we have not compensated 
for differences in spatial distribution of damage as we have done in the visual skin 
damage scoring system. Non-illuminated controls showed no damage.
Figure 2: The mean PDT induced damage scored using histology at 24 hours ALA or MAL-PDT. All groups 
were illuminated with 50 mW cm-2 to a cumulative light ﬂ uence of 100 J cm-2 delivered in a single fraction or 
in two fractions (5+95 J cm-2 with a 2 hours dark interval). The most severe damage was scored in each layer 
of the skin separately; epidermis (black bar), upper dermis (gray bar) and lower dermis (white bar). Mean ± 
SD.
FLUORESCENCE INTENSITY DURING MAL AND ALA APPLICATION
The mean PpIX ﬂ uorescence kinetics after topical MAL or ALA application and 
during illumination are shown in ﬁ gure 3. An insert shows the kinetics during the 
ﬁ rst 10 J cm-2 for clarity. The autoﬂ uorescence of normal mouse skin was 39.3 ± 9.7 
counts. The PpIX ﬂ uorescence 4 hours after the application of ALA or MAL was not 
signiﬁ cantly different (1107 ± 358 or 1021 ± 408 counts respectively, P=0.40). The 
relative ﬂ uorescence intensity during the application period at 1 and 2 hours was 
higher using ALA compared to MAL (15 ± 2% and 10 ± 6% at 1 h and 47 ± 11% 
and 32 ± 13% at 2 h respectively, p=0.17 and 0.22).
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Figure 3: The mean PpIX ﬂ uorescence during illumination with 50 mW cm-2 to 100 J cm-2 delivered in (a) a 
single fraction or in (b) two fractions (5+95 J cm-2 with a 2 hours dark interval) after topical ALA (●) or MAL 
(○) application (n=12 for both ALA groups and 20 and 19 for the MAL groups respectively). The results over 
the ﬁ rst 10 J cm-2 are shown in the inserts for clarity. Mean ± SD.
FLUORESCENCE KINETICS DURING MAL AND ALA-PDT
There was no signiﬁ cant difference in the extent of photobleaching during the 
ﬁ rst illumination using ALA or MAL (46.8 ± 3.3 % and 50.1 ± 5.3% respectively, 
P=0.06). Furthermore, we saw no signiﬁ cant difference in the amount of PpIX re-
synthesis during the dark interval between the two light fractions (62.1 ± 14.0 
% and 71.3 ± 24.6% respectively, P=0.25). The photobleaching kinetics during 
illumination followed a second order decay for both porphyrin precursors. This is 
illustrated by the linearity of the reciprocal of the normalized PpIX ﬂ uorescence, as 
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a function of light ﬂ uence. Figure 4 shows the kinetics of photobleaching over the 
ﬁ rst 5 J cm-2 for each light fraction.
Figure 4: The weighted mean reciprocal of the normalised PpIX ﬂ uorescence during the ﬁ rst 5 J cm-2 of each 
light fraction of illumination with 50 mW cm-2 to 100 J cm-2 delivered in (a) a single fraction or in (b) two 
fractions (5+95 J cm-2 with a 2 hours dark interval) after topical ALA (●) or MAL (○) application (n=12 for both 
ALA groups and 20 and 19 for the MAL groups respectively). Mean ± SD
 Figure 5 shows the variation between animals in the calculated initial rate of 
photobleaching for each light fraction. Combining photobleaching data from the 
ﬁ rst 5 J cm-2 of the single illumination scheme and the ﬁ rst light fraction of the 
two-fold illumination, PpIX ﬂ uorescence bleached at a greater rate following the 
application of ALA compared to MAL. While this difference is small it is signiﬁ cant (P 
= 0.005; n=39 for MAL-PDT and n=24 for ALA-PDT). The rate of PpIX photobleaching 
during the second light fraction of the two-fold illumination was not signiﬁ cantly 
different using ALA or MAL although for both PpIX precursors it was signiﬁ cantly 
lower compared to the ﬁ rst light fraction.
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Figure 5: A box & whisker plot of the rate of photobleaching during the ﬁ rst 5 J cm-2 of each illumination 
after topical ALA or MAL application. * signiﬁ cant difference in rate of photobleaching with P=0.005 between 
MAL and ALA. ** signiﬁ cant difference in rate of photobleaching with P< 0.001 between the ﬁ rst and the 
second light fraction of the two-fold illumination.
DISCUSSION
Contrary to our expectations, we have found signiﬁ cant differences in the 
response of normal mouse skin to MAL-PDT compared to ALA-PDT (12). We have 
shown that there is signiﬁ cantly more visual skin damage following MAL-PDT 
compared to ALA (12) using a single light fraction although the difference was small 
and may not be clinically relevant. More importantly, we have also shown that light 
fractionation does not enhance efﬁ cacy in MAL-PDT in the way it does using ALA. 
Histological examination 24 and 48 h after therapy supports these ﬁ ndings. While the 
differences in response to PDT using ALA and other pro-drugs of ALA is an interesting 
subject for investigation they may also expand our understanding of the mechanism 
underlying the response of tissues to PDT using the two-fold illumination scheme. 
Numerous in-vitro studies have compared the uptake of ALA and its derivatives, and 
investigated porphyrin synthesis and cell survival (23,24). However relatively few in-
vivo pre-clinical studies have compared the pharmacokinetics of PpIX synthesis (25) 
and importantly none, to our knowledge, have investigated the response to PDT. 
Only two clinical studies have compared the clinical response of AK (26) and BCC 
(27) to ALA and MAL-PDT. Both studies found no difference in clinical response 
to PDT with ALA and MAL although they were probably insufﬁ ciently powered to 
detect small differences in response of the magnitude that we have observed in the 
present study. 
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The pharmacokinetics of PpIX ﬂ uorescence in normal mouse skin during the 
4-h application period is similar for both porphyrin pre-cursors. At 1, 2 and 4 hours 
during the application period the ﬂ uorescence intensity is not signiﬁ cantly different 
for animals receiving MAL or ALA. This is in agreement with the results reported by 
Moan who found similar PpIX ﬂ uorescence intensities and concentrations in mouse 
skin after 1 and 5 hours topical ALA or MAL application (25). We have chosen a 4-h 
application period for both precursors. While this is longer than the 3 hours that is 
normally used clinically,Juzenas et al (28) have shown that there is no clear difference 
in PpIX ﬂ uorescence intensity using an application time of 3 or 4 hours. That equal 
PpIX ﬂ uorescence intensities are found immediately prior to the start of the ﬁ rst 
light fraction is advantageous since large variations in initial PpIX concentration can 
inﬂ uence visual skin response for standardised illumination conditions (29). 
The kinetics of PpIX ﬂ uorescence during the two-fold illumination scheme show 
that we do not observe signiﬁ cant differences in the extent of photobleaching 
after each light fraction between ALA and MAL. The kinetics of PpIX ﬂ uorescence 
during MAL-PDT are similar to that published by Moan et al. (30) Also we observed 
similar amounts of PpIX re-synthesis in the dark interval between light fractions 
for both ALA and MAL. Therefore the total amount of PpIX utilized during the 2-
fold illumination is not signiﬁ cantly different for MAL and ALA. The fact that these 
observations are accompanied by a dramatically different PDT response adds weight 
to our previous conclusions that the total amount of PpIX re-synthesized during 
the dark interval is not involved in the mechanism of action behind the response 
of tissues to the two-fold illumination scheme (11,31).  We have previously shown 
that the PDT dose delivered during the ﬁ rst light fraction is a critical parameter that 
can strongly inﬂ uence the effectiveness of the 2-fold illumination scheme (10,11). 
Furthermore we have shown that the rate of PpIX photobleaching can be used as 
an indirect measure of the amount of singlet oxygen produced during PDT and can 
be used to report PDT dose and correlates with response (29, 32-34). Recently direct 
evidence for the relationship between the generation of singlet oxygen during PDT 
and visual skin response in normal mouse skin has been reported (35). Monitoring 
photobleaching during fractionated ALA-PDT gives an important indication of the 
PDT dose delivered. A faster rate of photobleaching correlates with a higher PDT 
dose. In the present study we observe that the rate of photobleaching during the 
ﬁ rst light fraction of ALA-PDT is slightly but signiﬁ cantly greater than that of MAL-
PDT. According to our current understanding of the magnitude of the PDT dose 
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delivered during the ﬁ rst light fraction on the response of tissues to the 2-fold 
illumination scheme, this difference in the rate of photobleaching is small and does 
not explain the lack of an increase in efﬁ cacy in MAL-PDT. The rate and extent of 
PpIX photobleaching during the ﬁ rst light fraction of MAL-PDT is well within the 
margins of what is considered optimal using ALA (11).
An important difference between ALA and MAL, or other ester derivatives of 
ALA, is their tissue distribution due to their different biophysical and biochemical 
characteristics. The cellular uptake of MAL is different from that of ALA (36). While 
the vehicle in which the pre-cursors are dissolved might also effect the distribution 
this seems less important since Moan et al (25) used the same vehicle for both 
MAL and ALA and still showed a different distribution. The authors detected PpIX 
ﬂ uorescence at distant sites after topical ALA application whereas it remained within 
the application site after MAL application. From this observation they concluded 
that ALA is systemically distributed after topical application whereas MAL is not. 
The consequences of these effects for the distribution of ALA or MAL and therefore 
PpIX within the treatment volume are unknown. It is possible that there is a different 
distribution of PpIX following the application of ALA and MAL and this has an 
important effect on the response of tissues to PDT. The present study is limited 
by the fact that normal mouse skin is relatively thin (approximately 50 μm) and 
layered and that the PpIX ﬂ uorescence is monitored from the surface of the skin. 
The microscopic distribution of PpIX ﬂ uorescence within mouse skin has not been 
systematically investigated. Besides the difference in (depth) distribution of MAL or 
ALA within the tissue also other factors may play a role. The microenvironment of 
a cell may be different when it is loaded with MAL or ALA due to the differences 
in molecular structure and processes involved in the de-esteriﬁ cation of MAL. How 
these factors effect the PDT response in mouse skin is unknown but they have 
not been found to be important factors in vitro (23, 24).A different distribution 
of MAL and therefore PpIX in the treatment volume leads to a different site of 
PDT damage and could explain the difference in visual damage following ALA and 
MAL-PDT using the single illumination scheme. The small but signiﬁ cantly lower 
initial rate of PpIX photobleaching during MAL-PDT (ﬁ gure 5, see above) may be 
a consequence of a different microenvironment due to a different localization of 
PpIX. We acknowledge that superﬁ cial photobleaching measurements are probably 
not a particularly sensitive method of determining differences in photosensitiser 
localization. It is important to recognize that it is necessary to perform a ﬁ rst light 
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fraction followed by a two-hour interval to observe a signiﬁ cant increase in response 
using ALA (12). Previously we have hypothesized that cells surviving the ﬁ rst light 
fraction are more susceptible to the second light fraction (12). Since this is not 
true for MAL-PDT the site of PDT induced damage should be considered as an 
important parameter in the mechanism underlying the 2-fold illumination scheme. 
Apparently the site of PDT induced damage combined with the two-hours dark 
interval between light fractions is important for the increased efﬁ cacy observed 
using light fractionation during ALA-PDT. 
We have previously shown that pre-clinical results obtained in normal mouse 
skin using ALA-PDT can be successfully translated to a clinical treatment protocol for 
sBCC that results in a signiﬁ cantly improved CR (6). The results of the present study 
imply that simply combining MAL-PDT and the most effective two-fold illumination 
scheme, determined for ALA, in the clinic would not enhance the efﬁ cacy of MAL-
PDT using a single light fraction. It is possible that the illumination parameters 
used in the present study are not optimal for MAL. However, it is important to 
note that light fractionation in ALA-PDT always enhances the response of tissue 
compared to a single illumination. We note that more pre-clinical research on the 
mechanism behind the increased effectiveness of the two-fold illumination using 
ALA and the mechanism of PDT induced damage using MAL is needed to conﬁ rm 
this assumption. 
REFERENCES 
1. Kennedy JC, Pottier RH and  Pross DC. Photodynamic Therapy with endogeneous 
protoporphyrin IX, basic priniciples and present clinical experience. J. Photochem. Photobiol. 
B:Biol. 1990, 6, 143-148.
2. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of 
a workshop of the British Photodermatology Group. Br. J. Dermatol. 2002; 146: 552-567. 
3. Kelty CJ, Ackroyd R, Brown NJ et al. Endoscopic ablation of Barrett’s oesophagus: a 
randomized-controlled trial of photodynamic therapy vs.Argon plasma coagulation. Aliment. 
Pharmacol. Ther. 2004; 20: 1289-1296.
4. Bogaards A, Varma A, Zhang K et al. Fluorescence image-guided brain tumour resection 
with adjuvant metronomic photodynamic therapy: pre-clinical model and technology 
development. Photochem. Photobiol. Sci. 2005; 4: 438-442.
124 | Chapter 6
5. Star WM, van ‘t Veen AJ, Robinson DJ et al. Topical 5-aminolevulinic acid mediated 
photodynamic therapy of superﬁ cial basal cell carcinoma using two light fractions with a 
two hour interval: long-term follow up. Acta Derm. Venereol. 2006; 86: 412-417. 
6. de Haas ERM, Kruijt B, Sterenborg HJCM et al. Fractionated illumination signiﬁ cantly improves 
the response of superﬁ cial basal cell carcinoma to aminolevulinic acid photodynamic therapy. 
J. Invest. Dermat. 2006; 126: 2679-2686.
7. van der Veen N, van Leengoed HLLM,Star WM. In vivo ﬂ uorescence kinetics and photodynamic 
therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple 
irradiations. Br J Cancer. 1994; 70: 867-872. 
8. van der Veen N, Hebeda KM, de Bruijn HS, Star WM. Photodynamic effectiveness and 
vasoconstriction in hairless mouse skin after topical 5-aminolevulinic acid and single- or two-
fold illumination. Photochem Photobiol. 1999; 70: 921-929.
9. de Bruijn HS, van der Veen N, Robinson DJ, Star WM. Improvement of systemic 5-
aminolevulinic acid photodynamic therapy in-vivo using light fractionation with a 75-minute 
interval. Cancer Res. 1999; 59: 901-904.
10. Robinson DJ, de Bruijn HS, de Wolf J et al. Topical 5-aminolevulinic acid-photodynamic 
therapy of hairless mouse skin using two-fold illumination schemes: PpIX ﬂ uorescence 
kinetics, photobleaching and biological effect. Photochem Photobiol. 2000; 72: 794-802.
11. Robinson DJ, de Bruijn HS, Star WM, Sterenborg HJCM. Dose and timing of the ﬁ rst light 
fraction in two fold illumination schemes for topical ALA-mediated photodynamic therapy 
of hairless mouse skin. Photochem Photobiol. 2003; 77: 319-323.
12. de Bruijn HS, van der Ploeg-van den Heuvel A, Sterenborg HJCM, Robinson DJ.Fractionated 
illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice; 
the inﬂ uence of the dark interval. J Photochem Photobiol B:Biol. 2006; 85: 184-190.
13. Casas A, Fukuda H, Di Venosa G, Battle AM. The inﬂ uence of the vehicle on the synthesis 
of porphyrins after topical application of 5-aminolaevulinic acid. Implications in cutaneous 
photodynamic sensitization. Br J Dermatol. 2000; 143: 564-572.
14. Lopez RF, Bentley MV, Begona Delgado-Charro M, Guy RH. Optimization of aminolevulinic 
acid delivery by iontophoresis. J Control Release. 2003,;88: 65-70.
15. Choudry K, Brooke RC, Farrar W, Rhodes LE. The effect of an iron chelating agent on 
protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic 
therapy.Br J Dermatol. 2003; 149: 124-130.
16. Curnow A, McIlroy BW, Postle-Hacon MJ et al. Enhancement of 5-aminolaevulinic acid-
induced photodynamic therapy in normal rat colon using hydroxypyridione iron chelating 
agents. Br J Cancer 1998; 78: 1278-1282.
light fractionation does not enhance the efﬁ cacy of MAL-PDT | 125
17. Curnow A, MacRobert AJ, Bown SG. Comparing and combining light dose fractionation 
and iron chelation to enhance experimental photodynaimic therapy with aminolevulinic acid. 
Lasers Surg Med. 2006; 38: 325-331.
18. Kloek J, Beijersbergen van Hennegouwen G. Prodrugs of 5-aminolevulinic acid for 
photodynamic therapy. Photochem Photobiol. 1996; 64: 994-1000.
19. Casas A, Battle A. Rational design of 5-aminolevulinic acid derivatives aimed at improving 
photodynamic therapy. Curr Med Anticancer Agents. 2002; 2: 465-475.
20. Fortinos N, Campo MA, Popowycz F et al. 5-Aminolevulinic acid derivatives in photomedicine: 
basics, application and perspectives. Photochem Photobiol. 2006; 82: 994-1015.
21. Battah S, O’Neill S, Edwards C et al. Enhanced porphyrin accumulation using dendritic 
derivatives of 5-aminolaevulinic acid for photodynamic therapy: an in vitro study. Int J 
Biochem Cell Biol. 2006; 38: 1382-92.
22. Tarstedt M, Rosdahl I, Berne B et al. A randomized multicenter study to compare two 
treatment regimens of topical methyl aminolevulinate (Metvix) – PDT in actinic keratosis of 
the face and scalp. Acta Derm Venereol. 2005; 85: 424-428.
23. Gaullier JM, Berg K, Peng Q et al. Use of 5-aminolevulinic acid esters to improve photodynamic 
therapy on cells in culture. Cancer Res. 1997; 157: 1481-1486.
24. Casas A, Fukuda H, Di Venosa G, Batlle A. Photosensitization and mechanism of cytotoxicity 
induced by the use of ALA derivatives in photodynamic therapy. Br J Cancer. 2001; 85: 279-
284.
25. Moan J, Ma LW, Juzeniene A  et al. Pharmacology of protoporphyrin IX in nude mice after 
application of ALA and ALA esters. Int J Cancer. 2003; 103: 132-135.
26. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 
versus methyl aminolevulinate. J Am Acad Dermatol. 2006; 54: 647-651.
27. Kuijpers DI, Thissen MR, Thissen CA, Neumann HAM. Similar effectiveness of methyl 
aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal 
cell carcinoma. J Drug Dermatol. 2006; 5: 642-645.
28. Juzenas P, Sharfaei S, Moan J, Bissonnette R. Protoporphyrin IX ﬂ uorescence kinetics in UV-
induced tumours and normal skin of hairless mice after topical application of 5-aminolevulinic 
acid methyl ester. J. Photochem. Photobiol. B:Biol. 2002; 67: 11-17.
29. Robinson DJ, de Bruijn HS, van der Veen N et al. Fluorescence photobleaching of ALA-
induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the 
effect of light dose and irrandiance and the resulting biological effect. Photochem Photobiol. 
1998; 67: 140-149. 
126 | Chapter 6
30. Moan J, Ma LW, Iani V, Juzeniene A. Inﬂ uence of light exposure on the kinetics of 
protoporphyrin IX formation in normal skin of hairless mice after topical application of 5-
aminolevulinic acid methyl ester. J Invest Dermatol. 2005; 125: 1039-1044.
31. de Bruijn HS, Sluiter W, van der Ploeg-van den Heuvel A et al. Evidence for a bystander role of 
neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy. 
Photodermatol Photoimmunol Photomed. 2006; 22: 238-246. 
32. Boere IA, Robinson DJ, de Bruijn HS et al. Monitoring in situ dosimetry and protoporphyrin 
IX ﬂ uorescence photobleaching in the normal rat esophagus during 5-aminolevulinic acid 
photodynamic therapy. Photochem Photobiol. 2003; 78: 271-277.
33. Robinson DJ, de Bruijn HS, van der Veen N et al. Protoporphyrin IX ﬂ uorescence photobleaching 
during ALA-mediated photodynamic therapy of UVB-induced tumours in hairless mouse 
skin. Photochem Photobiol. 1999;69: 61-70.
34. Boere IA, Robinson DJ, de Bruijn HS et al. Protoporphyrin IX ﬂ uorescence photobleaching 
and the response of rat barret’s esophagus following 5-aminolevulinic acid photodynamic 
therapy. Photochem Photobiol. 2006; 82: 1638-1644.
35. Niedre MJ, Yu CS, Patterson MS, Wilson BC. Singlet oxygen luminescence as an in vivo 
photodynamic therapy dose metric: validation in normal mouse skin with topical amino-
levulinic acid. Br J Cancer 2005; 92: 298-304. 
36. Rud E, Gederaas O, Høgset A , Berg K. 5-Aminolevulinic acid, but not 5-aminolevulinic acid 
esters, is transported into adenocarcinoma cells by system BETA transporters.  Photochem. 
Photobiol. 2000; 71: 640-647.
37. van der Veen N, de Bruijn HS, Berg RJ, Star WM. Kinetics and localisation of PpIX ﬂ uorescence 
after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated 
mice. Br J Cancer 1996; 73: 925-930.
CHAPTER 7
Quality of clinical practice guidelines in 
dermatological oncology
Ellen RM de Haas, Hannah C de Vijlder, 
Wibbien Siewertz van Reesema, Jannes JE van Everdingen, 
HA Martino Neumann
Journal of the European Academy of 
Dermatology and Venereology, 2007; 21: 1193-8
128 | Chapter 7
ABSTRACT
Background: Clinical practice guidelines are increasingly used. To determine the 
quality of guidelines the Appraisal of Guidelines and Research and Evaluation 
(AGREE) instrument was developed and introduced in 2001. The AGREE instrument 
consists of 23 criteria, grouped in six domains.
 
Objective: Assessment of quality of evidence-based guidelines in dermatological 
oncological care according to the AGREE instrument.
Methods: We searched MEDLINE, PubMed, EMBASE and Cochrane literature 
and relevant websites of guidelines development programmes and the national 
dermatological society to identify evidence-based dermatological guidelines 
especially in the treatment of  basal cell carcinoma, squamous cell carcinoma and 
melanoma. Twenty guidelines, published between 1990 and 2005, were appraised 
according to the AGREE instrument by three authors. Standardized domain scores 
were calculated as advised by AGREE. We compared guidelines published before 
2002 with those published later.
Results: Domain scores in the domains Scope & Purpose and Clarity were scored 
best. Applicability and Editorial Independence were scored worse (see Table 1). In 
time a weak trend towards better guidelines was seen. This trend can be attributed to 
better scores in the domains Search Strategy and Level of Evidence which are closely 
related to evidence-based medicine. The increase in score is due to more explicitly 
mentioning the search strategy, possible conﬂ ict of interest and involvement of 
different specialties in development of the guideline. Using the Mann–Whitney test 
to compare guidelines published before the AGREE and afterwards only a statistically 
signiﬁ cant better score was found for the domain Clarity ( P < 0.05; Table 2).
Conclusions: Guidelines in dermatological oncological care are of reasonable 
quality according to the  AGREE instrument. The domains in the AGREE instrument 
concern especially the methods of  development of guidelines. The score according 
to AGREE can be improved by explicitly mentioning the different items. As clinical 
guidelines are regarded to be an important instrument to improve quality of care, 
improvements are needed.
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INTRODUCTION
Clinical practice guidelines are increasingly used throughout the world to improve 
the quality of patient care.(1) They are expected to facilitate more consistent, 
effective and efﬁ cient medical practice and improve health outcomes. The quality 
of clinical practice guidelines is varying. Underlying principles of evidence-based 
medicine seems to be clear, but in daily practice it may be hard to judge quality of the 
methodology of published guidelines and their clinical content. Several studies have 
suggested that many guidelines are of poor quality. (2–5) The research community 
recognized the need for  internationally accepted criteria for guidelines and in 
1998 the Appraisal of Guidelines and Research and Evaluation (AGREE) project was 
established. Researchers from 13 countries developed the AGREE instrument.
This is a validated generic instrument for the appraisal of guidelines applicable to 
any disease.(6)
The instrument, published in 2001, provides a tool consisting of 23 criteria, grouped 
in six domains (Scope & Purpose, Stakeholder Involvement, Methodology, Clarity 
and Presentation, Applicability, and Editorial Independence; see Appendix 1, www.
agreecollaborationgroup.org). This instrument is designed to assess the process 
of guidelines development and how well this process has been reported. In this 
article, we  present a quality assessment of clinical practice guidelines on dermato-
oncological care. We assessed the quality of guidelines on the treatment of basal 
cell carcinoma, squamous cell carcinoma and   melanoma.
METHODS
Selection of guidelines
The authors conducted a MEDLINE, PubMed, EMBASE and Cochrane literature search 
of guidelines from 1990 to 2005 using search terms alone and/or in combination:
skin disease, practice guidelines, healthcare planning,evidence-based medicine, 
meta-analysis, consensus development. In addition, a search was  performed using 
the search engine provided by the websites of guideline development programmes 
and national dermatological societies. The search provided 200 guidelines. By 
narrowing the search to  guidelines concerning the three most common forms of 
skin cancer – melanoma, squamous cell  carcinoma and basal cell carcinoma – 59 
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guidelines remained. Search results that were duplicates of the same guidelines, 
published before 1990, background documents were removed. Twenty guidelines 
remained and were appraised according to the criteria of the AGREE instrument 
(see Appendix 2). Two versions of the Dutch melanoma guideline were appraised, 
one version published in 1997 and the updated version published in 2005. A 
comparison of  two groups of guidelines was performed: those published before 
2002 reﬂ ecting the guidelines published before the AGREE instrument and those 
published afterwards.
Appraisers 
Three authors (EdH, HdV, WSvR) assessed the quality according to the AGREE 
instrument. HdV and WSvR are residents in dermatology. EdH is a dermatologist.
 
Analysis 
Standardized domain scores are calculated as advised by AGREE. A standardized 
score above 60% is concordant with a positive agreement of the involved criteria. 
All appraisers scored individually. The deﬁ nitive score was noted in consensus. To 
compare differences in scoring between guidelines published before the introduction 
of the AGREE instrument in 2001 and after, the guidelines published before 2002 
and afterwards were statistically compared by using the non-parametric Mann–
Whitney t-test. P< 0.05 was considered to be statistically signiﬁ cant.
RESULTS
There was a marked difference in scoring between the six domains in all 25 guidelines 
as is shown in Table 1. A standardized domain score above 60% is considered to be 
good and is marked in the table.
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Table 1:  Standardized domain scores 
author country
Year of 
publ.
Scope 
&Purpose
Stakeholders Rigour Clarity Applicability
Editorial
indepen-
dence
Drake USA 1992 28 21 5 13 0 0
Drake USA 1993 72 25 14 25 0 0
Drake USA 1995 67 25 5 25 0 0
De Ruiter NL 1997 33 21 29 66 11 3
Cox UK 1999 67 33 24 46 6
Telfer UK 1999 89 29 43 58 28 0
Reeve AUS 1999 100 100 88 71 44 0
Negrier FR 2000 72 46 48 66 0 50
Dummer Swiss 2001 83 63 36 63 0 8
Cook USA 2001 83 25 67 58 11 50
Sober USA 2001 100 38 67 67 0 33
Sober USA 2001 100 33 55 42 0 0
Motley UK 2002 83 25 45 58 0 33
Motley UK 2002 89 38 40 67 0 0
Roberts UK 2002 78 33 45 58 0 0
Roberts UK 2002 100 50 29 71 61 0
Marks AUS 2002 100 100 57 71 50 0
Beljaards NL 2003 78 54 88 67 44 0
Doherty Scotland 2004 89 88 69 88 39 75
Rademaker NZ 2004 11 25 17 50 0 0
Houghton USA 2004 56 33 52 67 44 0
Quirt Canada 2004 100 75 93 71 56 58
Miller USA 2004 33 4 21 38 0 0
De Ruiter NL 2005 62 54 95 79 33 33
The domains Scope & Purpose and Clarity were scored best. Eighteen guidelines 
scored above 60% in the domain Scope & Purpose and 12 guidelines scored above 
60% in the domain Clarity. The domain Editorial Independence was scored worse. 
Only one guideline scored above 60%. Guidelines are listed in chronological order. 
The total score of the updated version of the Dutch melanoma guideline published 
in 2005 is higher than that of the ﬁ rst version published in 1997. The median score 
of guidelines published before and after 2002 only the domain Clarity shows a 
statistically signiﬁ cant different score (P < 0.05; Table 2).
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Table 2: Statistics 
Guidelines before AGREE, n=12 median Percentile< >
Scope & purpose 77.5 <67.0 97.3>
Stakeholders 31.0 <25.0 44>
Rigour 39.5 <16.5 64.0>
Clarity 58 <29.3 66.0>
Applicability 0 <0 11>
Editorial independence 4 <0 33>
Median standardized domain score of guidelines published before the AGREE instrument (<2002).
Guidelines after AGREE, n=11 median Percentile< >
Scope & purpose 83 <56.0 100.0>
Stakeholders 38 <25.0 75.0>
Rigour 45 <29.0 69.0>
Clarity 67 <58.0 71.0>
Applicability 39 <0 50.0>
Editorial independence 0 <0 0>
Median standardized domain score of guidelines published after the publication of the AGREE instrument 
(>2002)
Domain P<
Scope & purpose 0.74
Stakeholders 0.32
Rigour 0.35
Clarity 0.05 9.3-14.9
Applicability 0.21
Editorial independence 0.38
Guidelines published  before AGREE and guidelines published after publication of the AGREE 
instrument.
Using non parametric t test Mann Whitney
DISCUSSION
Clinical practice guidelines are increasingly used. Several studies suggested that 
many of them are of poor quality.(2–5) In order to improve the quality of guidelines, 
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the AGREE instrument was developed and  introduced in 2001. This instrument is 
used for judging and developing guidelines.(7–14)  We used the AGREE instrument 
to appraise 20 guidelines. Those guidelines are of reasonable quality: all but two 
guidelines had at least one domain scoring above 60% which is considered to be 
good. In the course of time between 1990 and 2004 more often the methods 
of searching are mentioned explicitly, combined with a level of evidence. Besides, 
conﬂ ict of interest is mentioned more clearly. The appraisal of the Dutch melanoma 
guideline published in 1997 compared to its updated version published in 2005 is a 
good example of improvement in scoring in time. However, we did not demonstrate 
an overall improvement in guidelines in time. A statistically signiﬁ cant difference 
between the guidelines published before the introduction of the AGREE instrument 
and those published afterwards is only seen in the domain Clarity ( P < 0.05). Our 
opinion is that guidelines of higher quality are developed by using the 23 criteria 
of AGREE. However, describing the 23 criteria in the guideline results in a large 
document and guidelines need to be clear and short for easy use. For that reason a 
short overview on a separated card is added to guidelines in the Netherlands. Useful 
additional information-related literature and links can be discussed at length in a 
background document. 
Evidence-based medicine and AGREE 
Evidence-based medicine is a methodology for evaluating the validity of research in 
clinical medicine and applying the results to the care of individual patients. Evidence 
is gathered through systematic review of literature, and is critically appraised. The 
results are then integrated with physician/patient decision-making. Evidence-based 
medicine (EBM) uses a simple scale to assign a level to evidence. Systematic reviews 
that summarize randomized controlled trials are assigned the highest level of 
evidence. Expert opinions and ‘personal communication’ are assigned the lowest 
level of evidence. The AGREE instrument is based on the principles of evidence-
based medicine. It originates from an international collaboration of researchers and 
policymakers, who work together to improve the quality and effectiveness of clinical 
practice guidelines by establishing a shared framework for their development, 
reporting and assessment. According to EBM and AGREE, guideline development 
requires a clearly deﬁ ned and dated literature search and deﬁ ned levels of evidence. 
Mentioning search strategies makes it easy for users to weigh the quality of a 
guideline. Appraising the actuality of the guideline and suggestions for updating 
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are  underexposed aspects in the AGREE instrument. By mentioning those aspects 
more explicitly in guidelines an updating can be made by the user himself or herself. 
In general the lifespan of a guideline is regarded to be 3 years.(15) In the appraised 
guidelines a limited lifespan is recognized, but only in one-third of them information 
about updating is given. Guidelines based on substantial high level of evidence may 
be more robust over time than those based substantially on experts views.(16) On 
the other hand, using EBM and levels of evidence introduce a risk of overweighing 
randomized  controlled studies. Experts’ opinions and views of stakeholders in the 
ﬁ eld represent an important part of evidence especially because of the longstanding 
empirical base of medical science. (17,18) We suggest to use the most complete 
literature to assign levels of evidence in guidelines. The actuality and an estimated 
lifespan should also be included. 
Patients opinion and AGREE
In guidelines concerning oncological treatment, opinions and preferences of patients 
should be included. Especially important in situations in which ‘quality of life’ plays 
an important role, the patient’s opinion is crucial. Subjects such as morbidity, side-
effects, cosmetic outcome and time consumption can be an important aspect for 
patients.(19) In the appraised guidelines these aspects are not (clearly) included. 
Patients’ instructions, information brochures and other supporting material are 
often not a part of the guideline. In some guidelines, addresses or Internet links of 
supporting societies are provided for general support or support in a special ﬁ eld, for 
example genetic counseling. Sufﬁ cient information and communication is nowadays 
an important requirement in general healthcare.Quality of guidelines can have an 
inﬂ uence on the quality of care. Quality of guidelines should not only be regarded 
in the development phase but also in the practical phase.(20) Furthermore, quality 
of care needs acceptance, implementation and evaluation in a circular way, ﬁ nally 
leading to improvement.(21) Acceptance and implementation is also depending on 
the impact on organizations and patient outcomes as ﬁ nancial consequences and 
recognition of existing barriers. (22–24) Only few guidelines mention these factors.
Quality of clinical practice guidelines in dermatological oncology | 135
CONCLUSION
In this study, we used the standardized domain scores of AGREE to appraise 
guidelines in dermato-oncological care in which we conclude most guidelines to be 
of reasonable quality but improvements are possible and needed as clinical guidelines 
are regarded to be an important instrument to improve quality of care. In course of 
time, trends towards better developed or at least better documented development 
of guidelines is seen. Although only in one domain (Clarity) a statistically signiﬁ cant 
difference is seen between guidelines published before the AGREE instrument and 
after the AGREE instrument. This may be seen as an illustration of the limitations 
of the AGREE instrument. We believe that the AGREE instrument is especially of 
value for those involved in guidelines development more than to be an instrument 
to evaluate quality of guidelines. The 23 criteria can serve as a recipe to prepare 
a complete guideline reﬂ ecting EBM and shared opinions for all participants and 
possible users.
APPENDIX 1: AGREE DOMAIN STRUCTURE
Scope and purpose (item 1-3) is concerned with the overall aim of the guideline, the 
speciﬁ c clinical questions and the target population.
1. The overall objective(s) of the guideline is (are) speciﬁ cally described 
2. The clinical question(s) covered by the guideline is (are) speciﬁ cally described 
3. The patients to whom the guideline is meant to apply are speciﬁ cally described 
Stakeholder involvement (items 4-7) focuses on the extent to which the guideline 
represents the views of its intended users.
4. The guideline development group includes individuals from all the relevant 
     professional groups 
5. The patients’ views and preferences have been sought 
6. The target users of the guideline are clearly deﬁ ned 
7. The guideline has been piloted among end users 
Rigour of development (items 8-14) relates to the process used to gather and 
synthesise the evidence , the methods to formulate the recommendations and to 
update them.
 8. The systematic methods were used to search for evidence 
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9.   The criteria for selecting the evidence are clearly described 
10. The methods used for formulating the recommendations are clearly described 
11. The health beneﬁ ts, side effects and risks have been considered in formulating the 
      recommendations 
12. There is an explicit link between the recommendations and the supporting evidence 
13. The guideline has been externally reviewed by experts prior to its publication 
14. A procedure for updating the guideline is provided Clarity and presentation (items 
      15-18) deals with the language and format of the guideline.
15. The recommendations are speciﬁ c and unambiguous 
16. The different options for management of the condition are clearly presented 
17. Key recommendations are easily identiﬁ able 
18. The guideline is supported with tools for application 
Applicability (item19-21) pertains to the likely organizational, behavioural and cost 
implications of applying the guideline.
19. The potential organisational barriers in applying the recommendations have been 
      discussed 
20. The potential cost implications of applying the recommendations have been 
      considered 
21. The guideline presents key review criteria for monitoring and/or audit purposes 
Editorial independence (item 22-23) is concerned with the independence of the 
recommendations and acknowledgement of possible conﬂ ict of interest from the 
guideline developmentgroup. 
22. The guideline is editorially independent from the funding body
23. Conﬂ icts of interest of guideline development members have been recorded
APPENDIX 2: GUIDELINES AUTHORS AND REFERENCES
1 Drake et al , AAD 1992 ; Guidelines of care for basal cell carcinoma. 
J Am Acad Dermatol. 1992;26:117-20.
2 Drake et al,  AAD 1993; Guidelines of care for cutaneous squamous cell carcinoma.
J Am Acad Dermatol. 1993;28:628-31.
3 Drake et al , AAD 1995 ; Guidelines of care for actinic keratoses. 
J Am Acad Dermatol. 1995;32:95-8.
4 Cox et al,  BAD 1999 ; Guidelines for management of Bowens disease. 
  Br J Dermatol 1999;141:633-41.
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5 de Ruiter et al , CBO 1997 & 2005 ;  Richtlijn melanoom van de huid. 
6 Telfer et al, BAD 1999; Guidelines for the management of basal cell carcinoma.
Br J derm 1999;141:415-23.
 7 Reeve et al ,NHMRC 1999;  Clinical practice guidelines the management of cutaneous 
 melanoma. 
8 Negrier et al, SOR 2000; Standards, options and recommendations clinical practice 
guidelines for diagnosis treatment and follow up of cutaneous melanoma.
Bulletin du cancer 2000 
9 Dummer et al, SKL 2001;  Guideline zur Therapie und Nachsorge des kutanen 
 Melanoms.
10 Cook et al AAO 2001; Treatment options and future prospects for the management of 
eyelid malignancies an evidence based update.
Opthalmology 2001;108:2088-2100.
11 Sober et al , AAD 2001 & NCH; Guidelines of care for primary cutaneous melanoma.
  J Am Acad Dermatol. 2001;45:579-86.
12 Motley et al, BAD, BAP 2002; Multiprofessional guidelines for the management of the 
patient with primary cutaneous squamous cell carcinoma.
Br J Dermatol. 2002 ;146:18-25 & Br J Plast Surg. 2003 ;56:85-91. 
13 Roberts et a,l BAD. BAP 2002; UK guidelines for the management of cutaneous 
 melanoma. 
Br J Ddermatol .2002;146:7-17 &  Br J Plast Surg. 2002 ;55:46-54. 
14 Marks et al ,NHMRC 2002; Clinical practice guidelines non-melanoma skin cancer: 
guidelines for treatment and management in Australia.
15 Beljaards et al, CBO 2003 ; Richtlijn behandeling van het basaalcelcarcinoom 
16 Doherty et al, SIGN & NCH 2003; Cutaneous melanoma.
17 Rademaker et al, 2004;  New Zealand guidelines on the management of malignant 
 melanoma. 
18 Houghton et al , NCCN  2004; clinical practice guidelines melanoma 
19 Quirt et al, MDSG, 2004 ; Systemic adjuvant therapy for patients at high risk for recurrent 
 melanoma.  
20 Miller et al,  NCCN 2004;  Clinical practice guidelines in oncology , basal cell an squamous 
 cell skin cancers.
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ABSTRACT
Background: PDT is an accepted treatment for sBCC and Bowens disease. 
In Rotterdam extensive preclinical research has lead to an optimized two fold 
illumination scheme for ALA-PDT. 
Objective: To provide additional evidence of ALA-PDT for sBCC, BD, nBCC and AK 
using a two fold illumination scheme after a single application of ALA.
Methods: 552 lesions (430 sBCC, 20 nBCC, 32 BD, 70 AK) were treated with 
ALA-PDT using a 2-fold illumination scheme. ALA was applied topically for 4 hours. 
Lesions  were treated with two light fractions of 20 and 80 J cm-2 separated by a 2 
hours dark interval. 
Results: After a minimum FU of  12 months, in average FU 2 years an overall CR of 
95% was seen for all lesions. For sBCC the CR at two years was 97%, for AK  98%, 
for BD  84 % and for nBCC 80% . A sub- analysis of the results of lesions larger than 
2 cm’s showed CR at two years of 89% for all lesions (n=57). Cosmetic outcome 
was good to excellent in 95% of the treated lesions. 
Conclusion: ALA-PDT using a two fold illumination scheme of 20 plus 80 J cm-2 
separated by a two hours dark interval leads to high CR rates at two years and can 
be regarded as an evidence based treatment modality for superﬁ cial growing non 
melanoma skin cancer and the (pre)malignant AK.
The Rotterdam fractionated approach should be included in future guidelines. 
Fractionated ALA-photodynamic therapy provides additional evidence for the use of PDT | 143
INTRODUCTION
Photodynamic therapy (PDT) is an accepted treatment for non melanoma skin 
cancer especially superﬁ cial growing lesions (1). The use of 5-ALA in a topical 
preparation was ﬁ rst described by Kennedy and Pottier in 1990 (2). Since then 
many studies and case series have been published. In 2001 the FDA (Food and 
Drug Administration) approved the use of topical ALA (Levulan ®) combined with 
blue light in the treatment of actinic keratosis (AK). The methyl-ester of ALA (MAL, 
Metvix®) was subsequently introduced  and registered for treatment of superﬁ cial 
basal cell carcinoma (sBCC) and AK in 2004 and for treatment of  Bowens disease 
in 2006 in most European countries. Although the mechanism behind PDT using 
porphyrin precursors is still not completely elucidated, high complete response rates 
combined with excellent cosmetic outcome have been obtained in many studies. 
PDT is now  included in several clinical guidelines (1, 3). Extensive preclinical research 
in Rotterdam stimulated clinical participation and clinical trials which resulted in 
three recently published clinical studies using ALA-PDT with a two fold illumination 
scheme for the treatment of superﬁ cial non melanoma skin cancer (4,5,6). In addition 
to these research clinical studies PDT is now part of our daily practice in which we 
utilize light fractionation. This treatment scheme is well tolerated by patients and 
results in excellent cosmesis. Recently Braathen et al (1) published an international 
consensus in which they formulated guidelines on the use of PDT. Guidelines are 
increasingly important in dermatology. As guideline development is an ongoing 
process, the results achieved in Rotterdam have important implications for future 
guidelines on PDT. 
Here we present an analysis of a subgroup of patients treated in our centre. Our 
clinical work to date in treating patients with AK, sBCC, nBCC and Bowens disease 
shows high complete response rates and adds evidence to PDT as a treatment 
modality for superﬁ cial skin cancer.
PATIENTS AND METHODS
Patients 
All patients were diagnosed in our department of Dermatology in Rotterdam. In 
patients with  sBCC 39% of lesions were histological proven, all patients had at 
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least one primary sBCC diagnosed histologically. All nBCC and Bowens disease 
lesions were histological proven. For patients with AK, 66% of lesions were 
histological proven. Our patient population consists of both ﬁ rst-line and secondary 
dermatological care. All patients are adult Caucasians. The mean age for AK was 62 
(range 53-86), for nBCC 59 (range 45-75), for sBCC 58 (range 33-81), for Bowens 
disease 74 (range  50-90). Sex distribution was in AK 17males, 15 females; in sBCC 
53 males, 37 females; in nBCC 12 males, 4 females; in Bowens disease 10 males, 
16 females. The average diameter of lesions was 10.6 mm for AK, 10 mm for sBCC, 
10.3 mm for nBCC and 16 mm for Bowens disease. The overall range in lesion size 
was between  3 and 70 mm (see also table 1). Lesions were located at different sites 
of the body, details are shown in table 1, the most commonly treated lesion was a 
sBCC on the trunk. We note that the clinical response data from a small number of 
the patients with sBCC and Bowens disease have been reported previously (5, 6).
Methods 
Our methods were similar to those that we have described previously (5). In brief, 
the topical ALA ointment we used was freshly prepared by our Hospital Pharmacy 
using 20% ALA (FLUKA, The Netherlands) in Instilagel (Medeco BV, Oud Beijerland, 
The Netherlands).The ointment was stored in a refrigerator and used within 7 
days. Before application of ALA, crusts and scaling were gently removed using a 
disposable curette. The lesion was covered with a margin of 1 cm and dressed with 
a semipermeable dressing (Tegaderm 3M, The Netherlands) and light-protecting 
covering (Aluminum foil). In addition to the topical anaesthetic in the ALA ointment, 
patients received ﬁ eld block anaesthesia with lidocaine 1% (without epinephrine) 
if required. Three light sources were used. A 630 nm diode laser (Carl Zeiss, 
Oberkochen, Germany) was used to provide 630 nm illumination. Two commercially 
available broadband light sources were  also used. The ﬁ rst had a spectral output 
between 590 and 650 nm (Medeikonos, Gothenburg, Sweden). The second was a 
light-emitting diode, a light source with a spectral output centered on 633nm with 
a bandwidth of 20nm (Omnilux, Waldmann,  Tiel, The Netherlands). All three light 
sources were used to illuminate lesions with a margin of at least 5mm at a constant 
measured ﬂ uence rate of 50 mWcm-2. Lesions received light fractions of 20 and 80 
J cm-2, 4 and 6 hours after a single application of ALA.  During the 2-h dark interval 
between light fractions, lesions were covered with a light protective dressing. 
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RESULTS
Analysis of our treated patients in Rotterdam with a minimum follow up of 12 
months is shown in table 1. 
We treated in total 552 non melanoma skin cancer lesions (AK, Bowens disease, 
superﬁ cial and nodular BCC) with  fractionated ALA-PDT. The majority were sBCC’s. 
After a follow up at least 12 months with an average two  years (range 12-42) a 
complete response rate of 95% was observed . Bowens disease lesions that showed 
partial response were retreated and responded in all cases (follow up 12 months 
after re-treatment). These data were not included as responders in the present 
analysis. The response rate for AK was 98%.The response rates for nodular BCC 
and M Bowen were 80% and 84% respectively. 
Table 1: Results of fractionated ALA-PDT at a minimum follow up of 12 months
AK sBCC nBCC Bowens Remarks
No lesions 70 430 20 32
No patients 32 90 16 26
Histological proven 46 (66%) 167(39%) 20(100%) 32 (100%)
Localization
vertex 6 5
face 25 43 6 9
arm 14 77 2 10
leg 9 43 1 8
trunk 16 262 11 5
Average size of lesions 10.6mm 10mm 10.3mm 16mm
Min-max 3-25mm 4-50mm 4-30mm 3-70mm
Light source used
Diode laser 2 45 4
Medeikonos 12 87 4
Waldmann  omnilux 56 298 12 32
Pain requiring local 
lidocain
11 (16%) 20(5%) - 5 (16%) All AK lesions on vertex 
CR 69 (98%) 419(97%) 16(80%) 27 (84%) Bowen’s after second PDT treatment CR 
30(94%)
FU average 20 months 23months 23months 20 months
FU range 12-41 
months
12-42 
months
12-31 
months
12-32 
months
Cosmetic outcome
fair 4 (6%) 18(4%) 2 (10%) 2(6%)
good 66 412 18 30
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A subanalysis of the larger lesions with a diameter above 2 cm for all types of lesion 
is shown in table 2. In total 57 lesions were above 2 centimeters in diameter. A 
complete response at a follow up of two years of 89% was seen for these large 
lesions. The complete response rate for AK lesions was 100% at two years. Bowens 
disease lesions larger than 2 cm responded in 78% and sBCC lesions in 91% at a 
follow up time of 24 months. The complete response of  large nodular lesions was 
lower, a complete response of  50% after 24 months follow up.
Table 2: Results of fractionated ALA-PDT for AK, Bowens disease, sBCC and nBCC lesions larger than 2 cm 
with a minimum follow up of 12 months (range 12-40), mean 22 and median 23 months
AK M Bowen sBCC nBCC remarks
No lesions 14 9 32 2
No patients 12 9 20 2
Localization
Vertex 3
Face 2 1 4 1
Arm 5 1 1 1
Leg 1 4 4
Trunk 3 3 23
Light source used
Diode laser 5 1
Medeikonos 1 4 15
Waldmann  omnilux 13 5 12 1
Pain requiring local lidocain 3 1
CR 14 (100%) 7(78%) 29(91%) 1(50%)
Cosmetic outcome
Fair 2 4 1
Good 12 9 28 1
Fractionated ALA-PDT is well tolerated. Patients required only in few lesions local 
anesthesia during treatment. The cosmetic outcome varies from excellent to good. 
Fair cosmetic outcome was only seen in 5% of the lesions and  was due to (transient) 
hypo-or hyperpigmentation.
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DISCUSSION
The use of ALA-PDT with a fractionated illumination scheme, in which two light 
fractions are delivered separated by a two-hours dark interval, following a single 
ALA application, is in our opinion, an evidence based PDT treatment modality. This 
conclusion is based on clinical response data published in the literature (4,5,6) and 
the data presented in this article. The fractionated illumination scheme has been 
designed, based on a range of pre-clinical studies in a variety of pre-clinical models 
(10). Results of these studies show that fractionated ALA-PDT results in signiﬁ cantly 
higher responses compared to ALA-PDT performed with a single illumination 
(11,12). Studies have also shown the importance of the time interval between ALA 
application and the ﬁ rst light fraction and its relation to the synthesis of PpIX (13). 
Besides the inﬂ uence of the ﬂ uence (rate) of the individual light fractions (13,14) and 
importantly the time interval between light fractions has been shown to be critical 
(15). Enhanced PDT response is achieved if two light fractions are delivered 4 and 
6 hours after the application of ALA, separated by a 2 hours dark interval. Dividing 
the illumination in a small ﬁ rst and a substantially larger second light fraction further 
enhance the PDT response (12). The mechanism behind this increase in response 
is under investigation (16) but seems to be closely related to the response of the 
vascular endothelial cells in-vivo.
Our ﬁ rst (pilot) study was performed using an illumination scheme 45 Jcm-² + 45 
Jcm-²  separated by a two hours dark interval. A follow up of mean 59 months (range 
44-82) with a complete response rate of 84% and excellent cosmetic outcome in 
88%.(4) Secondly we did a large comparative study in superﬁ cial basal cell carcinoma 
(n=505) comparing a single illumination (75 Jcm-²) with a fractionated illumination 
(20+80 Jcm-²) with a two hours dark interval. The results clearly favor fractionated 
illumination. Complete response rate in the fractionated illuminated lesions 
was 97%, in the single illuminated group the complete response rate was 89% 
(p<0.002 log rank) (5). We also studied the response of squamous cell carcinoma 
in situ (Bowens disease) using the same parameters as in the basal cell carcinoma 
study. In this (pilot) we included 50 patches of Bowens disease. These results were 
also in favor of fractionated illumination (80%vs 88%) but did not reach statistical 
signiﬁ cance (possibly due to the small number of lesions included)(6). Nodular BCC 
do respond, but in all studies (ALA and MAL) this seems to be limited (17,18,19). 
More research to deﬁ ne criteria according to which lesions are suitable for ALA-
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PDT using light fractionation  is necessary. Prior curettage and repeated optimized 
light fractionated ALA-PDT are also possible options. It is important to investigate 
the maximum depth of PDT damage  and the different mechanisms of PDT as 
direct and indirect damage, necrosis, apoptosis and immunological responses to 
malignant and surrounding cells including the vasculature. The data we have shown 
here establish our previous clinical work. Besides they show high response rates 
for AK. AK is considered as pre-malignant condition which has the potential to 
become malignant. The need for optimization of the treatment of AK is highlighted 
by the recent classiﬁ cation of these lesions as carcinoma in situ. (20). The results 
we present using light fractionated ALA-PDT shows optimization for sBCC, Bowens 
disease and AK. Changes in application time, illumination time and other parameters 
will inﬂ uence the ultimate PDT effect. Changes should be subject of well designed 
research and not be used as trial and error. 
To improve the quality of medical care guidelines are extensively used. 
Guidelines are expected to facilitate more consistent, effective and efﬁ cient medical 
practice and improve health outcomes. In 1998 Appraisal of Guidelines and Research 
and Evaluation (AGREE) project was established (7, www.agreecollaborationgroup.
org). These criteria can be used to appraise a guideline but can be considered of 
importance in the developmental phase (8,9). Recently the American Academy 
of Dermatology (1) published an international consensus in which guidelines are 
formulated on the use of PDT. This shows clearly the importance of PDT in the 
treatment of  non melanoma skin cancer. As guideline development is an ongoing 
process we would like to suggest in future to develop an integrated guideline for 
PDT and the other treatment modalities for non melanoma skin cancer according to 
the AGREE instrument. Results achieved in Rotterdam should be incorporated.
IN CONCLUSION
PDT is an evidence based treatment modality for superﬁ cial growing skin cancer like 
superﬁ cial basal cell carcinoma, Bowens disease and actinic keratosis. A fractionated 
illumination of 20 + 80 Jcm-2 separated by a two hours dark interval after a single 
application of 20% ALA in treatment of sBCC, Bowens disease and AK-lesions 
achieve high complete response rates after a two year follow up period. To a lesser 
extent is this high complete response rate established for the treatment of nBCC 
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using light fractionated ALA-PDT. Treatment optimization for nodular lesions and/
or better deﬁ ned lesion inclusion criteria are desirable. Light fractionated ALA-PDT 
should be incorporated in future clinical guidelines for non melanoma skin cancer.
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THE IMPORTANCE OF PATIENT REPORTED OUTCOMES (PRO)
In the evaluation of therapies, the physician-based clinical model (e.g., physician 
global assessment, change in affected body surface area, index scores, disease free 
interval, survival and recurrence rate) alone is no longer sufﬁ cient. In addition to 
traditional methods of evaluating disease, regulatory agencies now require the 
assessment of the patient reported outcomes (PRO).(1) These outcomes are pivotal 
in dermatology, because most dermatological diseases are chronic, intermittent, 
non fatal, very visible, cause no permanent physical damage and their disease 
activity can not be measured using serological markers. Initially, PRO focused on 
inﬂ ammatory dermatoses, but it now also includes non inﬂ ammatory diseases 
and (benign and malignant) neoplasms, which are associated with to some extent 
different and speciﬁ c issues. Because non melanoma skin cancers (NMSC) rarely 
metastasize, cause few symptoms and treatment is often locally, interest in patients’ 
perspectives on their skin cancers and its treatments has been very recent. However, 
NMSC are cancers, often located on the face, surgery may be associated with 
substantial fear, functional and cosmetic morbidity, and the risk of subsequent skin 
cancer is close to 50% making this a chronic disease. These issues are troubling to 
patients and should be incorporated in the assessment of global disease severity and 
evaluation of skin cancer therapy.(2) A better understanding and documentation 
of patients` views is helpful in improving patient-physician interaction, skin cancer 
care, treatment outcome and the selection of patients in need of additional pre-
treatment counseling.  
In clinical studies, there are three obvious ‘players’ that should be evaluated separately 
(i.e., disease, patient and intervention). The disease is evaluated using traditional 
clinical methods, the effect of the intervention on patients` lives is captured by health 
related quality of life (HRQOL) and symptom assessment, and treatment is evaluated 
by assessing its adverse events and satisfaction with medication or intervention 
(Figure 1). In addition to physicians who assess clinical measures, patients are more 
and more actively involved in judging the other aspects of therapy and their opinions 
as end users are increasingly important. Of these PROs, HRQOL is by far the most 
commonly used measure. The World Health Organization (WHO) deﬁ nes QOL as 
`the individuals` perception of their position in life, in the context of the cultural 
and value systems in which they live and in relation to their goals, expectations, 
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standards and concerns`. QOL is multidimensional and includes health and multiple 
non-medical aspects such as socioeconomic status, marital status, professional 
career, personality, expectations and religion. In medicine, QOL measures focus on 
HRQOL that should measure physical, psychological and social health domains both 
in a subjective and objective manner (3,4).
Figure 1: The three key players and corresponding outcomes in the evaluation of a treatment.
HRQOL IN SKIN CANCER PATIENTS
Of the available generic or dermatology speciﬁ c HRQOL instruments, the Short 
Form (SF)-36, Sickness Impact Proﬁ le (SIP), Dermatology Life Questionnaire Index 
(DLQI) and Skindex-16 have been used to assess the impact of BCC on patients’ 
lives and demonstrated a minimal to little impact of this disease.(5-9) This can, in 
part, be explained by the fact that these instruments lack speciﬁ city (i.e., asking 
about concepts relevant to patients with skin cancer), sensitivity (i.e., detects small 
impairments) and responsiveness (i.e., detects HRQOL changes after improving/
worsening of health status) in patients with NMSC. These non speciﬁ c instruments 
are likely to suffer from ‘ﬂ oor’ effects (i.e., substantial proportion of respondents 
will tick off the lowest response category) and summing scores are likely to be in the 
lowest quartile of the instruments’ range because several pivotal concepts such as 
susceptibility of skin cancer, worrying about (facial) health problems, appearances 
(e.g., scars and dysmorphism), fear of recurrence or new skin cancer, and fear of 
surgery are not assessed (in detail).(9) The skewed distribution of item responses 
         
154 | Chapter 9
and total scores to the low levels make it difﬁ cult for these tools to differentiate 
within the range of limited impairment and to detect changes over time. Therefore, 
skin cancer speciﬁ c HRQOL questionnaires such as the Skin Cancer Index have 
been introduced recently, which should be validated before they can be used in 
conjunction of dermatology speciﬁ c, cancer speciﬁ c and/or generic tools.(2,10,11) 
Recently, Chren and colleagues have used HRQOL as a primary outcome in a 
comparative cohort study in the treatment of NMSC. This very interesting study 
showed that the emotional impact of NMSC was almost three folds compared 
to that of functioning and symptoms as measured by the Skindex-16.(12) Also, 
patients treated with surgical excision and Mohs surgery but not electrodessection 
and coagulation (ED&C) improved in all three HRQOL domains. 
PREDICTORS OF HRQOL IMPROVEMENT
In this issue of the Archives, the same group investigated the predictors of this 
observed HRQOL improvement after skin cancer therapy. The objective of this study 
was to understand why NMSC therapy affects people in different ways and to identify 
individuals who are at higher risk of not experiencing a therapeutic beneﬁ t after a 
‘successful’ therapy. The authors have used a heterogeneous cohort of 663 patients 
with new basal cell carcinoma (BCC; 77.3%) and squamous cell carcinoma (SCC; 
32.7%) who received therapy at a VA or private practice.(12) Of multiple patient, 
tumor and care characteristics, pre-treatment skin related HRQOL, comorbidity, health 
status (i.e., SF-12 scores) and being white signiﬁ cantly improved post-treatment 
Skindex-16 scores after adjusting for confounding factors in a multivariate model. 
The strongest independent predictor of skin-related HRQOL post-treatment was pre-
treatment skin-related HRQOL. This is in accordance with a previous study showing 
that individuals` pre-operative health beliefs such as worrying, fear and susceptibility 
determine for a large part the extent to which patients respond to BCC therapy.(2) 
Therefore, clinicians should gauge patients` perceptions of NMSC and its treatment 
and inform patients about both before therapy is administered, especially those who 
express higher levels of worrying and fear. This may seem obvious, but clinicians may 
have an ambiguous attitude towards BCC and to a lesser extent SCC. On the one 
hand NMSC is considered a malignancy that requires an oncological approach (e.g., 
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the cosmetic and functional outcome is inferior to complete removal) and on the 
other hand it may be trivialized because it is so common and its risk of metastasize 
is rare. This (subconscious) attitude may result in physicians saying phrases like ‘it 
is skin cancer, but it is not a malignancy’, ‘BCC is the best of the bunch’ or ‘it is 
cancer, but it is not serious’, which is confusing to patients. People with skin cancer 
should be informed about the necessity to treat NMSC adequately (including a long 
term follow up), the risk of metastases (exceptional for BCC and up to 10% for 
SCC)(13,14) ways to actively participate in the prevention of skin cancer (e.g., skin 
self examination, sun protection and chemoprevention) and reassured at the same 
time about the behavior of most NMSC.    
Another predictor of skin related HRQOL after therapy was the general health of the 
treated individuals (measured by a comorbidity index and the SF-12). The importance 
of respondents` health status on patients HRQOL is recognized in the development 
of some HRQOL assessments (e.g., VAS for general health of the EuroQOL-5D). It 
is also conﬁ rmed by observations demonstrating that the presence of comorbidity 
affected the fear of developing a new BCC and is a signiﬁ cant predictor of HRQOL 
impairment in psoriasis patients.(2,15) Patients with a high comorbidity index score 
or those who indicated that health has a large impact on their QOL (i.e., low SF-12 
scores) are less likely to notice an effect of skin cancer therapy than those who are in 
better health. Whether this is due to item bias (patients with the same level of skin 
related HRQOL impairment who are in poor health score several Skindex-16 items 
differently than those in better health), patients’ inability to differentiate the impact 
of different diseases on their lives or a lack of the sensitivity of the measurement 
is not yet clear. But again, this population is in extra need of counselling prior to 
NMSC therapy to optimize its outcome.
The primary outcome of the study in this issue of the Archives is the mean Skindex-16 
score of multiple assessments and each obtained Skindex-16 at time of assessment 
score is the mean of its three scales. This approach was chosen to minimize loss of 
data and based on the assumption that Skindex-16 scores did not change after 12 
months, which is in contrast with other dermatological HRQOL studies that suggest 
that some concepts change in time as patients cope with and adjust to chronic 
conditions(2,15) Also, the proportion of patients who responded one, two or three 
times is unclear and a substantial loss of follow up may have affected the results 
of this study. Although it is stated throughout the result section that similar trends 
were detected for the three scales, the presentation of a total Skindex-16 score is 
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unfortunate because it does not allow to assess the effect of therapy on the emotion 
scale, which represents most NMSC induced variance of the Skindex-16 scores 
because it include two items that are highly relevant to skin cancer patients (i.e., 
how often patients have been bothered by ` the persistence/reoccurrence` and ` worry 
about spreading, getting worse, scarring and being unpredictable` about their skin 
condition). The later item is a composite question, which assesses multiple issues at 
once, providing important but non-speciﬁ c information about the impact of NMSC. 
Moreover, from a theoretical perspective the use of a total score is inappropriate 
because it has no face validity, it was not formally tested and factor analysis have 
shown that the structure of the Skindex-16 is multidimensional (16). This implies 
that each dimension should be presented with separate scale score and that an 
overall score is suboptimal and should not be used as an interval measurement. 
Although it is comprehensible from a methodological perspective that the authors 
only included new NMSC patients, the studyresults are not generalizable for all 
NMSC patients. A substantial proportion of patients with NMSC has a history of 
multiple (pre)malignant skin tumours and it would be interesting to investigate 
whether these patients experience NMSC differently than those with their ﬁ rst 
NMSC. Does a history of several NMSC enhance patients’ anxiety of recurrence 
and subsequent cancers or are they  more likely to psychologically adapt to living 
with NMSC than those with a ﬁ rst NMSC? Another interesting issue is the effect of 
patient education about NMSC on HRQOL and treatment satisfaction. It could be 
that patients appreciate more detailed information or that the proverb ‘let sleeping 
dogs lie’ applies and that it increases their worry and fear.  
INTERPRETATION OF COMPARISONS
Statistical comparisons between HRQOL scores before and after an intervention 
should be interpreted with caution because a statistical signiﬁ cant difference does 
not always equal clinical signiﬁ cant difference. The requisites of comparing HRQOL 
scores are that nonparametric statistical techniques are used and that the measure 
is reliable (i.e., provide similar scores in patients with unchanged disease status 
at different time points), responsive to clinical change and that the meaning of 
obtained scores and differences are known. An aid in interpreting HRQOL scores is 
categorization of a continuous score in different levels of impairment. The authors 
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have created categories based on the tertile distribution of the mean scores, which 
is helpful in presenting data but is not a formal way of categorizing PRO’ outcomes 
such as distribution based or banding techniques.(17) The minimal clinical important 
difference (MCID) informs clinicians that a difference in HRQOL scores observed 
after therapy is likely to have at least some clinical relevance to most patients. The 
authors assumed that the MCID of the total Skindex-16 score is 10 points because it 
was estimated to be about 10 points for each of the three scales. (8) Although with 
some limitations, the authors have presented the HRQOL data in such a way that 
statistical and clinical signiﬁ cance are likely to overlap. 
ADVANTAGES OF NEW TREATMENTS
No statistical difference in HRQOL changes was detected between traditional excision 
and Mohs surgery of NMSC suggesting that patients primary concern is the excision 
of the malignancy. Although it is expected that a detailed examination of tumor 
margins in Mohs surgery would result in a more satisﬁ ed and reassured patient, 
which would be reﬂ ected in an improvement of HRQOL, the work by Chren et al 
suggests that patient do not appreciate it as much as expected. Also, undergoing a 
more complicated procedure such as Mohs surgery may affect patients’ perception 
about NMSC differently than a traditional excision or ED&C. For now, the theoretical 
advantages of Mohs surgery compared to traditional excision such as a reduced 
recurrence rate, improved cosmetic outcome, detailed examination of tumor margins 
and cost effectiveness have not (yet) been conﬁ rmed from a physician, patient 
and regulatory perspective.(8,18,19) The advantage of Mohs surgery for NMSC 
concerning recurrence rate and HRQOL improvement may be more pronounced 
for high risk facial NMSC such as micronodular, morpheaform or recurrent BCC in 
the H-zone and after long term follow up (i.e., 5 years). This implies that there is 
no evidence to treat every (facial) BCC with Mohs surgery and that a strict patient 
selection is appropriate.         
The recent trend in the care of NMSC is to use non or minimal invasive treatments 
such as photodynamic therapy (PDT) and imiquimod. The primary advantage of 
these options is to reduce the functional and cosmetic morbidity associated with 
the treatment of skin cancer. Interestingly, Chren and colleagues have demonstrated 
that ED&C, which can be considered a minimal invasive technique that may scar, did 
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not signiﬁ cantly improve HRQOL in NMSC patients. In part, this may be explained 
by the fact that patients’ worry and fear do not substantially improve after therapies 
that do not ‘physically’ remove the skin cancer. Although the new minimal invasive 
techniques focus on the beneﬁ t of avoiding scars, patients’ perceptions about the 
efﬁ cacy and safety of these therapies is not well documented and may not reassure 
patients as much as surgical excisions. Patients’ beliefs about therapies warrant 
further investigation.
SENSIBLE RESOURCE ALLOCATION
NMSC treatment is in the top ﬁ ve of most costly cancers and consumed about half 
a billion dollars annually in the US.(20) The costs of NMSC are likely to continue 
to grow due to an increasing NMSC incidence in the next decades.(21) In addition 
to clinical guidance, the effect of therapy on HRQOL can be used to justify the 
societal costs associated with NMSC therapy. Preference based HRQOL measures 
such as the EuroQOL-5D and the SF-6D are expressed in quality adjusted life years 
(QALY), which combines information about the level of HRQOL impairment and 
its duration (i.e., a QALY equals one year of full quality). Because of the relatively 
limited mortality of NMSC and HRQOL impact the costs per QALY for NMSC therapy 
may be high, especially for Mohs surgery. The high NMSC incidence warrants the 
development and use of cost-effective therapies to control the impact of NMSC 
on national health care budgets. To make an evidence-based decision in NMSC 
management well-performed HRQOL and pharmacoecomonic studies alongside 
randomized clinical trials are needed.(22) 
CONCLUSION
Demonstrating HRQOL improvements after NMSC therapy and its predictors is 
important because it may affect treatment choice and outcome, identify patients in 
need for additional information, and allocation of health care budget. For now, the 
obvious advantages of Mohs surgery have not yet been conﬁ rmed from physicians’, 
patients’ and regulatory agencies’ perspective and additional studies are warranted 
to study the effect of NMSC therapies.
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GENERAL DISCUSSION
The subject of this thesis is the investigation of the role of, and mechanism(s) 
underlying light fractionation in ALA-PDT for the treatment of non-melanoma skin 
cancer. In addition the role of evidence based medicine, guideline development and 
quality of life in clinical PDT are addressed.
CLINICAL RESPONSE TO LIGHT FRACTIONATED ALA-PDT
Since its introduction in the 1990’s photodynamic therapy (PDT) using 
porphyrin pre-cursors is now widely accepted as an attractive treatment option for 
non melanoma skin cancer. It has also been applied to a variety of non-malignant skin 
diseases and is under investigation for the treatment of other malignant conditions 
in various organs. Initial high complete response rates (CR), well above 90%, for the 
treatment of superﬁ cial basal cell carcinoma (BCC) using ALA are reported. However 
long term clinical results have shown considerable variations, where CR has been 
found to be as low as 30%. This was a particular problem for nodular lesions. 
Clinically this led investigators to adopt approaches to enhance clinical response. 
The minimal side effects of PDT using topical ALA or its derivatives mean that repeat 
treatments were a simple option. Indeed the recommended regime for the PDT 
using methyl-5-aminolevulinate (MAL) is two treatments one week apart. Further 
subsequent treatment sessions are often performed. Our approach however has 
been to ﬁ rst optimize PDT after a single application of porphyrin pre-cursor.
The results presented in chapters 2 and 3 clearly show that light fractionated 
ALA-PDT can signiﬁ cantly improve the response rates in the treatment of sBCC and 
Bowens disease. While follow up remains short (12 months) we believe that all 
dermatologists, both within and outside academic hospitals should consider to use 
this type of light fractionated regime for patients with superﬁ cial BCC and Bowens 
disease. The rising incidence of non melanoma skin cancer illustrates that optimised 
treatment protocols are relevant not only for dermatologist but for wider health 
policymakers.
Our sBCC study included clinically diagnosed secondary BCC, just as occurs 
in routine clinical practice. Clinical diagnostic accuracy in a dermatology university 
faculty has been shown to be approximately 70% for BCC (Presser and Taylor, 
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1987). Therefore a small number of nodular BCC’s were included due to these 
treated lesions. Analysing our results, and assuming a similar accuracy as Presser 
and Taylor predicts the three recurrent or non-responding nodular BCC’s in the light 
fractionated illumination arm, represents a signiﬁ cantly lower number than expected 
(P = 0.0003 Fisher’s exact test). This is an indication that clinically light fractionated 
ALA-PDT may lead to deeper tissue damage. We have previously shown that the 
two-fold illumination leads to deeper histological damage in pre-clinical models (De 
Bruijn et al, 1999; Robinson et al, 2003). Clinically, in sBCC and Bowens disease a 
more severe acute response is observed following light fractionated PDT, compared 
to a single illumination. Importantly however healing times remain relatively short 
and the cosmetic outcome, in almost all cases, is good or excellent. The longer 
overall treatment time and the increase in acute response may have lead to a more 
painful therapy. However we did not ﬁ nd a signiﬁ cant increase in the need for pain 
relief in our clinical studies and most patients tolerated the treatment without any 
form of pain medication. For Bowens disease an extra argument in favour for PDT 
can be found in the fact that these lesions often occur on so called ‘difﬁ cult to treat’ 
areas as lower legs and face .For patches in these areas, and in particular for the 
larger ones, there is a need for an alternative to surgery. 
THE MECHANISM BEHIND THE INCREASE IN RESPONSE
One aim of this thesis was to investigate the mechanism underlying the 
increase in response of tissues to light fractionation and to conﬁ rm that our pre-
clinical mechanistic studies were representative of aspects of clinical PDT of non-
melanoma skin cancer. We investigated the process of PpIX photobleaching, in 
which the photosensitiser is progressively destroyed during clinical ALA-PDT. In 
earlier work photobleaching has been proven to limit the PDT dose which can be 
delivered in a single illumination at ﬁ xed ﬂ uence rate and this was our original 
rationale for investigating the use of extended dark intervals between light fractions. 
As described below we have found that the overall amount of PpIX utilised seems 
not to be directly related to the increase in response that we observe. Clearly the 
mechanism behind the increased response to fractionated ALA-PDT is complex and 
the data presented here are part of an ongoing investigation. We have however 
conﬁ rmed that the kinetics of PpIX ﬂ uorescence photobleaching and re-synthesis 
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are very similar in animal models and in the clinic. 
In chapter 4 we investigated the distribution of PpIX ﬂ uorescence in sBCC 
using a surface measurement and microscopic PpIX ﬂ uorescence. We found wide 
variations in the average intensity of PpIX ﬂ uorescence in biopsies of control lesions 
and in biopsies of lesions 2 hours after illumination with 20 J cm-2. We also found 
wide variations in ﬂ uorescence-intensity within individual sections of biopsies. Given 
these large standard deviations on average ﬂ uorescence-intensities we found a 
reasonable correlation between the two different methods of performing ﬂ uorescence 
microscopy. In the described  study we have shown for superﬁ cial BCC, where ALA 
penetration and transport are unlikely to be limiting factors, there remain regions 
of tumour that accumulate and re-synthesize relatively small amounts of PpIX. It 
is also clear that regions of low PpIX ﬂ uorescence accumulation are not located at 
the base of superﬁ cial tumours and high PpIX ﬂ uorescence is often observed at the 
periphery of tumour islands at the base of the tumour. Availability of ALA therefore 
is unlikely to induce these differences. We have shown that highly proliferating 
normal and tumour cells synthesize relatively more PpIX and that this corresponds 
with the nuclear stain Ki-67 a marker for cellular proliferation. The results of this 
study also have illustrated the complexity of using surface ﬂ uorescence detection 
as a diagnostic procedure. Our results suggest a limited value in the discriminating 
capacity by using PpIX ﬂ uorescence and this is certainly an area of interest in the 
future.
Our mechanistic investigations also included some apoptotic markers. The 
role of the Bcl-2 protein family in PDT is not fully determined but its seems to play an 
important role in the response of ALA-PDT in general. In BCC the presence of Bcl-2 
and Bax has been described in literature. We were able to conﬁ rm this presence in 
our study (chapter 5).  In literature expression of apoptosis markers is predominantly 
not investigated in vivo and not  in BCC. Therefore  it may be not applicable to sBCC 
after  ALA-PDT but the results support strongly mitochondrial apoptosis is involved 
in PDT mediated cell death. Our ﬁ ndings, an increased expression of Bax after a 
small dose ALA-PDT suggest a relatively large cell population Bax- positive cells in 
BCC is prone to apoptosis. After a single full dose still Bax expression is found. 
Due to small number investigated we modestly conclude Bax plays a role. Caspase 
3 , the executor caspase has been described early after PDT. A rapidly increasing 
expression of caspase 3 is seen in almost all specimens in our data 2 hours after 
a single small dose ALA-PDT. This suggests early apoptosis is induced by ALA-PDT 
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and conﬁ rms the ﬁ rst fraction’s importance for the ultimate complete response of 
the BCC to ALA-PDT. In future, serial observations in time and quantitative analysis 
may contribute to a better understanding of the apoptosis induced by ALA-PDT in 
human BCC.
In chapter 6 we investigated the role of light fractionation using methyl 
aminolevulinate (MAL) in normal mouse skin. This is particularly interesting since it is 
MAL that is the registered porphyrin pre-cursor for the treatment of AK, superﬁ cial 
BCC and Bowens disease. Contrary to our expectations, we have found signiﬁ cant 
differences for MAL and ALA. Light fractionation proved not to be effective using 
MAL. This is despite the fact that pharmacokinetics of PpIX ﬂ uorescence in normal 
mouse skin during the 4-h application period are identical for both ALA and MAL 
and the rate and extent of PpIX photobleaching after each light fraction for ALA or 
MAL are almost identical. One critical difference between ALA and MAL, and other 
ester derivatives of ALA, is their tissue distribution due to their different biophysical 
and biochemical characteristics. After topical application of MAL, PpIX ﬂ uorescence 
is retained at the application site whereas after ALA application PpIX ﬂ uorescence is 
also measured at distant sites in the skin. ALA is distributed more systemically after 
topical application whereas MAL is not. This seems to be a clear indication that the 
tissue distribution of PpIX (mediated by the different prophyrin-precursor) plays a 
signiﬁ cant role in mechanism behind the response of tissue to light fractionated 
ALA-PDT. This is clearly an area for detailed future investigations.
EVIDENCE BASED MEDICINE, GUIDELINES AND QOL
We strongly support the idea of evidence based medicine and this was the 
basis for the reaming chapters of the thesis. We appraised the existing clinical 
guidelines in dermato-oncological care using the European standard ‘the AGREE 
instrument’.(chapter 7) Dermatological clinical guidelines have good quality but 
– as always- improvements can be made. Clear formulation and participation of all 
involved users can be particularly improved.  An extra argument in favour of the 
AGREE instrument is, in our opinion, its recipe function in the development phase 
of a guideline. In respect to allocation of sources collaboration and consensus lead 
to more uniform clinical care, which is desirable for standard care. We like to note 
every patient is an individual and needs personal attention of his/her dermatologist. 
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The rapidly rising incidence of non melanoma skin cancer and its burden on society 
attributes to the need of dermatological evidence based care. 
An aspect of social impact is expressed by patient reported outcomes. The last 
chapter (chapter 9) is an editorial in answer to a study investigating improvement 
of health related quality of life (HRQOL) after treatment of non melanoma skin 
cancer. Surgery, Mohs’ micrographic surgery and electro-dissection & coagulation 
were the involved treatments. The most important factor was the HRQOL before 
treatment in predicting the HRQOL after treatment. HRQOL is a fairly unexplored 
ﬁ eld in skincancer treated patients. Demonstrating HRQOL improvements after 
NMSC therapy and its predictors is important because it may affect treatment choice 
and outcome, identify patients in need for additional information, and allocation of 
healthcare budget. This is a ﬁ eld to be explored in future. Patients expectations and 
experiences should be two of the leading themes and should be accommodated in 
the choices associated in dermato-oncology.
LIGHT FRACTIONATED ALA-PDT IN ROUTINE CLINICAL PRACTICE
Light fractionated ALA-PDT is now used in daily practice in Erasmus MC 
in Rotterdam for AK, sBCC, ‘superﬁ cial growing” nBCC and for Bowens disease 
(chapter 8). The complete response-rates after a follow up of two years are 
concordant with our published clinical studies in which a follow up period of 12 
months was described. For AK a complete response-rate of 98% was achieved. In 
all treated sBCC’s  97% responded. For Bowens disease a complete response-rate 
of  84% was achieved, a result comparable to results in literature. And for nBCC 
a complete response-rate of 80% was found. The Bowens disease lesions which 
did not respond completely at ﬁ rst treatment session were retreated and showed 
a complete response after the second treatment, that is sustained  for at least 12 
months.
FUTURE PERSPECTIVES
The follow up in our clinical studies is limited to 24 months. In oncology 5 
years follow up rates are considered to be the gold standard. While we obviously 
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intend to follow these patients for 5 years we expect no great reduction in response-
rate of our fractionated illumination scheme. Basset-Sequin et al have shown that 
for MAL-PDT response rates have been shown to be more or less equal after 48 
and 60 months follow up. Our results in nodular BCC raise a range of questions 
and give weight to the need of optimization of PDT for these lesions or to more 
accurately deﬁ ne which lesions are suitable for treatment with PDT. Nodular BCC 
does respond, but in all studies using ALA and MAL this seems to be limited. More 
research is needed to deﬁ ne criteria according to which lesions are suitable for 
ALA-PDT using light fractionation. Prior curettage and repeated optimized light 
fractionated ALA-PDT is a clear treatment option. 

CHAPTER 11
Summary
(English and Dutch)
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SUMMARY
 
Chapter 1 is an introduction to this thesis “ALA-PDT; the treatment of non 
melanoma skin cancer re-illuminated” . In the  ﬁ rst part the reason for concerns 
about non melanoma skin cancer and its treatment is described. The incidence of 
BCC is  growing rapidly and this is leading to an important problem in healthcare. 
The etiology of non melanoma skin cancer is primarily behavioral  and related 
especially to exposure to sunlight. Current treatment modalities are surgery, 
topical chemotherapy, cryotherapy, immuno-modulating therapy, curettage & 
electrodessication, radiotherapy and photodynamic therapy. Phototherapy in 
dermatology is an ancient modality. This in also illustrated in a historical overview. 
Furthermore the principles of PDT are described in the introduction. In ALA-PDT 
the prodrug ALA is applied and leads to the synthesis of the true photosensitiser 
PpIX which leads to production of reactive oxygen species such as singlet oxygen 
by absorption of light. Singlet oxygen is responsible for the destruction of 
(tumor-)cells. The important factors in ALA-PDT, porphyrin synthesis, PpIX 
distribution, light and photophysics, photochemistry, photobleaching, photobiology 
are brieﬂ y explained.
ALA (and MAL) PDT have their limitations and therefore a need for optimization 
is recognized. Optimizing ALA-PDT by light fractionation in animal studies and a 
ﬁ rst pilot study are the base for the clinical study described in chapter 2. Here 
a comparative study of 505 superﬁ cial BCC’s treated with ALA-PDT either single 
illumination (75 Jcm-2 ) or two-fold illumination (20+80 Jcm-2 separated by a two 
hours dark interval) is descibed. The complete response to a two fold illumination 
is statistically signiﬁ cant higher than to a single illumination ( CR 97% vs 89%, 
p<0.002) at a minimum follow up of 12 months. Most patients did not require any 
form of pain relief. In almost all cases the cosmetic outcome was regarded good 
to excellent by patients and physicians. In chapter 3 a pilot study in 50 patches 
of Bowens disease is described. The same treatment parameters as in the sBCC-
study were used. Also in Bowens disease the response to a two-fold illumination is 
higher than to a single illumination, 88% vs 80% CR at a minimum follow up of 
12 months. An argument in favor for PDT in the treatment of Bowens disease is the 
relatively short healing time and excellent functional and cosmetic outcome. This is 
especially an advantage on so called difﬁ cult to treat areas such as lower leg and 
face.
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Besides clinical studies we studied the PpIX kinetics in sBCC in relation to our earlier 
work. In chapter 4 the PpIX ﬂ uorescence measured at surface and microscopically 
is described. We found a wide variation between biopsies as well as within biopsies. 
A relatively good correlation was found between the two techniques we used.  Both 
control lesions and treated lesions were included. Biopsy was taken at 6 hours after 
ALA application or at 2 hours after 20 Jcm-2 ,i.e. 6 hours after ALA application. The 
specimens were immunohistochemically stained for the proliferation marker Ki-67. 
PpIX ﬂ uorescence pattern follows the Ki-67  positive stained cells.  PpIX ﬂ uorescence 
conﬁ rmed relative re-synthesis in the dark interval in a two-fold illumination scheme 
consistent with our earlier work. In our search to enlighten the mechanism of 
ALA-PDT and especially the increased response to fractionated ALA-PDT we also 
investigated cell death. Cell death in (ALA)-PDT is due to necrosis, apoptosis and 
an immunological response. We performed immunohistochemical stainings for the 
Bcl-2, Bax, Caspase 3 in single illuminated and two fold illuminated sBCC’s which 
is described in chapter 5. Biopsies were taken after a full single  dose (n=10), 
just before the second illumination in the twofold scheme(n=25) and after ALA 
application only (control, n=7)). One sBCC was serial biopted in time. (3 biospies). 
The Bcl-2 protein family is recognized to play a role in the apoptotic process induced 
by PDT. Caspase 3 can be regarded as the executor caspase in apoptosis. Early after a 
full dose ALA-PDT as well as after only a small dose, apoptotic markers show altered 
expression indicating apoptosis is occurring. We conﬁ rm the idea apoptosis induced 
by the mitochondrial pathway plays a role in cell death in ALA-PDT in sBCC.
Because of the increased use of MAL in dermatological practice we investigated the 
response of fractionated MAL-PDT in normal mouse skin. These results are described 
in chapter 6. We expected to gain efﬁ cacy by fractionating the illumination in 
correlation to the increase response we gained by fractionated ALA-PDT. Our results, 
however, show that fractionated illumination does not enhance the efﬁ cacy of PDT 
using MAL as it does using ALA despite the comparable ﬂ uorescence intensities at 
the end of the ﬁ rst light fraction and at the start of the second light fraction. Only 
the initial rate of photobleaching was slightly greater during ALA-PDT although the 
difference was small. Our data suggest that the distribution of MAL and ALA in 
tissues, and therefore the site of PDT induced damage, is an important parameter in 
the mechanism underlying the two-fold illumination scheme.
In chapter 7 we are back to clinical dermatology. The quality of guidelines in 
dermato-oncology are described. We appraised the available (till 2006) clinical 
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guidelines (n=20) according to the AGREE instrument. The AGREE instrument is the 
result of an European collaboration. The domains in the AGREE instrument concern 
especially the methods of development of guidelines. The score according to AGREE 
can be improved by explicitly mentioning the different items. Guidelines in dermato-
oncology appeared to be of reasonable quality. In a comparison of guidelines before 
and after publication of the AGREE instrument improvements are seen concerning 
the clarity. As clinical guidelines are regarded to be an important instrument to 
improve quality of care, improvements are needed.
The results of fractionated ALA-PDT in Erasmus MC in Rotterdam for AK, sBCC, 
nBCC and Bowens disease (in a total of 552 lesions) are described in chapter 8. 
After a follow up of 2 years high complete response-rates are achieved using a 
fractionated regime of 20 + 80 J cm-2 separated by a 2 hours dark interval. For 
sBCC the CR at two years was 97%, for AK  98%, for Bowens disease  84 % and 
for nBCC 80%. The results of Bowens disease is comparable to other results in 
literature as to the result of surgery suggesting ALA-PDT is a good treatment option 
but improvements are desirable. Also in nodular BCC the CR rates are subject to 
optimization. A sub-analysis of the results of all lesions larger than 2 cm showed CR 
at two years of 89% for all lesions (n=57). Cosmetic outcome was good to excellent 
in almost all cases. The obtained results should be included in future guidelines.
Chapter (9) is an editorial about health related quality of life. In addition to CR rates, 
disease free interval and other physician based parameters patient reported outcomes 
are important. Skin cancer speciﬁ c HRQOL questionnaires such as the Skin Cancer 
Index have been introduced recently.  A better understanding and documentation 
of patients` views is helpful in improving patient-physician interaction, skin cancer 
care, treatment outcome and the selection of patients in need of additional pre-
treatment counselling. Demonstrating HRQOL improvements after NMSC therapy 
and its predictors is important because it may affect treatment choice and outcome, 
identify patients in need for additional information, and allocation of health care 
budget. For now, the obvious advantages of Mohs surgery have not yet been 
conﬁ rmed from physicians’, patients’ and regulatory agencies’ perspective and 
additional studies are warranted to study the effect of NMSC therapies.
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SAMENVATTING 
Hoofdstuk 1 van dit proefschrift ‘ ALA-PDT de behandeling van (niet-melanoom) 
huidkanker opnieuw belicht’ is een inleiding. Hierin  wordt beschreven waarom het 
nodig en noodzakelijk is aandacht te besteden aan huidkanker en de behandeling 
hiervan. De incidentie (het voorkomen) van het basaalcelcarcinoom stijgt snel 
en zal in de nabije toekomst leiden tot een probleem in de gezondheidszorg. 
Huidkanker wordt voornamelijk veroorzaakt door zonlicht blootstelling. De 
huidige behandelmogelijkheden zijn chirurgie, lokale chemotherapie, cryotherapy 
(bevriezen), immunomodulerende (weerstand-beinvloedende) therapie, curettage 
en electrodessicatie (weghalen met een scherpe lepel en nabranden), radiotherapie 
en fotodynamische therapie (PDT). 
Behandeling met licht bestaat al heel lang in de dermatologie. Dit wordt 
geïllustreerd in het historisch overzicht (en tabel). De principes van fotodynamische 
therapie worden in de inleiding beschreven. Bij gebruik van ALA-PDT wordt een 
voorloper van protoporphyrine IX (PpIX) aangebracht.PpIX is een lichtgevoelige 
stof die bij belichting zorgt voor de productie van reactieve zuurstofmoleculen. 
Deze reactieve zuurstofmoleculen zorgen voor schade en vernietiging van de 
(kanker-)cellen. Belangrijke factoren die een rol spelen bij ALA-PDT zoals de 
aanmaak van PpIX, de verdeling van PpIX , de eigenschappen van licht, her-verbruik 
van PpIX, de natuurkundige, biologische  en chemische processen van PDT worden 
kort uitgelegd. Er zijn beperkingen van ALA-PDT en MAL-PDT  zodat verbetering, 
optimalisering gewenst is. In dierstudies en in een eerste beperkte klinische studie is 
aangetoond dat fractionering van de belichting kan leiden tot een beter resultaat. Dit 
was de basis voor de studie die is beschreven in  hoofdstuk 2 van dit proefschrift. Een 
vergelijkende studie naar het resultaat van behandeling van oppervlakkig groeiende 
basaalcelcarcinomen (sBCC) tussen een enkelvoudig (75 Jcm-2 ) en een tweevoudig 
belichtingsschema (20+80 Jcm-2 .met een twee uur durende donkere pauze tussen 
de belichtingen). Het resultaat na minimaal 12 maanden van de tweevoudige 
behandeling is statistisch signiﬁ cant beter dan van de enkelvoudige belichting.( 97% 
genezen in vergelijk met 89% genezen. p<0.002). De meeste patiënten konden de 
behandeling goed verdragen, zij hadden geen pijnstilling nodig. Het cosmetisch 
resultaat werd goed tot excellent beoordeeld door de patiënten en behandelaars.
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In hoofdstuk 3 wordt een kleine studie beschreven naar de behandeling van M 
Bowen. Dezelfde behandelschema’s als in de sBCC studie werden gebruikt. Ook bij 
M Bowen heeft een tweevoudige belichting een beter resultaat. Na 12 maanden 
was in de enkelvoudige groep 80% genezen tegenover 88% in de tweevoudig 
belichte groep. Een extra reden om M Bowen te behandelen met ALA-PDT is de 
korte genezingstijd na de behandeling. Dit is met name een voordeel voor die 
afwijkingen die voorkomen op lastig te behandelen plaatsen zoals het gelaat of het 
onderbeen.
Naast klinische studies hebben wij ook onderzoek gedaan naar de PpIX kinetiek 
in relatie tot eerder dierexperimenteel onderzoek. In hoofdstuk 4 worden de 
resultaten beschreven van ﬂ uorescentie onderzoek aan het oppervlak gemeten en 
microscopisch gemeten. Een goede correlatie werd gevonden tussen deze twee 
methoden om PpIX ﬂ uorescentie te meten. Zowel behandelde sBCC’s als controle 
biopten werden onderzocht. Zes uur na het aanbrengen van ALA werd een 
biopsie gedaan of 2 uur na een eerste belichting (20 Jcm-2 ),dat is ook 6 uur na 
het aanbrengen van ALA. De biopten werden immunohistochemisch gekleurd voor 
Ki-67 een marker voor proliferatie. Het ﬂ uorescentie patroon komt goed overeen 
met de positief aankleurende cellen voor Ki-67. De PpIX ﬂ uorescentie bevindingen 
bevestigen het eerder gevonden feit dat er relatief nieuw PpIX aangemaakt wordt in 
het donkere interval tussen de belichtingen in een tweevoudig behandel schema. In 
onze zoektocht naar een verklaring van het werkingsmechanisme van ALA- PDT en 
met name van een gefractioneerde behandeling hebben we ook onderzoek gedaan 
naar het patroon van celdood. Bij ALA-PDT gaan de cellen dood door necrose 
(versterf) en/of door apoptose (geprogrammeerde celdood zonder resten) en door 
een immunologische respons.Immunohistochemisch kleuringen werden verricht 
naar Bcl-2, Bax en caspase 3 in  enkelvoudig belichte sBCC’s, in tweevoudig belichte 
sBCC’s en in controle sBCC’s. Deze resultaten worden beschreven in hoofdstuk 
5. Biopten werden genomen 6 uur na het aanbrengen van de ALA (controle, 7 
biopten), 2 uur na een enkelvoudige belichting (10 biopten) of net voor de tweede 
belichting in het tweevoudig belichtingsschema (25 biopten). Bij één patient werd 
een sBCC driemaal gebiopteerd. Eiwitten van de Bcl-2 familie worden geacht een 
rol te spelen bij de celdood door apoptose bij ALA-PDT. Caspase 3 kan worden 
beschouwd als een uitvoerder in apoptotische celdood. Snel na een enkelvoudige 
behandeling worden  kenmerken gevonden van apoptose, zoals  een veranderde 
uitdrukking van  Bcl-2 en Bax eiwitten. Onze resultaten bevestigen dat apoptose. 
Summary (English and Dutch) | 175
aangezet via het mitochondrium (energiefabriek van de cel) in de cel een rol speelt 
bij de celdood door apoptose bij ALA-PDT.
Omdat in Nederland MAL in toenemende mate wordt gebruikt bij PDT hebben we 
ook onderzoek gedaan naar het effect van een gefractioneerde belichting bij MAL-
PDT. In hoofdstuk 6 zijn de resultaten van dit dierexperimenteel onderzoek bij muizen 
beschreven.Wij hadden verwacht een groter effect te bereiken door fractionering 
van de belichting  zoals wij een groter effect verkregen bij gefractioneerd ALA-PDT.
Echter de effectiviteit van MAL-PDT neemt niet toe zoals bij ALA-PDT hoewel de 
ﬂ uorescentie intensiteit  bij beide sensitisers (lichtgevoelige stoffen of hun voorloper) 
na de eerste belichting en juist voor de tweede belichting vergelijkbaar zijn. De 
mate waarin PpIX verbruikt wordt bij ALA-PDT is in eerste instantie iets sneller 
dan bij MAL-PDT. Dit is echter een te klein verschil om het grote verschil in PDT 
schade / resultaat te verklaren. De verkregen gegevens suggereren dat de verdeling 
van ALA en MAL in het weefsel en daarmee de plaats van de schade door PDT een 
belangrijke rol speelt in de toegenomen schade bij gefractioneerde ALA-PDT.
In hoofdstuk 7 wordt onderzoek in de klinische dermatologie beschreven. De 
kwaliteit van richtlijnen voor de behandeling van huidkanker wordt beschreven. De 
(20) richtlijnen die beschikbaar waren tot 2006 werden beoordeeld met het AGREE 
instrument. Dit is tot stand gekomen in samenwerking met een aantal Europese 
landen en betreft met name de kenmerken en methodes van totstandkomen van 
een richtlijn. De score die verkregen wordt met het AGREE instrument kunnen 
worden verbeterd door het expliciet noemen van de verschillende onderdelen van 
een richtlijn. De kwaliteit van dermatologische richtlijnen voor de behandeling van 
huidkanker is redelijk gebleken. Richtlijnen gepubliceerd na de publicatie van het 
AGREE instrument zijn helderder geformuleerd dan die tevoren zijn gepubliceerd. 
Omdat richtlijnen belangrijk zijn voor een goede kwaliteit van zorg blijven 
verbeteringen wenselijk.
In hoofdstuk 8 worden de resultaten van de gefractioneerde ALA-PDT voor 
actinische keratose, sBCC, nodulair BCC en M Bowen beschreven. Na twee jaar 
zijn goede genezingspercentages verkregen na behandeling met het tweevoudig 
belichtingsschema van 20 + 80 J cm-2 met een twee uur durend donker interval van 
totaal 552 afwijkingen. sBCC reageerde in 97%  van de gevallen, AK in 98%, nBCC 
in 80% en M Bowen in 84% met een genezing. De resultaten bij M  Bowen zijn 
vergelijkbaar met de in de literatuur beschreven resultaten van PDT en chirurgie, maar 
maken duidelijk dat verbetering gewenst is. Ook een verbetering in de genezing van 
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nBCC is gewenst. Een analyse van de 57 afwijkingen groter dan 2 cm voor BCC’s, 
AK en M Bowens gaf in 89% een genezing na 2 jaar. Het cosmetisch resultaat 
was in nagenoeg alle gevallen excellent.Onze resultaten zouden moeten worden 
opgenomen in toekomstige richtlijnen voor de behandeling van niet-melanoom 
huidkanker. 
Hoofdstuk (9) bestaat uit een editorial over kwaliteit van leven die gerelateerd is 
aan gezondheid. Naast genezingpercentages, ziektevrije overlevingstijd en andere 
doktergerelateerde parameters zijn de door de patiënt gerapporteerde uitkomsten 
belangrijk. Vragenlijsten over kwaliteit van leven die speciﬁ ek huidkanker gerelateerd 
zijn, zijn recent ontwikkeld. Een voorbeeld is de Skin cancer index (huidkankerindex). 
Beter begrip en vastlegging van de mening van patiënten kan behulpzaam zijn in 
de arts-patiënt relatie, de huidkanker behandeling en de selectie van patiënten die 
aanvullende begeleiding of informatie nodig hebben. Het aantonen van effecten 
op de kwaliteit van leven voor en na een behandeling van huidkanker is belangrijk. 
Deze effecten kunnen belangrijk zijn voor patiëntselectie, informatiebehoefte 
van patiënten, therapiekeuze en resultaat evenals voor de verdeling van budget 
en mogelijkheden in de gezondheidszorg. Tot heden zijn de voordelen van Mohs’ 
micrograﬁ sche chirurgie, een speciale operatietechniek voor de behandeling van 
huidkanker niet bewezen vanuit patiënt perspectief. Aanvullende onderzoeken 
hiernaar zijn nodig.
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Misschien wel de meest gelezen pagina van een proefschrift ……..
Natuurlijk wil ik iedereen bedanken die op welke wijze ook bijgedragen heeft aan 
de totstandkoming van mijn proefschrift of een bijdrage geleverd heeft aan mijn 
geluk en wijsheid in de weg die op 15 november de mijlpaal van een promotie gaat 
bereiken. 
Allereerst wil ik met nadruk alle patiënten bedanken! De velen die patiënt geweest 
zijn in ons onderzoek en ook hen die mij in de loop van de jaren veel geleerd 
hebben. 
Ik wil graag een aantal mensen  met name noemen en speciaal bedanken;
Mijn promotor, professor Martino Neumann. Martino bedankt!. Je hebt me op een 
goed moment toevertrouwd dat je in het begin je twijfels had over mijn bijdrage 
aan wetenschap, gelukkig heb je me dit vertrouwen geschonken op een moment 
dat alleen ik nog twijfelde… ..?. Het boekje is af, het onderzoek gaat door!
Dominic Robinson, mijn copromotor, een cliché kent een hoog waarheidsgehalte 
“zonder jou was het niet gelukt”. Thank you so much for all those suggestions, 
comments and support! I’m proud to be your PhD student and hope we will work 
together for many more years.
De leden van de kleine commissie,professor Levendag, professor Oosterhuis en 
professor Szeimies wil ik danken voor de tijd en moeite die zij genomen hebben 
het manuscript te lezen. Peter wie had gedacht dat je zou zitten in de kleine 
commissie van een promovenda dermatologie,van je AGNIO radiotherapie? Onze 
gemeenschappelijke hobby de oncologie kent vele gezichten. Ik ben nog altijd blij 
een tijdje bij je gewerkt te hebben in de Daniël. Wolter, zelfs op zaterdagochtend 
vroeg heb je aan mijn manuscript gedacht en mij gemailed, dank hiervoor. Rolf 
Markus thank you, not only for reviewing my manuscript of this thesis but also 
for being one of the anonymous (at least I guess you are) reviewers of submitted 
articles. 
Ook de leden van de grote commissie, professor Bruijnzeel- Koomen, professor 
Wilson en doctor Sterenborg wil ik bedanken voor hun tijd en moeite. Carla, 
Utrecht is en blijft onze stad. Ik heb er veel goede herinneringen aan. Ik ben blij 
dat je naar Rotterdam komt de 15e november. Professor Wilson, ik weet dat u net 
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gepensioneerd bent, maar zeer betrokken bij Pp’s. Ik hoop dat ik uw vragen kan 
beantwoorden als “jong wetenschapper”  Dick , je hoort bij ons onderzoek en bij 
het CODT, je bent zeer betrokken geweest, dank voor alle input! Na 15 november is 
er een doctor bijgekomen (hoop ik) wanneer komt er een professor Sterenborg?
De mensen van het CODT, met name Riëtte, Lique, het lijkt zo rustig als je binnen 
komt op de Westzeedijk of in het lab, maar er wordt hard gewerkt. Dank voor alle 
gezelligheid en steun en werk dat jullie voor me gedaan hebben. Riëtte wannneer 
jij?
Mijn collegae staﬂ eden, met name Bing, Kai, Michael, Tamar. Bing de pandabeer 
dank voor de rust die je uitstraalt ! Kai voortaan gaan de samen naar de Daniël. 
Michael wanneer mag ik voor je koken? Tamar, ik kan me geen betere kamergenoot 
wensen!, ik hoop dat we nog lang naar Christina Branco luisteren. 
En natuurlijk de dermatologen in opleiding en in opleiding geweest: Annette, 
Annieke, Babs, Marlies, Minouche, Esmee, Ewout, Femke, Gijs, Hilde, Karin, Melanie, 
Oded, Patrick, Renate, Saskia, Sarah2, Shiva, Simone, Sterre, Suzanne, Tim, Tom, 
Willemijn, Yvette; zonder jullie is het niet gezellig en leuk in het Erasmus.
Hanke, jij hoort natuurlijk ook in bovengenoemde rij, maar voor jou op de 15e een 
speciale plaats naast mij. Ik vind het leuk dat jij samen met Tom ook een warm hart 
hebt voor de PDT en ons onderzoek.
Mijn vrienden van altijd! Vaak heb ik jullie moeten teleurstellen, ik ben druk, maar 
ja…..
Margreet, jou ken ik het langst, we zaten bij elkaar in de klas en waren al gauw 
goede vriendinnen. Ik verheug me erop je vaker te zien. Rian tegelijktijd opgeleid 
tot huisarts, jij bent het gebleven net zoals de goede uren gebleven zijn , uren 
aan de telefoon of samen. Danny, Derck, Eric, Erik, Gerda, Helma, Joost, Manon, 
Ineke, Pauline, Peter en Soﬁ ek mijn oude studiematen met aanhang zijn en blijven 
goede maten. Een extra weekendje na al die jaren ?Soﬁ eke,in 1982 zagen we elkaar 
bij een introductiebijeenkomst van de studie geneeskunde.‘Samen op’is lang van 
toepassing geweest, nu samen naar binnen de 15e, ik ben blij dat je ook deze keer 
naast me staat, Bedankt!
En dan zijn er natuurlijk ook al die andere mensen die een warm plekje in mijn hart 
hebben verdiend. Familie, vrienden, collegae allemaal enorm bedankt! Blijvers en 
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woorden: heel veel liefs en dank voor alles!!!
En Frederik waar zit je ……..?! ik wil met je mee! Voor jou een dikke kus, de rest 
vertel ik je straks zelf………
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